Systems biology of breast cancer by Dhondalay, GKR
 
 
SYSTEMS BIOLOGY OF BREAST CANCER 
 
 
 
 
 
 
 
 
GOPAL KRISHNA RAMADAS DHONDALAY 
 
 
 
 
 
A thesis submitted in partial fulfilment of the requirements  
for the degree of 
Doctor of Philosophy 
 
 
 
 
 
November 2013 
 
 
 
 
 
 
 
Nottingham Trent University 
School of Science and Technology 
Clifton lane 
Nottingham NG11 8NS. 
  
  
 
 
 
 
 
 
 
 
 
 
 
Dedicated to my parents and family…  
Copyright statement 
 
This work is the intellectual property of the author, and may be owned by the 
School of Science and Technology, Nottingham Trent University. You may copy 
up to 5% of the work for private study, or personal, non-commercial research. 
Any re-use of the information continued within the document should be fully 
referenced, quoting the author, title, university, degree level and pagination. 
Queries or requests for any other use, or if a more substantial copy is requested, 
should be directed in the first instance to the author of the Intellectual Property 
Rights. 
  
Acknowledgements 
 
 
Firstly, it is my privilege to thank Prof Graham R Ball for his very valuable 
guidance at each and every stage of this research. Without his extremely 
motivating support this research could not have happened. I also thank Dr Tony 
Allen for his expert advice and apt critics which have refined my work. 
My thanks are due to Prof Robert Rees and Prof Graham Pockley for their 
encouragement and motivation throughout my entire research period. 
I also thank my colleague Dr Dong L Tong for her friendly support and 
valuable discussions during our lunch together. 
I would also like to thank Dr Desmond Powe for his support in clinical 
samples and biological validation. 
I would like to thank entire staff and colleagues from John van Geest 
cancer Research Centre for their help. 
I would like to thank all my friends from the Nottingham Trent University 
and also from India who are directly or indirectly helped me throughout. 
I also thank my better half Shwetha for her lovely support at every moment. 
Finally, it’s my pleasure to thank my parents and family for their ever 
encouraging blessings and unstinted support. 
  
Contents 
  
 
List of figures ...................................................................................................................... i 
List of tables...................................................................................................................... iii 
Abbreviations .................................................................................................................... v 
 
ABSTRACT ..................................................................................................................... viii 
 
Chapter 1 
INTRODUCTION ............................................................................................................. 1 
1.1. Breast cancer ........................................................................................................... 2 
1.2. Oestrogen Receptors ............................................................................................... 2 
1.2.1. ERα and ERβ subunits: ................................................................................... 4 
1.2.2. The ER pathway .............................................................................................. 5 
1.2.3. ER in breast cancer ......................................................................................... 8 
1.3. Classification of breast cancer ................................................................................ 9 
1.3.1. Molecular classification ................................................................................ 10 
1.4. Breast cancer heterogeneity .................................................................................. 13 
1.5. Biomarker identification in breast cancer ............................................................. 16 
1.5.1. Predictive and Prognostic biomarkers in breast cancer ................................. 16 
1.6. Gene expression profiling ..................................................................................... 19 
1.6.1. Microarray ..................................................................................................... 20 
1.6.2. Principles ....................................................................................................... 20 
1.6.3. Applications of microarray in breast cancers ................................................ 22 
1.6.4. Limitations .................................................................................................... 23 
1.7. Machine learning for biomarker identification ..................................................... 24 
1.7.1. Unsupervised machine learning approaches ................................................. 24 
1.7.1.1. Clustering methods ............................................................................... 25 
1.7.1.2. K-means clustering ............................................................................... 27 
1.7.1.3. Self-Organising Maps ........................................................................... 27 
1.7.1.4. Principle component analysis ................................................................ 28 
1.7.2. Supervised machine learning approaches ..................................................... 28 
1.7.2.1. K-Nearest Neighbours ........................................................................... 29 
1.7.2.2. Linear-discriminant analysis ................................................................. 29 
1.7.2.3. Support Vector Machines ...................................................................... 30 
1.7.3. Reinforcement machine learning approach ................................................... 31 
1.8. Databases and gene signatures using machine learning ........................................ 32 
1.9. Challenges for biomarker identification................................................................ 33 
 
Chapter 2 
ARTIFICIAL NEURAL NETWORKS ........................................................................ 35 
2.1 Introduction ........................................................................................................... 35 
2.2 Biological neural networks ................................................................................... 36 
2.3 Historical background ........................................................................................... 37 
2.4 Artificial neurons: structure and architecture ........................................................ 38 
2.4.1 The perceptron .............................................................................................. 38 
2.4.2 Multilayer perceptron .................................................................................... 41 
2.4.3 Back-propagation algorithm ......................................................................... 42 
2.4.4 MLP training ................................................................................................. 44 
2.4.5 Gradient descent algorithm ........................................................................... 45 
2.4.5.1 Escaping local minima with momentum ................................................... 46 
2.4.5.2 Generalisation and avoiding over-fitting .................................................. 46 
2.5 Optimisation of ANN parameters in predictive modelling ................................... 47 
2.5.1 Randomisation of initial network weights .................................................... 47 
2.5.2 Learning rate and Momentum ....................................................................... 48 
2.5.3 Hidden layer size ........................................................................................... 49 
2.6 Variants of neural network architectures .............................................................. 50 
2.7 Stepwise ANN approach ....................................................................................... 53 
2.8 Interaction algorithm ............................................................................................. 56 
2.8.1 Overview of interaction algorithm ................................................................ 58 
2.8.2 Interaction model development ..................................................................... 59 
2.8.3 Filtering ......................................................................................................... 59 
2.8.4 Visualisation of model .................................................................................. 60 
2.9 Comparison of ANN with other methods ............................................................. 60 
2.10 Advantages and disadvantages of ANN ................................................................ 61 
2.11 ANNs in medicine and Biomarker discovery ....................................................... 62 
2.12 Systems biology approach using ANN ................................................................. 64 
 
Chapter 3 
CLASSIFICATION OF OESTROGEN RECEPTOR STATUS IN A BREAST 
CANCER MICROARRAY DATASET USING ARTIFICIAL NEURAL 
NETWORKS ................................................................................................................... 66 
3.1 Introduction ........................................................................................................... 67 
3.1.1 Need for ER associated gene markers ........................................................... 67 
3.2 Aims and Objectives ............................................................................................. 68 
3.3 Materials and Methods .......................................................................................... 69 
3.3.1 E-GEOD-20194 dataset ................................................................................ 69 
3.3.2 Other breast cancer datasets .......................................................................... 69 
3.3.3 Stepwise ANN .............................................................................................. 70 
3.4 Results and Discussions ........................................................................................ 72 
3.4.1 Stepwise ANN consistency ........................................................................... 72 
3.4.2 Classification accuracy of Stepwise-ANN .................................................... 75 
3.4.3 Top100 probe list for ER status from Stepwise-ANN .................................. 75 
3.4.4 Comparison of ANN result with original study ............................................ 79 
3.4.5 ER-class prediction comparison between protein and gene expression based 
classification ................................................................................................. 81 
3.4.6 Investigation of probe variants ...................................................................... 83 
3.4.6.1 Rank positions ........................................................................................... 83 
3.4.6.2 Population distribution charts ................................................................... 84 
3.4.7 Gene Ontology of the top 100 probes ........................................................... 87 
3.4.7.1 Molecular function .................................................................................... 87 
3.4.7.2 Biological function .................................................................................... 88 
3.4.7.3 Pathways ................................................................................................... 88 
3.4.8 Cross validation with other breast cancer datasets ........................................ 92 
3.5 Conclusion ............................................................................................................ 95 
 
Chapter 4 
OESTROGEN RECEPTOR NETWORK INFERENCE WITH ARTIFICIAL 
NEURAL NETWORKS 
(using pre-identified ER-associated markers by Stepwise-ANN approach) .............. 98 
4.1 Introduction ........................................................................................................... 99 
4.2 Network Inference ................................................................................................ 99 
4.3 Aims and Objectives ........................................................................................... 102 
4.4 Methodology ....................................................................................................... 103 
4.4.1 Gene-Gene Interaction analysis .................................................................. 103 
4.4.2 Visualisation of network models ................................................................. 104 
4.4.3 Clinical validation of ER-associated markers ............................................. 104 
4.4.3.1 Immunohistochemistry reagents ............................................................. 105 
4.4.3.2 Immunohistochemistry protocol ............................................................. 106 
4.4.3.3 Univariate and Multivariate statistical analysis ...................................... 109 
4.5 Results ................................................................................................................. 110 
4.5.1 ER interactomes .......................................................................................... 110 
4.5.2 ER-Positive and ER-Negative interactomes ............................................... 112 
4.5.3 Clinical validation of ER-associated markers ............................................. 116 
4.5.3.1 VAV3 protein expression ........................................................................ 116 
4.5.3.2 DACH1 protein expression ..................................................................... 123 
4.6 Discussion ........................................................................................................... 129 
4.6.1 Literature validation of ER-associated markers .......................................... 129 
4.7 Conclusion .......................................................................................................... 138 
 
Chapter 5 
SYSTEMS BIOLOGY OF ER RELATING TO BREAST CANCER ..................... 140 
5.1 Introduction ......................................................................................................... 140 
5.1.1 Systems biology in breast cancer ................................................................ 142 
5.2 Aims and objectives ............................................................................................ 144 
5.3 Materials and methods ........................................................................................ 145 
5.3.1 Breast cancer microarray dataset ................................................................ 145 
5.3.2 ANN architecture and model development ................................................. 145 
5.3.3 ESR1 and ESR2 interactome simulation and validation ............................. 147 
5.3.4 ER system simulation.................................................................................. 147 
5.4 Results ................................................................................................................. 148 
5.4.1 ESR1 and ESR2 predictive markers ........................................................... 148 
5.4.2 ESR1 and ESR2 interactomes ..................................................................... 148 
5.4.3 Modelling known ER pathway elements using ANN ................................. 151 
5.5 Discussion ........................................................................................................... 155 
5.6 Conclusion .......................................................................................................... 160 
 
Chapter 6 
NON-REDUCTIONAL SYSTEMS BIOLOGY APPROACH TO ESR1 WITH 
BROADER CONSIDERATION AND RELATIONSHIP TO PGR AND ERBB2 . 162 
6.1 Introduction ......................................................................................................... 163 
6.1.1 ER, PR and Her2 ......................................................................................... 163 
6.1.2 Non-reductional systems biology approach ................................................ 164 
6.2 Aims and objectives ............................................................................................ 164 
6.3 Materials and methods ........................................................................................ 165 
6.3.1 Predictive gene identification using stepwise-ANN ................................... 165 
6.3.2 Non-reductionist approach .......................................................................... 166 
6.3.3 ANN interaction network inferencing ......................................................... 167 
6.4 Results ................................................................................................................. 169 
6.4.1 Non-reductional ESR1 Interactome ............................................................ 169 
6.4.2 Extension to PGR and ERBB2 interactomes .............................................. 169 
6.4.3 Cumulative ESR1, PGR and ERBB2 non-reductional model ..................... 172 
6.5 Discussion ........................................................................................................... 174 
6.6 Conclusion .......................................................................................................... 179 
 
 
Chapter 7 
OVERALL SUMMARY AND FUTURE WORK ..................................................... 181 
 
BIBLIOGRAPHY ......................................................................................................... 191 
 
APPENDIX 1 ................................................................................................................. 213 
APPENDIX 2 ................................................................................................................. 224 
APPENDIX 3 ................................................................................................................. 235 
 
COMMUNICATIONS ................................................................................................. 254 
 
ANNEXURE 1 ............................................................................................................... 257 
ANNEXURE 2 ............................................................................................................... 263 
 
  
 
 i 
 
List of figures 
 
FIGURE 1: Schematic representation of er mediated gene expression.. ................ 6 
FIGURE 2: Schematic representation of microarray technique.. ......................... 21 
FIGURE 3: Schematic representation of hierarchical clustering method.. ........... 25 
FIGURE 4: Schematic representation of single layer perceptron model.. ............ 39 
FIGURE 5: Multilayer perceptron (MLP). ........................................................... 43 
FIGURE 6: Illustration of error back-propagation................................................ 43 
FIGURE 7: Stepwise-ANN model.. ...................................................................... 56 
FIGURE 8: ANN model performance consistency.. ............................................. 74 
FIGURE 9: Heat map of the top 100 predictive genes.. ....................................... 80 
FIGURE 10: Population distribution of samples with IHC and gene expression 
based er classification. ..................................................................... 82 
FIGURE 11: Population distribution of ESR1 and APBB2 probe variants.. ......... 86 
FIGURE 12: Molecular functional ontology information of ER-associated genes..
 ......................................................................................................... 89 
FIGURE 13: Biological functional ontology information of ER-associated genes..
 ......................................................................................................... 89 
FIGURE 14: Pathway ontology information of ER-associated genes.. ................ 91 
FIGURE 15: ROC Curve analysis of breast cancer datasets.. .............................. 93 
FIGURE 16: Positive and negative interactions. INTERACTION. ................... 111 
FIGURE 17: Interactions in ER-Positive samples. ............................................. 113 
FIGURE 18: Interactions in ER-Negative samples. ........................................... 114 
 ii 
 
FIGURE 19: VAV3 protein expression by IHC. ................................................ 117 
FIGURE 20: DACH1 protein expression by IHC. ............................................. 124 
FIGURE 21: ASsociation of DACH1 protein expression with clinical outcome of 
patients. .......................................................................................... 128 
FIGURE 22: ESR1 interactome from ANN. ....................................................... 152 
FIGURE 23: ESR2 interactome from ANN. ....................................................... 153 
FIGURE 24: ER system (ER-alpha and ER-beta) interaction ............................ 154 
FIGURE 25: Schematic representation of non-reductional approach................. 166 
FIGURE 26: Overview of non-reductional systems biology approach. ............. 168 
FIGURE 27: Non-reductional ESR1 interaction model. ..................................... 170 
FIGURE 28: Non-reductional PGR interaction model. ...................................... 171 
FIGURE 29: Non-reductional ERBB2 interaction model. .................................. 172 
FIGURE 30: Cumulative ESR1, PGR and ERBB2 non-reductional systems model.
 ....................................................................................................... 173 
 
 iii 
 
List of tables 
 
TABLE 1: Summary of the breast cancer microarray studies. ............................. 33 
TABLE 2: Summary of breast cancer datasets considered for validation. ........... 71 
TABLE 3: Summary of Stepwise-ANN outcome. ................................................ 72 
TABLE 4: Sensitivity, specificity, classification accuracy and ROC analysis. .... 76 
TABLE 5: Summary of top ranked 100 genes from Stepwise-ANN.................... 77 
TABLE 6: Stepwise-ANN performance for ER (protein) and ESR1 (gene) 
expression based classification........................................................... 83 
TABLE 7: LIst of repeated probes for gene found in top 100 Stepwise-ANN..... 85 
TABLE 8: Detailed ontological information of ER-associated genes from 
Stepwise-ANN model. ....................................................................... 90 
TABLE 9: Stepwise-ANN classification performance in breast cancer datasets. 93 
TABLE 10: Rank position of top 10 probes across breast cancer datasets. .......... 94 
TABLE 11: ER-associated gene-gene interaction hubs. ..................................... 115 
TABLE 12: VAV3 expression association with clinicopathological markers. .. 118 
TABLE 13: VAV3 expression association with breast cancer markers. ............ 120 
TABLE 14: Mantle-Cox regression analysis of VAV3 for predicting patient 
outcome. ........................................................................................... 122 
TABLE 15: Association of DACH1 protein expression with clinicopathological 
markers. ............................................................................................ 125 
TABLE 16: Association of DACH1 protein expression with breast cancer 
markers. ............................................................................................ 127 
 
 
iv 
 
TABLE 17: The top 100 predictive probes for ESR1 classification. .................. 149 
TABLE 18: The top 100 predictive probes for ESR2 classification. .................. 150 
TABLE 19: Predictive gene list of ESR1, PGR AND ERBB2 non-reductional 
interactomes. .................................................................................... 175 
  
 
 
v 
 
Abbreviations 
 
ANN Artificial neural network 
AR Androgen receptor 
ATE Average test error 
AUC Area under curve 
BCSS Breast cancer specific survival 
BP Back-propagation 
BRCA1 Breast cancer 1 
BRCA2 Breast cancer 2 
CA12 Carbonic anhydrase 12 
cDNA complementary Deoxyribonucleic acid 
ChIP Chromatin Immuno Precipitation 
CISH Chromosomal In-Situ Hybridization 
DMS Distant metastasis-free survival 
DNA Deoxyribonucleic acid 
ELISA Enzyme Linked Immuno Sorbant assay  
ER Oestrogen receptor 
ERE Oestrogen Responsive Elements 
FISH Fluorescent In-Situ Hybridization 
GEO Gene Expression Omnibus 
HER2/neu/ErbB2 Human epidermal growth factor 2 
HIF1 Hypoxia inducible factor 1 
 
 
vi 
 
IGFBP Insulin like growth factor binding protein 
IHC Immunohistochemistry 
K-NN K-Nearest Neighbours 
LDA Linear discriminant analysis 
MCCV Monte Carlo Cross Validation 
MLP Multi-layer perceptron 
mRNA messenger Ribonucleic acid  
MSE Mean square error 
NPI Nottingham Prognostic Index 
PCA Principle Component Analysis 
PCR Polymerase Chain Reaction 
PR Progesterone receptor 
RBF Radial basis function 
RFS Relapse-free survival 
RNA Ribonucleic acid 
RNN Recurrent neural network 
ROC Receiver Operating Characteristic 
RT Room temperature 
RT-PCR Reverse Transcriptase-Polymerase Chain Reaction 
SERMS Selective estrogen receptor modulators 
SOMs Self-Organising Maps 
SVM Support vector machine 
TMA Tissue MicroArray 
 
 
vii 
 
 
  
 
 
viii 
 
ABSTRACT 
 
Breast cancer, with an alarming incidence rate throughout the globe, has 
attracted significant investigations to identify disease specific biomarkers. Among 
these, oestrogen receptor (ER) occupies a central role where overexpression is a 
prognostic indication for breast cancer. The cross-talk between the responsible 
contenders of ER-associated genes potentially play an important role in the 
disease aetiology.  Investigation of such cross talk is the focus of this thesis. 
The development of high throughput technologies such as expression 
microarrays has paved the way for investigating thousands of genes at a time. 
Microarrays with their high data volume, multivariate nature and non-linearity 
pose challenges for analysing using conventional statistical approaches. To 
combat these challenges, computational researchers have developed machine 
learning approaches such as Artificial Neural Networks (ANNs). 
This thesis evaluates ANNs based methodologies and their application to 
the analysis of microarray data generated for breast cancer cases of differing 
oestrogen receptor status.  Furthermore they are used for network inferencing to 
identify interactions between ER-associated markers and for the subsequent 
identification of putative pathway elements. The present thesis shows that it is 
possible to identify some ER-associated breast cancer relevant markers using 
ANNs.  These have been subsequently validated on clinical breast tumour samples 
highlighting the promise of this approach. 
 
 
ix 
 
This thesis will also demonstrate the novel application of ANNs in systems 
biology of ER, PR and Her2. Furthermore in this research, the integration of ER, 
PR and Her2 systems have been undertaken to represent a broader view of the 
breast cancer system. 
Finally, this thesis will discuss the advantages, limitations, potential 
application and future potential applications of the methods evaluated. 
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Chapter 1 
INTRODUCTION 
 
 
Chapter abstract: Breast cancer is the most common cancer diagnosed in the west 
and the incidence rate is increasing throughout the globe. Oestrogens play a major 
role in the mammary gland tissue development and preparation of the uterus for 
fertilization. Oestrogens initiate signalling through oestrogen specific receptors, 
whose overexpression is a prognostic indication in breast cancer. To identify 
specific sub group of patients that would benefit from endocrine and hormonal 
therapy, researchers have attempted molecular sub-typing of breast cancer using 
microarrays. However, the use of microarrays, with the potential of investigating 
thousands of genes at the same time, pose challenges for conventional statistical 
approaches in terms of data volume, highly multivariate nature, complexity and 
non-linearity. To combat these challenges, computational researchers have 
developed machine learning approaches. These approaches have an ability to learn 
the data pattern and classify samples or predict the outcome. Such process have 
the potential to enormously benefit high throughput biological data analysis. 
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1.1. Breast cancer 
Cancer is a disease characterised by an uncontrolled growth of cells, leading 
to benign (harmless) or metastatic (detrimental) tumours. Among the repertoire of 
cancers, breast cancer is the most commonly diagnosed. Due to the lack of 
effective therapeutic markers, the global burden of breast cancer is increasing with 
time, accounting for one in six of all cancer related deaths. Thus, makes it the 
second leading cause of death after lung cancer throughout the globe (Jemal et al., 
2011). Although, breast cancer rates vary largely with race, ethnicity and 
geographic region, caucasian women have higher incidence compared to black 
African American women (Ma and Jemal, 2013). In the United Kingdom alone, 
one third of all newly diagnosed cases are of breast cancer, with the rate of 
diagnosis increasing from 1 to 400 per 100,000 cases each year from 1960 to 2010 
(http://www.cancerresearchuk.org/). 
 
1.2. Oestrogen Receptors  
 
Oestrogens are steroidal hormones which function as signalling molecules. 
There are three basic oestrogen molecules: Estrone (E1; biologically inactive), 
Estradiol (E2 or 17β-estrone; most tumourigenic) and Estriol (E3; most 
beneficial). Both men and women have the same oestrogens which vary in 
concentrations. In women, they are produced and secreted by the ovaries, adrenal 
glands and breasts. Oestrogens mainly stimulate and maintain sexual 
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characteristics and reproduction. The breast and uterus, which play central roles in 
sexual reproduction, are two of the main targets of oestrogens. In addition, they 
also found to act on brain, bone, liver and heart tissue (Enmark and Gustafsson, 
1999). 
Oestrogens exert their function on various tissues by travelling through the 
blood stream. When an oestrogen molecule enters a cell and binds with their 
specific receptor, called an Oestrogen Receptor (ER) found in the nucleus, 
wherein the oestrogen-receptor complex is formed and a cascade of signalling 
events governing cellular proliferation, growth, and gene regulation ensues. 
Oestrogens play a vital physiological role in mammary tissue development 
prior to the induction of lactation (Anderson, 2002), and uterus to facilitate 
adhesion of fertilized egg in adult females (Shao et al., 2012). Overexpression of 
ER leads to increased cellular stimulation resulting in a decreased repair of 
genetic material potentially leading to breast tumour development (Anderson, 
2002). Contrastingly, females who have undergone oophorectomy before the age 
of 30, are known to be at lower risk of breast cancer development and circulating 
sex hormones in post-menopausal women are found to be predictive for hormone 
receptor positive breast cancers in 20 year follow-up study (Zhang et al., 2013).  
Clinically, ER-positive (ER+) patients benefit from enhanced disease free 
survival rates with better response to hormonal therapy (tamoxifen), compared to 
women with aggressive ER-negative (ER-) breast tumours (Lemieux and Fuqua, 
1996). About three-fourth of advanced ER+/Progesterone receptor (PR)+ breast 
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cancer patients responds to tamoxifen treatment, whereas only 10% of ER-/PR- 
patients will also respond similarly (Zwart et al., 2011). 
Although ER expression is largely associated with a better outcome for the 
patients, this is somewhat paradoxical since low levels of ER in normal female 
breast depends on the menstrual cycle phase (Zhang et al., 2013). Even though ER 
expression is a good prognostic indication in breast cancer, some randomised 
control trials have confirmed that hormonal therapy is ineffective in invasive 
breast cancer that lacks ER expression (EBCTCG, 2005), hence ER status is also 
an excellent negative predictive factor. 
Studies have also shown that ER expression alone is a relatively poor 
predictor for hormonal therapy response in tumours (EBCTCG, 2005). Incomplete 
knowledge of the ER signalling pathway suggests that an investigation of ER-
associated genes may serve as better markers for disease progression and response 
to therapy. Thus, ER expression is now recognised as a prognostic marker in 
breast cancer, whether or not the usage of anti-oestrogen such as tamoxifen as 
adjuvant endocrine therapy for patients could be decided. 
  
1.2.1. ERα and ERβ subunits: 
 
The ER consists of two different forms, namely alpha (α) and beta (β) 
encoded by two different genes ESR1 (NM_000125; Ch.6q24-q27) and ESR2 
(NM_00104275; Ch.14q21-q24) respectively. Both ERα and ERβ are also able to 
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form homodimer or heterodimers among themselves upon activation (Li et al., 
2004). They have sequence and functional homology at their ligand binding and 
DNA binding domains, wherein ligand binding domain transactivates gene 
transcription in the absence of the ligand and the DNA binding domain binds with 
Oestrogen Responsive Elements (ERE) to initiate oestrogen-inducible gene 
transcription (Klinge, 2001). Both ERα and ERβ (ERs) are widely expressed in 
different tissue with notable differences in expression patterns (Couse et al., 
1997). For example, ERβ is expressed much lower compared to ERα at mRNA 
level in breast tumours (Dotzlaw et al., 1997), and in healthy tissue (Shaw et al., 
2002).   
 
1.2.2. The ER pathway 
 
In response to pituitary hormones, the oestrogens are synthesised in the 
ovary from cholesterol. Estradiol can be converted to 17β-estrone in an reversible 
reaction catalysed by the Cytochrome P-450 enzyme, forming the by-products 4-
hydroxy estrone and 16α-hydroxy estrone. Estradiol and estrone can both be 
converted to estriol, which is the active form of oestrogen. Being highly 
electronegative, 4-hydroxy estrone and 16α-hydroxy estrone (i) can actively bind 
with DNA bringing about conformational or transcriptional changes of specific 
genes or (ii) can bind with extra cellular oestrogen to facilitate aberrant expression 
of genes (Hayashi et al., 2003).  
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Oestrogens specifically binding to ERs present in the cell nucleus, produces 
conformational changes to form ER-complexes which later binds to promoter 
specific sites on the ERE DNA sequences and regulate the transcriptional 
activation of associated genes through binding with co-activators (Klinge, 2001). 
Oestrogen, by itself, serves as a transcriptional factor and upon binding with co-
activators regulates the transcription of genes. Figure 1 is a schematic 
representation of oestrogen metabolism coupled with involvement of oestrogen in 
regulation of genes. 
 
Figure 1: Schematic representation of ER mediated gene expression. Estrone 
metabolism and involment of extrinsic oestrogen in the aberrent gene expression. 
ER acting as trascriptional activator for oncogenes results in tumourigenisis. 
Cyt P450 Estrone 
17β-
estrone 
4-OHE 16α-OHE 
ER 
Aberrant expression 
Structural 
changes 
Transcriptional 
changes 
ERE Coactivators 
Tumorigenesis 
ER 
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ER interacts with growth factors to bring about up-regulation of their 
expression and/or others. ER up-regulates growth factor receptor tyrosine kinases 
such as human epidermal growth factor receptor 2 (HER2/Neu/ErbB-2) and 
insulin-like growth factor receptor-1 (IGFR1) (Schiff et al., 2004). Conversely, 
IGFR1 can also modulate and enhance ER activity. This bi-directional cross-talk 
between ER and the growth factor receptor pathway plays a significant role in 
acquired and de novo resistance to endocrine therapy in breast cancers (Nicholson 
et al., 2005). ER also up-regulates signalling molecules such as membrane 
proteins, adaptor molecules and kinases such as proline, glutamic acid and leucine 
rich protein-1 (PELP-1) (Chakravarty et al., 2010).   
Depending on the cell type, oestrogen exhibits different behaviours in 
tissues having beneficial effects. For example, in the liver oestrogens regulate the 
metabolism of high density lipoproteins and facilitates removal of fatty plaques 
from the inner walls of arteries and also regulates osteocyte matrix formation in 
bones (Lee et al., 2003). Overexpression of oestrogens is associated with cellular 
proliferation in  glandular epithelium in the breast and endometrium in the uterus 
(Pozharisski, 2005). On the contrary, imbalanced expression of oestrogens in 
breast and uterus may lead to detrimental effects, causing cancer. Even though, 
over expression of ER is seen in the majority of breast tumours, it is somewhat of 
a paradox (Ricketts et al., 1991, Schiff et al., 2004).  
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1.2.3. ER in breast cancer 
 
ER is overexpressed in almost 70% of breast cancers and plays an important 
role in the biology of breast cancer (Cordera and Jordan, 2006), ER directly 
stimulates mammary cell proliferation (Bocchinfuso and Korach, 1997) and  
division (Levin, 2009). This leads to increased genomic mutations through ER-
induced reactive oxygen species production (Okoh et al., 2011). Furthermore, 
evidence of accumulated genotoxicity through ER metabolism has also been 
found (Dhillon and Dhillon, 1995). Both these processes are likely to disrupt the 
cell cycle, DNA repair mechanisms and alter programmed cell death – Apoptosis 
causing tumorigenesis (Bocchinfuso and Korach, 1997). Although ERα is highly 
associated with well differentiated tumours, ESR1 variants tend to have 
differences in risk of disease development (Deroo and Korach, 2006). 
ER has long been considered as a “good” prognostic factor predicting 
favourable disease outcome and treatment in breast cancer (Samaan et al., 1981). 
Although the prognostic value of ER is still controversial, ER status is presently a 
valuable predictive factor for the success of endocrine therapy in breast cancer 
(Lopez-Tarruella and Schiff, 2007). 
To combat the disease, Selective Estrogen Receptor Modulators 
(SERMS) like tamoxifen are used as ER antagonist in primary breast cancer 
patients (Fabian and Kimler, 2005). Furthermore, in post-menopausal women, 
raloxifene as SERMS (Cummings et al., 1999) and anastrozole as aromatase 
inhibitors are widely used (Mokbel, 2004). A number of clinical studies have 
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shown that patients with ER+ tumours enjoy improved disease-free survival rates 
and respond better to hormonal therapy compared to women with clinically 
aggressive ER- tumours (Rasmussen et al., 1989). 
 
1.3. Classification of breast cancer 
 
Breast cancer is classified into numerous subtypes according to various 
systems. The real-world drive for classification is to define each subtype of breast 
cancer in a manner which helps to select specific treatment approaches to achieve 
good outcome or better response to treatment. Classification of breast cancer is 
usually based on histological appearance of tissue in the tumour under the 
microscope, but recently emerging methods like nucleic acid based classification 
are also being developed and in trial.   
On a histopathological basis, breast cancer consists of several types derived 
from the epithelial lining of mammary ducts or lobules. Among them, the invasive 
ductal carcinoma represents a dominant group, with invasive lobular carcinomas, 
invasive papillary and micropapillary carcinomas with a high frequency. Mixed 
type with lobular and ductal features and metaplastic carcinomas are lower in 
frequency (Webster et al., 2005). 
Based on the differentiation of cells in the tissue, breast cancer can be 
divided into three grades as; low grade (well differentiated), intermediate grade 
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(moderately differentiated) and high grade (poorly differentiated) with a 
worsening of prognosis from low to high grade (Elston, 2005). 
Tumour aggression, measured in terms of size of tumour (T), involvement 
of the lymph node (N) and metastatic activity (M), classifies breast cancer into 
five stages ranging from 0-4 representing good to worst prognosis respectively 
(Elston, 2005). 
Hormone receptor expression classifies breast cancer mainly into ER and 
PR, along with HER2/neu amplification or over expressing types (Tanos et al., 
2012). 
Cancer poses heterogeneity in pathology, morphology, and also in response 
to treatment. Such clinical heterogeneity was simplified by dividing tumours into 
molecular classes by gene expression patterns of DNA microarrays for human 
acute leukaemia (Golub et al., 1999) later extended to breast cancer. 
 
1.3.1. Molecular classification 
 
The molecular taxonomy of breast cancer was initiated by Perou et. al. in 
the beginning of 21
th
 century (Perou et al., 2000). Using cDNA microarrays of 65 
breast carcinomas and an unsupervised hierarchical clustering method, they 
grouped genes on the basis of similarities and variations. They classified breast 
cancer cases into three main subtypes as luminal, basal and HER2/neu subtypes 
based on differential expression of genes. A balanced correlation between 
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oestrogen receptor α gene and protein expression in the tumours expressing 
transcription factors GATA3, Xbox binding protein 1 and hepatocyte nuclear 
factor 3α was found. Interestingly, the gene expression pattern revealed 
relationship between specific genes with specific tumour subtypes and also 
facilitated biological interpretation. Thus, they proved that the phenotypic 
diversity of breast cancer can be represented by gene expression variation. 
Extending the Perou et. al. work, Sorlie et. al. classified 85 breast 
carcinomas into six subtypes as luminal A, luminal B, luminal C predominating 
ER positivity and basal-like, ERBB2+ and normal-like group (Sorlie et al., 
2001). Luminal A subtype was characterised by higher expression of ER alpha, 
ER-regulated LIV-1, GATA3, trefoil factor 3 (TFF3), X-box binding protein 1 and 
hepatocyte nuclear factor 3 alpha; luminal B and luminal C showed moderate 
expression of luminal specific genes; Basal-like subtype was characterised by 
higher expression of keratin 5/17, fatty acid binding protein 7 and lamin; whereas 
the ERBB2+ subtype had overexpression of ERBB2 and GRB7. This study was 
revised further by considering 115 breast carcinomas with 534 “intrinsic” gene 
signature along with two independent validation cohorts of samples from van’t 
Veer and West datasets (van de Vijver et al., 2002, West et al., 2001). Cross 
comparison between the subtypes revealed that luminal B, basal-like and 
ERBB2+ was found to be negative for the luminal A genes previously known and 
had their own distinct set of genes. The luminal A/luminal B distinction was less 
clear compared to the luminal/basal-like distinction. This was also proved by 
BRCA1 mutational patterns in the subtypes. It was observed that BRCA1 mutation 
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was primarily associated with the basal-like subtype. When clinical outcome, such 
as time to develop distant metastasis was studied, it was observed that, luminal A 
subtype as best, basal-like and ERBB2+ as worst and luminal B has an 
intermediate response to therapy (Sorlie et al., 2003). 
Simultaneously, Sotiriou et al made extensive studies to investigate the 
association of molecular subtypes of breast cancer with clinical outcomes. In one 
of their studies, clinical outcomes such as relapse-free survival (RFS) and breast 
cancer survival (BCS) were investigated with nodal status among 99 breast 
carcinomas (Sotiriou et al., 2003). It was observed that 16 genes were 
significantly associated with RFS. Based on the distinct differential gene 
expression profiles, basal-like showed two subgroups as Basal-like 1 and Basal-
like 2, whereas the luminal subtypes showed three subgroups such as Luminal-
like 1, Luminal-like 2 and Luminal-like 3. Luminal 1 had best outcome with 80% 
10 years RFS and luminal 2 had worst outcome with 40% 10 years RFS. In 
another study, to investigate the association of tumour grade with the risk of 
recurrence of the disease and to compare the histological grade with gene 
expression grade, 64 ER+ carcinomas were considered using a 97 gene signature. 
Clinical outcomes such as RFS and distant metastasis-free survival (DMS) were 
investigated with a gene expression grade index. It was observed that RFS was 
more strongly associated with gene expression grade than the histological grade 
(Sotiriou and Desmedt, 2006, Sotiriou and Pusztai, 2009). 
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1.4. Breast cancer heterogeneity 
 
Breast cancer exhibits diverse heterogeneity in pathological, molecular and 
clinical parameters. Calza et al. had classified tumour samples by considering 
clinical factors such as age at diagnosis, tumour size, tumour grade, lymph node 
status, receptor status, hormone replacement therapy and expression of p53 
mutation (Calza et al., 2006). They observed breast cancer tumour classification to 
be closely related to ER status. ER positive protein expression was observed in 
luminal A, luminal B and normal-like tumours. Basal-like and ERBB2+ tumours 
expressed high ER negativity. Younger pre-menopausal women were found in the 
basal subgroup with tumours having a high grade (Elston grade) and being 
genomically unstable. Furthermore, the majority of basal tumours had a p53 
mutation and most of the patients were present or former hormone therapy users. 
ERBB2+ tumours were observed in elderly patients having a very high grade, a 
large tumour size, with p53 mutation and almost 70% patients showing ER and 
PR positivity. 
The luminal B group showed a similar complex pattern as the ERBB2+ 
group, but with a less aggressive nature. The development of metastasis in the 
luminal B group with respect to tumour size and the receptor status was low, 
though a grade of III was observed. Luminal A tumours on the other hand were 
found in post-menopausal women with a smaller tumour size. These were 
genomically more stable, of lower grade and with wild type p53 expression. Very 
few patients in this group used hormone replacement therapy. Considering 
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prognosis it was observed that ERBB2 expressing tumours had the same poor 
outcome as tumours expressing cytokeratin 5 and 17 of the basal type. Worst 
recurrence free survival was observed in ERBB2+ tumours. Luminal B had a 
lower survival compared to the luminal A and normal-like group which had the 
best prognosis when treated with endocrine treatment. However, for the untreated 
patients the basal-like subgroup shared its survival pattern with luminal B and 
ERBB2+ expressing tumours. 
Another system was developed by Farmer et. al. (2005), classifying breast 
cancers by the presence of the androgen receptor (AR) and androgen signalling 
pathway in an negative ER cohort (Farmer et al., 2005). These were called as 
molecular apocrine containing tumours outside the basal group (Doane et al., 
2006). This group is defined by ERBB2 amplification along with genes like AR, 
SPDEF, FOXA1, XBP1, CYB5, TFF3, NAT1, APOD, ALCAM and AR presenting 
activation and response to the androgen signalling pathway. 
Herschkowitz et. al. through their study in murine models identified a gene 
subset of claudin low expression as a biologically different entity with 
characteristic of stem cells (Herschkowitz, 2010). This was observed to belong to 
metaplastic tumours with altered PI3K/AKT pathway; hormone receptor negative 
and low levels of ER associated GATA3 regulated genes and enriched with cell 
adhesion markers associated to stem cell function and epithelial mesenchymal 
transition (Hennessy et al., 2009).   
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Thus, from the above studies it was certain that transcriptional and genomic 
alterations differentiate tumour subtypes, suggesting that these aberrations could 
arise from transformed progenitor or stem cells possessing distinct biological 
properties (Sotiriou and Pusztai, 2009). It was observed that almost all cancers 
show BRCA1 mutations, irrespective of them being sporadic or hereditary 
possessing a basal like triple negative (ER-, PR-, HER2-) phenotype associating 
with poor prognosis and response to treatment. Luminal A tumours are low grade, 
indolent, and respond to therapy, while luminal B, ERBB2+ and ER-ve tumours 
show incomplete response to endocrine treatment. Aggressive ERBB2+ tumours 
show sensitivity to an anti-HER2 monoclonal antibody, Trastuzumab, while 
similar basal-like tumours show sensitivity to chemotherapy. 
The additional clinical value of the molecular classification and the tumour 
grade is limited by close association of the ER, PR and HER2 receptors. Since the 
molecular classification is able to provide molecular differences underlying the 
phenotypic expression of breast cancer which can enable revelation of new 
treatment targets, improvement in clinical trials is being witnessed. Detection of 
androgen receptor pathway in ER and PR negative tumours, DNA repair pathways 
in BRCA1 and BRCA2 mutation carriers and basal subtype by molecular studies 
also provide a new direction for future studies (Sotiriou and Pusztai, 2009). 
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1.5. Biomarker identification in breast cancer 
 
Biomarkers can be the indicators of biological, pathological and 
pharmacological responses of a therapeutic intervention. They can provide 
prognostic or/and predictive information regarding the therapy, which can be 
characteristically measured and evaluated from body fluids like urine, plasma and 
blood or by invasive techniques with tumour tissue samples by 
immunohistochemistry (IHC) or custom gene expression arrays. The clinical 
usefulness of a biomarker depends on the relative and absolute difference between 
marker positive and negative states enabling to explore treatment options to treat a 
particular disease (Andre and Pusztai, 2006, Dowsett and Dunbier, 2008, Duffy, 
2005, Oldenhuis et al., 2008).  
 
1.5.1. Predictive and Prognostic biomarkers in breast cancer 
 
Predictive markers are the set of markers which quantify the response of 
disease in terms of specific treatment’s sensitivity or resistance (Duffy et al., 
2011).  Different breast cancer subtypes show varied responses towards a 
particular therapy, making it impossible to have a common treatment regimen for 
all cancer types. For any given cancer type, it is likely that only a small group of 
the patients will benefit from the systemic treatment and some are likely to suffer 
from the severe side effects of the adjuvant therapy (Shapiro and Recht, 2001). 
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Hence, predictive markers play a vital role in the determining the likelihood of 
patient response to a treatment in advance. 
Candidates of predictive biomarkers in breast cancer are; 
 Topoisomerase II alpha is considered as an important marker for response to 
anthracycline and other cytotoxic drug therapy (Dowsett and Dunbier, 2008). 
 As marker for monitoring advance cancer therapy, Carcinoembryonic Antigen 
(CEA) and tissue peptide antigen (TPA) are helpful. 
Prognostic biomarkers provide information regarding disease outcome 
irrespective of the therapy. Generally, ER and PR have both predictive and 
prognostic importance as markers of endocrine and chemotherapy treatment. 
Overexpression of HER2 has established itself as a predictor of response to 
trastuzumab therapy or targeted antibody based therapy in response to Herceptin, 
whereas ER and HER2 as a pair are considered as positive and negative indicators 
of chemotherapy benefits respectively. 
Candidates of prognostic predictive biomarkers in breast cancer are; 
 As markers for prognosis assessment, traditional clinical factors like tumour 
size, tumour grade and lymph node status are important. 
 Overexpression of non-histone protein Ki67 and proliferating cell nuclear 
antigen (PCNA), tyrosine kinase 1 (TK1) are important markers for 
proliferative activity with response to chemotherapy and have prognostic value 
in node negative tumours. 
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 Tumour growth factor (TGF) alpha and epidermal growth factor receptor 
(EGFR) as transcription factors serve as oncogenic markers. 
 Overexpression of vascular epithelial growth factor (VEGF) as markers of 
angiogenesis. 
  As markers for risk assessment in breast cancer, the germline mutations in 
BRCA1 and BRCA2 has been showed to have a strong association with 
tumorigenesis with hereditary and familial history. 
 p53 as a cell cycle regulator whose accumulation represents cell signalling 
disorder. 
 Overexpression of Bcl2 and imbalance of Bcl2/Bax ratio in cytoplasm as 
apoptotic activity initiators as apoptotic markers.  
 Overexpression of oncogenic c-myc, loss or TGF-β II receptor and retinoic 
acid receptor alpha (RARA) as markers of cellular differentiation. 
 Biological prognostic markers include uro-plasminogen (uPA) and its inhibitor 
PAI-1, E-cadherin as metastatic markers. 
 A 62 gene signature developed by Yu et. al., called as Nottingham Prognostic 
Index (NPI) is a widely used clinicopathological staging system in breast 
cancer prognostication (Yu et al., 2004). 
There is an ever increasing number of identified contender biomarkers 
involved in the overall molecular and cellular events that take place in the breast 
cancer genesis and prognosis. However, the known markers and their 
relationships in breast cancer development are still unclear. As a result, the use of 
traditional quantitative techniques of receptor binding assays such as Enzyme 
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Linked Immuno Sorbant Assay (ELISA) and IHC becomes non-economic and 
laborious if one need to investigate multiple markers in limited precious samples.  
Recently, the usefulness of biomarkers accounted with breast cancer stem 
cells, addressed the need for the improvement in experimental designs and 
methods to detect biomarkers in clinical samples, work done by Golmen-Polar et. 
al. has validated their utility as predictors of the disease outcome, propensity for 
metastasis and response to treatment (Gokmen-Polar et al., 2011).  
Developing genomic technologies have helped in the discovery of new 
potential markers and gene expression signatures which provide predictive and 
prognostic information of tumours (Dowsett and Dunbier, 2008). Simultaneous 
advances in the field of microarrays, micro fluidics and nanoparticles have opened 
a huge potential for the researchers to quantitatively estimate the expression of 
thousands of markers in minimal samples. One such high throughput advance is 
the field of gene expression estimation is based on transcriptomic microarrays. 
 
1.6. Gene expression profiling 
 
Gene expression profiling is a branch of molecular biology, wherein the 
quantitative expression of thousands of genes is carried out simultaneously, to 
create a comprehensive depiction of cellular process and function. The gene 
expression profiling, apart from its vast uses in different fields of biosciences, is 
extensively used in oncological studies.   
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1.6.1. Microarray 
 
Microarrays comprise a grid of thousands of DNA spots (probes) attached to 
a solid substrate (usually a glass slide) in an orderly manner. Each spot contains 
millions of copies of identical DNA molecules (cDNA/genomic/oligonucleotides 
short sections) specific to given gene. The spots are printed on the slide by 
photolithographic synthesis (Lipshutz et al., 1999) or by piezoelectric (bubble jet) 
process (Okamoto et al., 2000).  
Microarray technology, used in monitoring genome wide expression levels 
of genes in a given organism, has become an indispensable tool for biologists 
(Cooper, 2001). 
 
1.6.2. Principles 
 
Microarrays are commonly used for comparing expressions of a set of genes 
from cells maintained in a particular condition (tumour/diseased) to the same set 
of genes from a reference cell maintained in normal condition (normal). Figure 2 
illustrates the general steps involved in a microarray experiment setup. 
Firstly, the process of cDNA probe preparation involves total mRNA 
extraction from the samples (both tumour and normal) and Reverse Transcription-
Polymerase Chain reaction (RT-PCR) for the production of cDNA clones. These 
cDNA clones are then labelled with fluorescent dyes, usually Cy3 (green) for 
normal sample and Cy5 (red) tumour sample, to distinguish sample conditions. 
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Later, these fluorescently tagged cDNA probes are hybridized on to microarrays 
by taking equal amounts of nucleic acid contents from both sample conditions. At 
this point, cDNA probes in the sample will hybridize to specific spots on 
microarray containing its complimentary sequence. Repeated washes are done to 
remove non-specific binding of probes. The amount of cDNA bound to a spot will 
be directly proportional to the initial number of RNA molecules present for that 
gene in both samples. Later, a suitable wavelength of laser is used to excite and 
detect the red and green fluorescent dyes. The amount of fluorescence emitted 
upon excitation corresponds to the amount of the bound nucleic acid (Murphy, 
2002). 
 
Figure 2: Schematic representation of Microarray technique. Representation of 
various steps involved in the microarray working and methodology. Microarray 
experimental design involves cDNA probe preparation and differential labelling 
with fluorescent dyes, simultaneous hybridization of both samples with microarray 
and scanning for the signals.  
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For instance, if cDNA of a particular gene from tumour was in greater 
abundance than that from normal sample, one would get the spot in red colour and 
conversely, the spot would be in green colour. If the gene was expressed in equal 
extent in both conditions of sample, the spot would be in yellow and if the gene 
was not expressed in both conditions, the spot would be black. 
Lastly, the image analysis of microarray would incorporate high resolution 
image capture by using charge-coupled device camera of each spots which 
corresponds to a gene has an associated fluorescence value representing the 
relative expression level of that gene.  
 
1.6.3. Applications of microarray in breast cancers 
 
Use of cDNA expression microarrays in breast cancer is ever increasing. 
Significant usage started with the identification of distinct gene expression 
patterns defining breast cancer subtypes (Perou et al., 2000). Later they were 
successfully used to distinguish cancers associated with BRCA1 and BRCA2 
mutations (Hedenfalk et al., 2002, Sorlie et al., 2001), to determine ER status 
(Gruvberger et al., 2001, Perou et al., 2000, van 't Veer et al., 2002), and to 
determine lymph-node status (Ahr et al., 2002, West et al., 2001). Numerous 
further milestones have been achieved.  
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1.6.4. Limitations 
High throughput data structures from the biological experimental setups 
poses three limitations; Firstly, the data being highly non-linear. Simple linear 
methods have proveed to be inefficient in classifying samples compared to non-
leniear methods (Lancashire et al., 2010). Secondly, the data points are highly 
multivariate comprising of multiple varaibles (genes) per sample. Thridly, the data 
possesses high dimensionality. 
Although high-throughput technologies carry high expectations, they have a 
few disadvantages too. Their inherent problem is their massive data structure 
making simple correlation and linear regression statistical methods impossible to 
deal with the aspect of dimensionality of the data, hence, the “curse of 
dimensionality” as coined by Bellman (Widrow and Hoff, 1960).  
Simultaneous investigation of tens of thousands of genes with a lack of 
standardised analytical steps for conversion of enormous amount of noisy data 
points into reliable and interpretable biological information can be troublesome 
(Simon, 2003).   
Conventional statistical approaches, with simple linear functions and 
correlational methods, are unable to address the non-linearity and high dimension 
in data points. The aggregation of non-linearity, reproducibility and 
dimensionality of high-throughput biological data, therefore poses challenges for 
the bioinformaticians to develop algorithms to tackle the inherent problems 
(Lancashire et al., 2009). In addition, the combined biological variability 
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commonly found in biological samples, makes it difficult to identify key features 
within biological datasets. Hence, machine learning approaches have been 
exploited and extensively used to address the problems. 
 
1.7. Machine learning for biomarker identification 
 
Machine learning is a branch of artificial intelligence, a scientific discipline 
concerned with the design and development of algorithms that allow computers to 
learn characteristic patterns based on the empirical data. As defined by Tom 
Mitchell, “a computer is said to learn from experience with respect to some class 
of tasks and performance measure, if its performance at tasks as measured by 
performance improved with experience” (Mitchell, 1997). 
Machine learning algorithms are classified as unsupervised learning, 
supervised learning, or reinforcement learning methods based on the desired 
output. 
 
1.7.1. Unsupervised machine learning approaches 
 
Unsupervised learning is a type of machine learning wherein the desirable 
output are not labelled. The machine is made to learn from the intrinsic 
characteristic patterns of input variables only. In other words, in the biological 
data instance, by learning the patterns in the variables, the algorithm classifies 
samples in to desirable classes.  
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1.7.1.1. Clustering methods 
Clustering is an unsupervised machine learning approach used to classify 
data into groups with similar patterns that are characteristic to the features or 
variables. For instance in this clustering machine learning nomenclature we refer a 
gene or a sample as an Object and a set of objects having similar pattern as a 
Cluster. Clustering methods can be Hierarchical or Non-Hierarchical (Tefferi et 
al., 2002). 
HIERARCHICAL CLUSTERING 
Hierarchical clustering is a method of cluster analysis wherein the data 
patterns are clustered based on the specific relationships of the features of clusters 
resembling a phylogenetic tree. Hierarchical clustering can be of 
Aggregative/Agglomerative or Divisive method. Figure 3 illustrates the general 
flow of analysis. 
 
 
 
Figure 3: Schematic representation of Hierarchical Clustering method. 
Aggregative and Divisive Hierarchical clustering methods. Arrows indicates the 
direction of analysis process.  
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Aggregative/Agglomerative Hierarchical Clustering: 
In Aggregative/Agglomerative hierarchical clustering method, clustering 
starts with an assumption that each object is a cluster. All the objects are 
subsequently merged into a single cluster based on the similarities of their 
pairwise distant measures, calculated in an iterative manner. This can then be 
represented in the form of a dendogram, where the distance from the branch point 
corresponds to the distance between the clusters (Tefferi et al., 2002). 
Divisive Hierarchical Clustering: 
Divisive hierarchical clustering, is contrary to aggregative/agglomerative 
clustering, starts with an assumption that all objects form a single cluster. Later, 
this is broken down into two or more clusters that have similar patterns. The 
divisive process is then repeated iteratively until all objects have been 
successfully separated (Chidananda and Ravi, 1995). 
Hierarchical clustering methods in biological transcriptomic data mining 
context are extensively used to build genes of coexpression i.e., genes with related 
expression patterns, assuming that such groups contains functionally related 
proteins such as enzymes for a specific pathway (Stryhn and Christensen, 2013).  
NON-HIERARCHICAL CLUSTERING 
In non-hierarchical clustering methods, the data patterns are clustered 
without specifying the relationships of the features of the clusters. This method 
still requires a predetermination of the number of input clusters. 
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1.7.1.2. K-means clustering 
 
The principle of K-mean clustering method arbitrarily groups objects into 
predetermined number of clusters (Initialization). The centroid-average expression 
profile of each cluster (Iteration) with respect to other clusters is then taken in an 
iterative manner for a fixed number of times (Convergence). The result is the 
convergence state where the composition of clusters remains unaltered by further 
iterations, usually 20,000-100,000. This form of non-hierarchical clustering 
method has become popular with its advantage of being scalable for large datasets 
(Khan and Ahmad, 2004). K-means clustering methods are used in various fields 
ranging from computer vision (Mignotte, 2008) to agriculture (Baskar et al., 
2010).  
   
1.7.1.3. Self-Organising Maps 
 
Self-Organizing Maps (SOMs) are also called as Kohonen maps (Kohonen, 
1990). The working of SOM starts from choosing the number and orientation of 
the clusters with respect to each data points i.e., during the initialization step, a 
grid of nodes is projected onto the expression space and each data point is 
assigned its closest node. Then, one data point is chosen at random and the 
assigned node is moved towards it, simultaneously moving all other data points 
depending on how much closer they are to the selected data point. The iteration 
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step is continued for fixed number of times or until the convergence is attained. 
SOMs are extensively used in data exploration (Stryhn and Christensen, 2013).  
 
1.7.1.4. Principle component analysis 
 
The principle of Principle Component Analysis (PCA) is to redistribute the 
data space of samples into a new data space (defined as Principle Component) 
depending of the variance among samples. These principal components are 
orthogonally arranged linear combinations of the original variables identified by 
the method and that can explain most of the variance, due to redundancy of 
information in the original data space (Raychaudhuri et al., 2000). PCA is usually 
considered as a tool for data reduction to tackle the issue of high dimensionality 
among biological data sets (Raychaudhuri et al., 2000). 
 
1.7.2. Supervised machine learning approaches 
 
Supervised learning is a type of machine learning wherein the desirable 
output(s) are labelled. The machine is made to learn from the intrinsic 
characteristic patters of the input variables together with a comparison of the 
actual current output and the desirable output. Here, some of the common 
supervised learning methods are mentioned. 
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1.7.2.1. K-Nearest Neighbours 
 
K-Nearest Neighbours (K-NN) are popular for their non-parametric simple 
classification characteristic wherein an expression profile of known class sample 
is compared with an unknown. The processes involves the assessment of gene 
expression profiles of samples, identification of nearest neighbours depending on 
the applied distance measurement (usually Euclidian) and finally determining the 
class of the unknown sample by its nearest neighbour’s class. (Vadrevu and 
Murty, 2010, Xiong and Chen, 2006). The limitations to this approach is the 
assumption that similar variables, being equally relevant, will have similar 
classifications becomes computationally complex as the number of variables 
increases (Cruz and Wishart, 2007). K-NN method with their varied applications, 
have been recently used in classification of microarray data (Parry et al., 2010).  
 
1.7.2.2. Linear-discriminant analysis 
 
Linear Discriminant Analysis (LDA) uses an approach of subgrouping the 
data by calculating the best splitting optimal linear line between populations. The 
whole process depends on the inter-sample and inter-group variability, giving it an 
added advantage to outperform when compared with other linear classification 
methods. However, LDA performs poorly on non-linear real-world biological data 
sets, with the major application being in the field of language analysis, image 
analysis and face recognition (Haykin and Gwynn, 2009). 
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1.7.2.3. Support Vector Machines   
 
Support Vector Machines (SVMs) are a learning paradigm based on finding 
the equation for an optimal line which can maximally separate the classes, thus 
creating a hyper-plane from the data points which maximises the difference 
between them. In this high-dimensional space, an appropriate (linear/non-linear) 
separator, such as a kernel function can be applied to calculate the scalar product 
of the data points (Dreiseitl et al., 2001).       
Among the supervised learning methods, K-NN has been shown to have 
good classification performances for a wide range of real-world data (Xiong and 
Chen, 2006). Miller and co-workers have compared the performances of K-NN, 
SVM and LDA supervised algorithms for the prediction of p53 status in breast 
cancer datasets (Miller et al., 2005). According to them, in spite of higher 
prediction accuracies (89.4% and 85.7%), K-NN performed with slightly higher 
specificity (95.3%) than that of SVM (94.3%) and LDA (84.0036%). 
Apart from above mentioned basic supervised and unsupervised machine 
learning methods, the following methods are also used for specific applications in 
pattern recognition:- 
Decision trees are simple predictive models which maps the conjunction of 
features (branches) to classification (leaves) and explicitly represents structured 
graph or flow-charts for decision and decision making (Mitchell, 1997). These are 
used in machine learning and data mining to predict the value of a target variable 
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based on several input variables. Decision trees are also called Classification 
Trees or Regression Trees. 
Bayesian Networks are a probabilistic graphical model representation 
wherein the association between a set of variables (symptoms) and their 
conditional independencies (disease) is investigated. The classification is based on 
the posterior probability of an event (Jiang et al., 2011). Due to its probabilistic 
nature, Bayesian networks are also called Belief Networks or Acyclic Networks. 
Genetic algorithms are a branch of artificial intelligence wherein a 
heuristic search is applied to mimic the process of natural evolution. A genetic 
algorithm is applied to optimise a population of solutions depending on the 
relation between genotype and reproductive success of an organism, inspired by 
genetic inheritance, crossover, mutation and natural selection (Muni et al., 2006). 
Collectively, genetic algorithms represent an evolutionary programming field 
called Genetic Programming. 
 
1.7.3.  Reinforcement machine learning approach 
 
Reinforcement learning, unlike supervised learning, is a strategy of 
exploration by exploitation of current knowledge is applied and input/output 
relationship is unknown. The characteristic feature of reinforcement learning is 
the ability of online-learning i.e., the programme learns from the environment and 
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optimises itself to the inputs provided to enhance the performance of output 
(Nikolic and Fu, 1986). 
Microarray data being highly complex with non-linear nature (reference) 
and high dimension 
Furthermore, artificial neural networks are a method that has been 
exploited in the field of pattern recognition and biological data analysis, as 
detailed further in Chapter 2.  
 
1.8. Databases and gene signatures using machine 
learning 
 
The implication of microarrays in breast cancer diagnosis and prognosis has 
also facilitated the use of gene signatures corresponding to particular disease state. 
In a classical gene signature study in breast cancer, a 70 gene prognostic signature 
has been developed by using 78 lymph node negative breast cancer patients by 
van’t Veer et al. (van 't Veer et al., 2002). The work has been further validated by 
van de Vijver et al. on a bigger cohort of 295 lymph node positive and negative 
samples treated with adjuvant therapy along with control non-treated breast cancer 
samples (van de Vijver et al., 2002). Later in 2005, another 76 gene signature for 
distant metastasis  was applied using 115 samples for training and 171 samples for 
validating on lymph node negative breast cancer patients (Wang et al., 2005). The 
76 gene signature was further validated by Foekens et al. on a multi centric cohort 
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of 180 lymph node negative patients who were untreated for adjuvant therapy 
(Foekens et al., 2006). Furthermore, the van’t veer and Wang studies have been 
independently validated on 302 breast cancer patients from 5 different centres 
within the TRANSBIG project (Buyse et al., 2006, Desmedt et al., 2007). Table 1 
summarizes some of the popular studies done by various groups to study different 
aspect of breast cancer using microarrays. 
Simultaneously, the use of microarrays and high throughput technology like 
mass spectrometry has equally contributed for the advent and experimentations in 
their high dimensional data. Computational researchers and statisticians have used 
various methods and models for analysis of high-throughput data. 
Table 1: Summary of the breast cancer microarray studies. 
Study Year Class Method 
No. Of 
samples 
Gene 
panel 
West et al.  2001 Oestrogen receptor  Bayesian regression  49 40 
Vijver et al.  2002 Distant metastasis  SC with clustering  248 70 
vant Veer et al.  2002 Survival  SC with clustering  117 70 
Minn et al.  2005 Distant metastasis  HC  62 48 
WangY et al.  2005 Distant metastasis  MCR  286 76 
Buyse et al.  2006 Survival  MCR  198 76 
Chin et al.  2006 Transcriptional Aberrations  MCR  145 9 
LiuQ et al.  2009 Pathological complete response  NBC, NMSC  278 34 
 
Popular breast cancer microarray datasets from 2001 to 2009. 
(Abbreviation: SC=Supervised clustering; HC=Hierarchical clustering; 
MCR=Multivariate Cox Regression; NBC=Naïve Bayes Classier; NMSC=Nearest 
mean scale classier). 
 
1.9. Challenges for biomarker identification 
 
In medicine, biomarkers are the measurable indicators of a particular disease 
state, progress of disease or the effect of treatment. Biomarkers could be a 
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biomolecules such as proteins or enzymes or even genes. The characteristic 
differential expression of a gene between the diseased state and normal state of 
samples could serve as a marker. Enormous efforts have been made from high- 
throughput transcriptomic data to identify biomarkers characteristic for specific 
diseases. As a result, it is well known that trying to find a single biomarker or a 
gene responsible for the complex disease such as breast cancer is inappropriate. A 
combination of genes or gene signatures in association may give more 
information about the behaviour of the disease. As the number of investigative 
genes increases, the needs for faster computational and statistical approaches 
arise.  Hence, machine learning approach such as Artificial Neural Networks has 
been exploited and will be the focus of following chapter. 
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Chapter 2 
ARTIFICIAL NEURAL NETWORKS 
 
 
Chapter abstract: An Artificial Neural Network (ANN) is a computational 
machine learning approach inspired by physiological working of biological 
neuron. The basic perceptron model incorporates products of inputs and weights, 
which are then processed with a threshold function to mimic the output of samples 
in training. The perceptron model is advanced with the use of multi-layer 
perceptron (MLP) network. The training of the MLP model incorporates back 
propagation of error algorithm for the update of weights. Computational 
researchers have developed various variants of ANN. In this study, we have used 
an in-house developed, Stepwise-ANN model for classification of biological 
samples. 
 
2.1 Introduction 
 
Artificial Neural Networks (ANNs) are a branch of machine learning 
inspired by the working of a human brain. They are characterised by high 
complexity, non-linearity and with parallel information processing abilities. ANN 
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is also a computational machine designed to model or classify in a way in which 
human brain performs a particular task or function. 
“A neural network is a massive parallel distributed processor made up of simple 
processing units that has a natural propensity for storing experimental knowledge 
and making it available for use”- (Haykin and Gwynn, 2009).  
 The basic structural units of human brain are the neurons which are inter-
connected in a systematic manner for efficient transfer and processing of 
information. Neurons have the feature of plasticity - adaptation to surrounding 
environment (Churchland and Sejnowski, 1994). Likewise, artificial neurons form 
the basic units of computational neural networks and are able to adjust their 
internal weights in order to optimise the network outputs for a given training set.  
 
2.2 Biological neural networks 
 
The brain is the central part of nervous system comprising a massive neural 
network of approximately 10 million neurons in the cerebral cortex region in  
humans (Pascual-Leone et al., 2005). One end of the network consists of the 
receptors which receive external stimuli or information and pass it on to the 
neuronal network which continually receives and processes the information. 
Processed information then travels to the other end of the network, the effectors 
which exhibit appropriate response to the processed information. The whole 
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process of information transmission is a forward process with the scope for 
feedback between the contenders.  
 The interactions between the neurons are controlled by Synapses through 
chemical reactions which can induce an excitation or inhibition, but not both, of a 
subsequent neuron. At a synapse, a presynaptic input (electrical signal) releases a 
transmitter substance (chemical signal) which diffuses across the synaptic 
junction between neurons to produce a postsynaptic output (electrical signal). In a 
biological neuron, the Axons acts as transmission lines and Dendrites as receptors 
for the impulses. Together they constitute a neural microcircuit. With this 
neurobiological analogy as the source of inspiration, ANNs have emerged as an 
efficient machine learning tool. 
 
2.3 Historical background 
 
The history of ANNs starts from the preliminary efforts of 
neurophysiologists and neuro mathematicians to model the working of a 
biological neuron during the late 1900s. Neuroscientists Warren S. McCulloch 
and Walter Pitts first described a mathematical function with simulated bias 
function as an artificial neuron, called the Threshold Logic Unit in 1943 
(McCulloch and Pitts, 1943). Later in 1958, the psychologist Frank Rosenblatt 
formulated the concept of the “Perceptron” in an attempt to describe perception 
(Rosenblatt, 1962). The perceptron (along with the artificial neuron) with its 
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ability of learning based on weighted connections between neurons, forms the 
basis for today’s advanced neural network architectures (Rojas, 1996). 
This theory of perceptron led to a formation of whole new field of learning 
methods and concepts in perception and classification. Simultaneous advances in 
Artificial Intelligence, and recognition of the limitations of perceptron methods, 
led to the diversification of interests of researchers from neural networks to 
artificial intelligence (Basheer and Hajmeer, 2000).  
The interest in ANN among the research community reappeared when the 
Back-Propagation (BP) algorithm adopted from Delta rule of Widrow and Hoff, 
was published by Rumelhart, Hinton and Williams (Rumelhart et al., 1986, 
Widrow and Hoff, 1960). The BP algorithm offered an output error correction 
strategy wherein the successive correction of weights was based on the errors 
generated in classification during training. The learning algorithm produces 
accurate classification prediction. ANNs, inspired by mechanisms of information 
processing thorough a neuron, have been applied with success in various fields of 
sciences such as physical, chemical, astronomical, agricultural, biological etc. 
 
2.4 Artificial neurons: structure and architecture 
 
2.4.1 The perceptron 
 
Perceptrons, coined by Rosenblatt, are the simplest form of the neural 
networks consisting of a single neuron with threshold activation function along 
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with adjustable synaptic weights and bias (Rosenblatt, 1962). These processing 
elements can be regarded as the basis functions of a generalised linear 
discriminant used for the classification of patterns said to be linearly separable. 
An algorithm is applied in a learning procedure to adjust the free parameters of 
the neural network. Rosenblatt, in Perceptron convergence theory, proved that if 
the patterns used to train the perceptron are drawn from two linearly separable 
classes, then the perceptron algorithm converges and positions the decision hyper 
plane between the two classes. A schematic representation of a single layer 
perceptron is represented in Figure 4. 
 
 
 
Figure 4: Schematic representation of single layer perceptron model. The 
number of input neurons is equal to the number of input variables, correspondingly 
equal number of weights. All the weights are passed on to the hidden neuron along 
with a bias. Activation function acts as a squashing function to scale-down the 
prediction. 
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 If the inputs of the perceptron are x1, x2,.…, xm, external bias applied as b 
and the corresponding synaptic weights are w1, w2,…, wm, then the applied hard 
limiter (φ) is given by; 
   ∑      
 
   
 (Equation 2.41) 
Activation function: Activation function introduces non-linearity into the neural 
processing. Some commonly used activation functions are: Logistic sigmoid 
function and Hyperbolic tangent function.  
A Logistic sigmoidal function is the most common activation function 
used to model the ‘S-shape’ behaviour of the data. The Hyperbolic tangent 
function is defined as the ratio between the hyperbolic sine and the cosine 
functions. 
Sigmoid function:  ( )  
 
     
 (Equation 2.42) 
Tangent function:     ( )  
    ( )
    ( )
 
      
      
 (Equation 2.43) 
where x is the data point and e is the Euler’s number which is the base of the 
natural logarithm. These functions are widely used because their derivatives are 
easy to compute and can be expressed directly as a function of the net input 
(Shenouda, 2006).  
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Feedforward mechanism: The feedforward neural network algorithm was the 
first and perhaps the simplest type of artificial neural network algorithm  
developed (Widrow and Hoff, 1960). In this network, the information moves in 
only one direction, i.e., forward, from the input nodes to the output nodes without 
any cycles or loops in the network. 
A major limitation of single layer perceptrons is that they are limited to the 
classification of linearly separable patterns. To overcome this practical limitation, 
multilayer perceptron models were developed. 
 
2.4.2 Multilayer perceptron 
 
 Multilayer perceptron (MLP) neural networks comprise multiple 
perceptrons existing in multiple layers. The network exhibits a high degree of 
connectivity which is determined by the extent of the synaptic weights of the 
network (Haykin and Gwynn, 2009).   
The basic multilayer perceptron representation can comprise of three or 
more layers namely; a layer consisting of input nodes as Input layer, output 
nodes as Output layer and a sandwiched Hidden layer. Each node of any layer is 
connected with the every nodes of the previous layer representing a fully 
connected architecture. In a multilayer perceptron, the hidden neurons in the 
hidden layer play a crucial role, acting as feature detectors. As the learning 
process continues, hidden neurons gradually map salient features that characterise 
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the training data by a process of nonlinear transformation of input data into 
feature space where pattern-classification may be more easily carried out. Indeed, 
it is this feature space which distinguishes multilayer perceptrons from 
Rosenblatt’s single layer perceptrons. Figure 5 gives a schematic representation of 
multilayer perceptron model.  
 
2.4.3 Back-propagation algorithm 
 
In a MLP network, if an output neuron produces an incorrect classification, 
the derivatives of the error with respect to the weights can be evaluated and can be 
used to minimise the error function.  
 In order to minimise the error function of weight values in the back-
propagation learning method, update of the weights at each and every weight 
vectors of the previous layer for every node has to be accomplished. This rule is 
famously known as the Delta rule or Least Mean Square method (Widrow and 
Hoff, 1960). The delta rule for a perceptron can be stated as      
       (     )   (Equation 4) 
where Δw is the weight difference,   is the learning rate (described in 
detail in Section 2.5.2), tj as the target vector and yi as the input vector. 
To evaluate the derivatives of the error function, Rumelhart et al 
developed an algorithm called the Back-Propagation algorithm (Rumelhart et 
al., 1986), illustrated in Figure 6. 
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Figure 5: Multilayer Perceptron (MLP). Schematic representation of MLP with 
single layer of hidden layer. Each node at input layer corresponding to the total 
number of variables connected with weights. Computational mechanism at hidden 
and output layer is also depicted in the figure. 
 
 
 
 
Figure 6: Illustration of Error back-propagation. A schematic representation of 
Error back-propagation algorithm. The actual output of the model is compared with 
the desired output and the error generated is back-propagated to alter the weights 
corresponding to the output. 
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2.4.4 MLP training 
 
The training process is the most crucial process in a learning algorithm 
where the machine learns the pattern of the data through the inputs and 
generalises the parameters for a global predictive performance.  
Consider a multilayer perceptron consisting of source nodes at the input 
layer, one or more nodes at the output layer and one or more hidden layers. Let 
yj(n) denotes the function signal produced at the output of the neuron j in the 
output layer by the stimulus x(n) applied to the input layer. Correspondingly, the 
error produced at the output of neuron j is define by:- 
   ( )    ( )    ( ) (Equation 5) 
where dj(n) is the j
th
 element of desired response vector and yj(n) is the j
th
 element 
of output vector. 
The instantaneous error (E ) of neuron j is defined as 
    ( )  
 
 
  
 ( ) (Equation 6) 
The Total instantaneous error at all the neurons in the output layer (C) will then 
be 
  ( )  ∑  ( )  
 
 
   
∑  
 ( )
   
 (Equation 2.47) 
Over a training set of N samples. The averaged error or the empirical risk can be 
defined as 
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    ( )   
 
 
∑ ( )   
 
  
 
   
∑∑  
 ( )
   
 
   
 (Equation 8) 
   
The goal of the learning process is to minimise the error (the difference 
between the desired output and supervised output). The same phenomena is 
exploited as the Back-propagation algorithm.   
 
2.4.5 Gradient descent algorithm 
 
Gradient descent, also called as Steepest descent, is one of the simplest 
network training algorithms. It is a first order optimisation of parameter algorithm 
for learning machines (Anderson, 1995). There are two versions of gradient 
descent; Batch and Sequential gradient descent. 
In the batch version, the initial learning is carried out following 
randomisation of the weight vectors. Later on, the weight vectors are iteratively 
re-evaluated and updated so that the distance from the gradient is reduced at each 
step i.e., moving in the direction of negative gradient on an epoch-by-epoch basis. 
The advantages of this version include an accurate estimation of gradient vector, 
convergence of the gradient descent to the local minimum and parallelisation of 
the learning process.  
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In the sequential or on-line learning version, the error function gradient is 
evaluated and updated for just one pattern at a time i.e., the adjustment of the 
synaptic weights are done on an example-by-example basis. 
 
2.4.5.1 Escaping local minima with momentum 
 
In a MLP network, with more than one layer of adaptive weights, the non-
linear functionality of the weights will correspond to the error function. Thus, 
there may exist more than one minima in the weight space. The one with the 
smallest value of the error function, defined as ‘Global minima’, compared to the 
others, which are ‘Local minima’. The goal of modelling is to reach the global 
minima. Since negative gradient learning works according to the error surface 
topologies, there may be instances where learning is trapped in a local minima. In 
such situations, very small change in the synaptic weights increases the cost of the 
error function. So trapping the network to address this problem adding an 
appropriate momentum term to the weight vector adjustment can help the network 
escape local minima (Morris, 1993). 
 
2.4.5.2 Generalisation and avoiding over-fitting 
 
Generalisation is the ability of an algorithm to learn the patterns in the 
training data in order to successfully classify unseen data or the neural network’s 
ability to produce a correct input-output mapping. Overfitting is the incorporation 
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of features that are unnecessary for learning patterns of data (Hawkins, 2004). To 
determine if a model has achieved generalisation, the dataset can be split into 
three subsets - a Training set for training the neural net in order to minimise the 
error, a Test set to optimise the stopping criteria of the training in order to prevent 
overfitting of the neural net, and finally a Validation set to determine the 
performance of trained patterns for completely unseen data. Model performance 
on this validation set determines the generalisation ability. 
There are several ways of splitting the dataset. A well-known method is the 
Monte Carlo Cross Validation (MCCV) method wherein the dataset is randomly 
divided into three subsets as training, test and validation subsets respectively (Xu 
and Liang, 2001). 
 
2.5 Optimisation of ANN parameters in predictive 
modelling 
 
2.5.1 Randomisation of initial network weights 
 
The speed of network convergence depends on the choice of initial weights. 
The weight update between the neurons depends on the weight specific derivative 
of the error function and also on the activation values of the neuron. Large weight 
can cause the network too quickly converge to a local minima, whereas small 
weights cause slow network learning (Fausett, 1994). To ensure that the initial 
signal of the hidden or output unit does not fall into the region where the 
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derivative of the sigmoid function is too small, the initial randomised weights of 
the network must not be of too large variance. If the derivative of the sigmoid 
function is small, the weight updates of the hidden or output neurons will be close 
to zero, making learning extremely slow. Thus, random initialisation of network 
weights results in appropriate convergence of the network (Rumelhart et al., 
1986).  
 
2.5.2 Learning rate and Momentum 
 
The back-propagation algorithm facilitates an ‘approximation’ to the 
trajectory in weight space by the gradient descent method. If the learning rate (η) 
is too small, the change in the weights from one iteration to another becomes 
small, resulting in smoother trajectory of weights and improved learning, but at 
the cost of time consumption. On the contrary, if the learning rate is too large, 
large changes in the weight results in unstable or oscillatory network. Addition of 
a momentum (α) term to the delta rule of learning avoids instability of the 
network as shown below 
     ( )       (   )     ( )  ( ) (Equation 2.59) 
Where Δwji is weight difference, α is momentum constant, η is the learning rate, δj 
is the local gradient and yi is the output signal. 
 The Momentum (α) parameter adds inertia to the movement through 
weight space, smoothing the oscillations of the network and leading to faster 
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convergence towards the global minimum. The optimum momentum range must 
lie between 0 ≤ α ≤ 1. 
 
2.5.3 Hidden layer size 
 
A hidden neuron will not have any specified desired response, but the back 
propagation of error signal needs to be determined in order to update the input 
layer weights. The optimal size of the hidden layer is very crucial. If too few 
hidden units are used, then the network will fail to achieve satisfactory 
performance, whereas too many hidden units will facilitate overfitting giving a 
poor performance on validation dataset. 
In the literature, two approaches to the estimation of the proper size of the 
hidden layer are discussed.  One is to start with a small network and iteratively  
increase the number of nodes in the hidden layer(s) until satisfactory learning is 
achieved, termed as constructive technique (Hernandez-Espinosa and Fernandez-
Redondo, 2002). However, the problems are that these networks are also more 
likely to be trapped in a local minima (Bebis and Georgiopoulos, 1994), and a 
large number of networks must be trained to find the optimum network structure, 
which is time consuming. The second approach is to begin with a larger network 
and make it smaller by iteratively eliminating nodes in the hidden layer(s) or 
interconnections between nodes, termed as Pruning (Kavzoglu and Mather, 
1998). Optimum brain damage, optimum brain surgery and skeletonization are the 
major pruning techniques in use. 
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As documented and shown by Lancashire et al., using two nodes in the 
hidden layer can successfully converge the variance of weights and give a higher 
performance on the validation subset (Lancashire et al., 2009), we have utilised 
the model architecture with two nodes in the hidden layer.  
2.6 Variants of neural network architectures 
 
 Feed-forward Neural Network – The feed-forward neural network was the 
first and arguably most simple type of artificial neural network devised. In 
this network the information moves in only one direction i.e., forward; from 
input nodes to the output nodes through hidden nodes (if any). There are no 
cycles or loops in the network (Bishop and Hinton, 1995). 
 Radial Basis Function Neural Network – A Radial Basis Function (RBF)  
network has a built in distance criterion with respect to a centre. RBFs are 
powerful techniques for interpolation in multidimensional space. These 
neural networks have the advantage of not suffering from local minima in 
the same way as multilayer perceptrons, but have the disadvantage of 
requiring good coverage of the input space by radial basis functions (Aslan 
et al., 2008). 
 Kohonen Self-organizing Neural Network – The self-organizing map is a 
form of unsupervised learning. A set of artificial neurons learn to map 
points in an input space to coordinates in an output space. The input space 
can have different dimensions and topology from the output space and the 
they will attempt to preserve these (Kohonen, 1990). 
Chapter 2: ARTIFICIAL NEURAL NETWORKS 
 
51 
 
 Learning Vector Quantization Neural Network – Learning Vector 
Quantization can also be interpreted as a neural network architecture 
wherein the prototypical parameterisation of classes is represented with an 
appropriate distance measure. Hence, it is a form of distance-based 
classification (Burrascano, 1991). 
 Recurrent Neural Networks – Recurrent neural networks (RNNs) are 
models with bi-directional data flow. Recurrent neural networks can be used 
as general sequence processors. Various types of Recurrent neural networks 
are fully recurrent network (Hopfield network and Boltzmann machine), 
Simple recurrent networks, Echo state network, long short term memory 
network, Bi-directional RNN, Hierarchical RNN, and Stochastic neural 
networks (Williams and Zipser, 1989). 
 Modular Neural Network – Biological studies have shown that the human 
brain functions not as a single massive network, but as a collection of small 
networks. This realization gave birth to the concept of modular neural 
networks, in which several small networks cooperate or compete to solve 
problems (Happel and Murrae, 1994). 
Other Special Types of Neural Networks 
 Holographic associative memory – Holographic associative memory 
represents a family of analogues, correlation-based, associative, stimulus-
response memories, where information is mapped onto the phase orientation 
of complex numbers operating (Khan, 1998). 
Chapter 2: ARTIFICIAL NEURAL NETWORKS 
 
52 
 
 Instantaneously Trained Neural Networks – Instantaneously trained 
neural networks were inspired by the phenomenon of short-term learning 
that seems to occur instantaneously and have been extensively used in web 
based search algorithms (Kak, 1999). 
 Spiking Neural Networks – Spiking neural networks are models which 
explicitly take into account the timing of inputs. The network input and 
output are usually represented as series of spikes (delta function or more 
complex shapes). These have an advantage of being able to process 
information in the time domain (signals that vary over time) (Jin et al., 
2008b). 
 Dynamic Neural Networks – Dynamic neural networks not only deal with 
nonlinear multivariate behaviour, but also include learning of time 
dependent behaviour such as various transient phenomena and delay effects 
(Sinha et al., 2000). 
 Cascade Correlation Neural Networks – Cascade Correlation is a 
supervised learning architecture that begins with a minimal network and 
then automatically trains and adds new hidden units one by one, creating a 
multi-layer structure (Riley et al., 2010). 
 Neuro-Fuzzy Neural Networks – A neuro-fuzzy network is a fuzzy 
inference system encoded within an artificial neural network. Depending on 
the inference system type, there are several layers that simulate the 
processes involved in a fuzzy inference engine i.e., fuzzification, 
aggregation and defuzzification. Embedding an fuzzy inference system in a 
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general structure of an ANN has the benefit of using available ANN training 
methods to find the parameters of a fuzzy system (Kasabov, 2001). 
 Compositional Pattern-producing Neural Networks – Compositional 
pattern-producing networks are a variation of ANNs which differ in their set 
of activation functions and how they are applied. While typical ANNs often 
contain only sigmoid functions (and sometimes Gaussian functions), these 
can include both types of functions and many others (Jin et al., 2012). 
 
2.7 Stepwise ANN approach 
 
ANNs have proven their ability in the field of data-mining and high-
throughput analysis of microarray data. However, one of the major limitation of 
ANNs in high throughput data analysis is the Curse of Dimensionality stated by 
Bellman as “the exponential growth of the input space as a function of 
dimensionality” (Wilcox, 1961). The importance of a particular feature of a gene 
can be hidden amongst the vast amount of other gene expression vectors. This 
occurs when the number of variables is far larger than the number of variables in 
the data. This additional noise from irrelevant inputs in the data space can hinder 
the performance of the model on unknown or validation data (Bishop and Hinton, 
1995). Various pre-processing and data-reductionist approaches such as Principle 
Component Analysis (PCA) are widely used for tackling dimensionality aspect, 
but generalization and feature extraction aspects are still challenging. 
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A Stepwise ANN approach enables identification of patterns within the data 
space by finding the set of individual variables giving the best performance to 
classify the dataset. The learning in the model is attained by an iterative manner 
along with the subsequent addition of variables. Initially the approach uses each 
gene from the microarray experiment as an input for the model. A total of n 
individual models are created, each representing a gene of the dataset. 
Subsequently, all the models are compared and sorted according to their 
predictive performances for the unseen cases from test class of samples. These 
learned weights and model specification are then applied for the further (n-1) 
instances of input facilitating a stepwise-additive features contributing to the 
maximum predictive performance during each iteration. The whole process is 
repeated until no further improvement in predictive performance is seen in the 
model or until the model reaches an optimal level of performance. The overall 
step-by-step events happening during Stepwise ANN training can be summarized 
as below 
 Each variable from the sample data set are assigned as the sole input 
node and used in the model. 
 Each model is trained for 50 times with random reshuffling of samples 
with 60% of the dataset used for training, 20% for testing and the 
remaining 20% for validation using Monte Carlo Cross Validation 
(MCCV) strategy. This random reshuffling of samples produces a more 
generalised model with improved predictive ability of networks for 
unseen cases. 
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 From a separate test subset of samples, the predictions and Mean 
Square Errors (MSE) are recorded for each input model and ranked 
based of their MSE. 
 The input within the model predicting the best is then selected for the 
second step. 
 Subsequently, in the further steps, the input that performed the best in 
the previous run is removed from the input and remaining n-1 inputs are 
used as the basis for the next-input models, every time creating n-1 
models. 
 The process is repeated until no improvement in the network 
performance is seen, or until the early termination threshold is met with 
the test set of samples. 
 
Figure 7 is a schematic representation of stepwise-ANN training. Briefly, 
The architecture of the stepwise ANN consisted of a single hidden layer MLP 
with two hidden nodes using a BP learning algorithm. The learning process is 
halted with an early stopping strategy to overcome over-fitting of the data by 
using a test subset of samples with maximum of 3000 epochs and a minimum 
window threshold of 1000 epochs if no further improvement in learning is seen. 
The BP algorithm was controlled with a learning rate of 0.1 and momentum of 
0.5. The initial weights of the model are set between 1 to -1.  
During this entire Ph.D. work, with some minor modifications, the 
architecture and the generalization settings of the stepwise ANN was maintained 
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as bespoke through an in-house developed and validated stepwise ANN software 
(Lancashire et al., 2009, Lancashire et al., 2008). 
 
 
Figure 7: Stepwise-ANN model. Schematic representation of Stepwise-ANN 
model. The data analysis begin with a random stratification of samples into training, 
test and validation subsets. Feed forward ANN with back-propagation of errors was 
incorporated with Monte Carlo Cross validation strategy. The final ranking of best 
predictive gene for classification uses MSE. 
 
2.8 Interaction algorithm 
 
With the advent of gene expression profiling technologies, many researchers 
have analysed high throughput data for the identification of biomarkers and 
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signatures associated with specific disease or disease state. Others have also 
attempted to decipher the biological pathways. Some methods such as protein or 
gene interaction networks have already been described, among which Bayesian 
based approaches are common (Hartemink et al., 2002). Some have even tried to 
interpret the functionality of the interaction in protein complexes (Shoemaker and 
Panchenko, 2007, Spirin and Mirny, 2003). Karlebach and Shamir in their work 
have focused on gene regulatory network modelling (Karlebach and Shamir, 
2008).  
However, the potential information contained within them is not exploited 
fully. Recently, some researchers have used microarray data to investigate gene 
regulation with respect to particular gene and gene-gene regulation studies in the 
quest for more information. Often, the information concerning the interaction is 
limited and measured from the perspective of the target and not within the 
complete gene set. Moreover, Barabasi and Otva state that “it is increasingly clear 
that a discrete biological function can rarely be attributed to an individual 
molecule” (Barabasi and Oltvai, 2004). Thus, identification of a relevant gene 
signature for each specific disease is seen to be important, with the investigation 
of association between these genes being crucial.  
The limitation of current interaction inferencing approaches are that they 
consider only one, or at best, very few counter-acting genes for the study. The 
interactions between the complete gene set with respect to each other can define 
how a given gene set change in expression subsequently changes the expression of 
other functionally relevant genes.  
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To overcome these limitations, Lemetre et al. has proposed a novel 
approach that considers the interactions of a whole gene set using an ANN trained 
with error back-propagation algorithm and Monte Carlo Cross Validation 
(MCCV) strategy (Lemetre et al., 2009). 
 
2.8.1 Overview of interaction algorithm 
 
This interaction algorithm measures the predictiveness of one gene with 
respect to all the others i.e., it predicts the expression of a single input gene by 
considering all the other genes as inputs, until all the inputs are predicted 
iteratively within the whole gene set. The weights connecting a given input to the 
output is then analysed by taking a sum of the weights leading to the output. This 
effectively represents intensity of the relation between a source (input) and the 
target (output). The predictive performance of the models and weights are 
monitored to represent the interaction vector. The input-output interaction vector 
determines the direction and the value of the weight representing the magnitude of 
the vector. Applying a threshold limit to all these interaction vectors allows a 
researcher to infer the information such as bi or unidirectional, stimulatory or 
inhibitory nature of the interaction. This study progresses upon the former 
methods by allowing direct prediction of association between expressions of 
genes. 
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2.8.2 Interaction model development 
 
The interaction model is based on a bespoke ANN algorithm (Lemetre et al., 
2009). Briefly, the interaction algorithm consists of a three-layer feed forward 
perceptron model trained with the error back-propagation algorithm. The 
activation function used in the hidden and output layer is of sigmoidal nature. A 
two and one node architecture in the hidden and output layers is maintained 
throughout. The learning was performed through 3000 epochs with a termination 
criteria of 1000 epochs without improvement of MSE on the validation subset or 
MSE threshold of 0.1. The momentum and learning rate were set at 0.5 and 0.1 
respectively. Prior to the training, a MCCV strategy was applied for random 
segregation of samples into subsets as fraction of 60:20:20 for training, testing 
and validation respectively. The whole process of training was repeated 50 times 
independently. The weights generated with respect to input-output relation were 
recorded. The input to output connection represents the directionality of the 
association, the value of weights represents the intensity of the association 
between the source and target and the sign of the weight represents the nature of 
the association. By considering the weights with respect to input-output relation, a 
matrix of interactions can be generated. 
 
2.8.3 Filtering 
The matrix of interactions generated represents the association between any 
pair of variables contained in the dataset, producing huge amount of results 
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wherein n number of inputs gives n(n-1) number of associations. Hence, most of 
the associations may be non-significant. Non-significant associations can be 
removed by an arbitrary threshold to select only relevant and significant 
associations (Lemetre et al., 2009). 
 
2.8.4 Visualisation of model 
 
An interaction map of the matrix of interactions is then produced with the 
source and targets being symbolised by nodes, the association between them being 
represented by the edge, the intensity of association by the thickness of the edge 
and an arrow giving the directionality. For the visualisation of interaction maps, a 
freely available visualisation software, Cytoscape
®
 version 2.7.3 was used 
(www.cytoscape.org). 
 
2.9 Comparison of ANN with other methods 
 
In recent years, considerable attention has been given to the development of 
sophisticated techniques for exploring relevant information from datasets. One 
such aspect which has been taken with great concern is classification. In medical 
applications, the goal is often to predict a patient’s outcome based on available 
data. For studies with a binary endpoint (e.g., yes/no, alive/dead), regression 
based methods are used frequently. Daniel Sargent has reviewed 28 studies and 
Chapter 2: ARTIFICIAL NEURAL NETWORKS 
 
61 
 
emphasised the usage of ANN along with other statistical methods such as 
Logistic and Cox proportional hazards regression methods for classification of 
medical data (Sargent, 2001). This review concludes that ANN outperforms 
regression-based methods. 
ANNs have also been compared with logistic regression and SVMs in 
identification of circulatory biomarkers, wherein ANNs outperformed SVMs and 
logistic regression in classification and has confirmed the outperformance of ANN 
over other studied machine learning methods (Lancashire et al., 2010). 
 
2.10 Advantages and disadvantages of ANN 
 
Advantages of ANNs 
 Ease to optimize, resulting in cost-effective and flexible in handling large 
data sets. 
 They can process complex and non-linear data which are difficult by 
conventional linear methods. 
 They can tolerate incomplete and fuzzy data.  
 Based on their training tends, they can generalize and predict the future 
outcome of even a completely new test sample. 
 With their reproducibility and accuracy for prediction, they can potentially 
support clinical decision making. 
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Disadvantages of ANNs 
Like all other machine learning approaches, ANN also inherits limitations.  
 The major limitation being the time consuming factor depending on the 
dimensionality and complexity of the data being modelled. As the total 
number of hidden layers required to capture the features of the data 
increases, so the time taken for training also increases.  
 Over-fitting of the learned patterns by an ANN represents memorization 
through training process, and causes poor performance of network.  
 Lastly, the apparent ‘Black Box’ situation exist wherein the path to reach a 
solution is unclear in an ANN, creating a barrier among researches for 
effective use of real-world data scenario. 
 
2.11 ANNs in medicine and Biomarker discovery 
 
The use of machine learning, and in particular the use of ANNs is increasing 
and occupying a central position as a predictive modelling tool in areas as diverse 
as computer-aided medical diagnosis, biological sequence analysis and  prediction 
of peptide cleavage sites (Jagla and Schuchhardt, 2000). In an editorial letter, 
Gohari et al has supported the use of ANN in identification of prognostic factors 
in colorectal cancer patients (Gohari et al., 2011). 
Lisboa et al. has extensively reviewed the ANN’s contribution in clinical 
diagnosis, prognosis of disease and survival analysis in the domains of oncology, 
critical care and cardiovascular medicine, primarily focussing on randomised 
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controlled and clinical trials (Lisboa, 2002). The review emphasises that the 
ANN’s role in evidence-based predictions is to reduce the information overload. 
The review also states that the use of ANNs in exploratory data analysis wherein 
complex hypothesis generation along with standard statistical methods is 
undertaken. A review on the usage of ANN in cancer clinical decision support can 
also be found (Lisboa and Taktak, 2006). 
Agotonovic-Kustrin et al has reviewed ANN’s application in 
pharmaceutical research and has recognised the potential application in pattern 
recognition, interpretation of analysed data, modelling drug response, drug and 
dosage prediction, formulation of product, modelling quantitative structure-
property relationship,  protein structure and function prediction. Analysis of 
pharmacokinetics-pharmacodynamics data is emphasised (Agatonovic-Kustrin 
and Beresford, 2000). 
ANNs have been used in lung cancer cell identification through an 
automatic pathological diagnosis procedure named Neural Ensemble-based 
Detection method (Zhou et al., 2002). ANNs have also been used in diagnosis of 
breast cancer (Abbass, 2002), polycystic ovary syndrome (Matharoo-Ball et al., 
2007), down syndrome (Coppede et al., 2010) and also for headache (Mendes et 
al., 2010). 
ANNs are also used in identification of biomarker (Lancashire et al., 2005, 
Gonzalez et al., 2010), and survival analysis in breast cancer (Chi et al., 2007), 
using microarray and proteomic datasets (Lancashire et al., 2009). Lancashire has 
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also extended the ability of ANNs in identification of  biomarkers in circulating 
blood (Lancashire et al., 2010). 
ANNs have been found efficient in handling complex biological data from 
high-throughput techniques such as gene microarray (Huang et al., 2003, 
Lancashire et al., 2010) and mass spectrometry (Ball et al., 2002). ANNs have 
also been used in predictive non-linear modelling (Almeida, 2002). ANNs are not 
only used for the classification of samples, but also in inferring gene-gene 
interactions (Lemetre et al., 2009) and in discovering DNA regulatory elements 
(Firpi et al., 2010). Finally, ANNs in combination with genetic algorithms have 
also been used for  feature selection (Tong and Schierz, 2011). 
 
2.12 Systems biology approach using ANN 
 
The advent of high throughput technologies has enabled a new and 
promising field of research called Systems Biology. Systems biology is a biology-
based inter-disciplinary science of study that emphasises the intricate interactions 
of biological systems, using a more holistic perspective than the traditional 
reductionism, approach to biological and biomedical research (Kitano, 2002b). 
"The reductionist approach has successfully identified most of the 
components and many of the interactions but, unfortunately, offers no convincing 
concepts or methods to understand how system properties emerge...the pluralism 
of causes and effects in biological networks is better addressed by observing, 
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through quantitative measures, multiple components simultaneously and by 
rigorous data integration with mathematical models" (Sauer et al., 2007). 
Some have even argued that the systems biology can be seen as a conceptual 
approach to biological research that consciously combines  ‘reductionist’  and 
‘integrationist’ research, to understand the nature and maintenance of system as a 
whole (Kohl and Noble, 2009). 
The challenges in systems biology is the complexity and dimensionality of 
data along with bias or noise induced by high throughput techniques. ANNs  
coupled with a robust cross-validation technique have been found to be efficient 
in addressing these challenges (Hart et al., 2006), and have motivated their 
application in systems biology of breast cancer. 
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Chapter 3 
CLASSIFICATION OF OESTROGEN 
RECEPTOR STATUS IN A BREAST 
CANCER MICROARRAY DATASET USING 
ARTIFICIAL NEURAL NETWORKS 
 
 
Chapter abstract: The classification of samples based on ER status (ER+/ER-) is 
vital for predicting the prognosis and endocrine treatment in breast cancer. 
Furthermore, the investigation of predictive gene signature for the ER class would 
benefit an understanding of the causal influence of ER-associated genes. Aiming to 
bespoke aspects, in this study we have utilised an in-house developed Stepwise-
ANN predictive model to classify breast cancer microarray dataset samples based on 
ER status and to generate a predictive gene signature for the ER class. The stepwise-
ANN model identified ESR1 as the best predictive gene for the ER class with a 
consistent performance of 90.45% on the test subset and 89.45% on the validation 
subset of samples. The classification accuracy of the ANN for ER status was found 
to be 87.72% with 95.09% sensitivity and 77.19% specificity. The ANN showed 
higher accuracy of 90.97% when using the median-based gene expression for ESR1 
gene coding for ERα. The gene expression based classification also showed higher 
sensitivity and specificity. The ontological investigation of the top 100 predictive 
markers for ER status was dominated with catalytic activity in molecular process 
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group and metabolic process in biological function group. Finally, the Stepwise-
ANN also showed consistent performance on external validation of breast cancer 
datasets. 
 
3.1 Introduction 
 
3.1.1 Need for ER associated gene markers 
 
By quantitative Reverse Transcription-Polymerase Chain Reaction (RT-PCR), 
immunohistochemistry (IHC) and Fluorescent In-Situ Hybridisation (FISH) on 
breast cancer samples, multiple potential biomarkers and proliferation signatures 
with respect to a particular disease state or condition can be studied (Cheang et al., 
2009). Through gene expression profiling on archival breast Tissue MicroArray 
(TMA) blocks of tumour tissue samples, it was observed that, the ontological 
distribution of previously studied genes can be evaluated to determine their role in 
breast cancer (Cimino et al., 2008). Meta-analysis of breast cancer microarray cDNA 
data for the expression of genes along with their transcriptional activators can 
facilitate tumour prediction in early stage breast cancer (Mehra et al., 2005). For 
improvement in the prognostic and therapeutic aspects of breast cancer, gene 
amplification by array-comparative genomic hybridisation has also been carried out 
using gene amplification techniques such as Chromosomal In-Situ Hybridisation 
(CISH) and FISH (Arnould et al., 2012). The conventional practice of identifying a 
single gene responsible for phenotype and cellular functionality lacks information 
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regarding the influence of associated genes, which can be overcome by investigating 
gene signatures using microarray technology (Simon, 2003). A gene signature 
representing disease state, such as patient diagnosis and classification, can help 
clinicians in treatment decisions appropriate to individual patients.   
The advantage of using ANNs in this study was supported with their ability to 
handle non-linearity which is a characteristic of biological data. The successful 
implementation of ANN in learning the gene expression patterns in microarray data 
by Lancashire at el has provoked this study (Lancashire et al., 2009). ANNs with 
their capacity of sample classification and gene signature development depending on 
the predictability for the class could be used to shortlist contenders associated with 
the classification feature. Thus, the evaluation of information shared by the ER-
associated genes on ER system could be carried out. 
3.2 Aims and Objectives 
 
 To successfully classify breast cancer samples based on the ER status derived 
from immunohistochemical method using an in-house developed Stepwise 
ANN model. 
 To generate a gene signature for ER status in breast cancer microarray 
dataset. 
 To investigate the efficiency of the predictive model for the ER status 
classification. 
 To validate the predictive efficiency of ANN for ER classification on 
multiple microarray datasets. 
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3.3 Materials and Methods 
3.3.1 E-GEOD-20194 dataset 
 
A pre-normalized microarray breast cancer cDNA expression profile was 
downloaded from the freely available EMBL-EBI database library 
(http://www.ebi.ac.uk/arrayexpress). The cDNA microarray profile was found to be 
developed on an Affymetrix HG-U133A array from the E-GEOD-20194 study (Shi 
et al., 2010). The breast cancer microarray dataset contained 22283 probesets 
corresponding to genes across 278 primary breast cancer samples before neoadjuvant 
therapy administration. The samples were categorized into 2 classes based on IHC 
ER status as ER-positive (164 samples) class and the remaining as ER-negative (114 
samples). 
 
3.3.2 Other breast cancer datasets 
 
Apart from E-GEOD-20194, other breast cancer cDNA microarray datasets 
developed on HG-U133A array were also selected from the Gene Expression 
Omnibus (GEO) library ArrayExpress.  
E-GEOD-2034: This dataset was submitted to the GEO library as GEO2034 series. 
It consists of 180 lymph-node negative relapse free patients and 106 lymph-node 
negate patients that developed a distant metastasis. The dataset was designed to 
develop a gene signature to predict the distant metastasis in lymph-node-negative 
primary breast cancer patients (Wang et al., 2005).  In their study, Wang et al. 
proposed a 76 gene signature predicted by univariate Cox’s regression model 
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coupled with bootstraps and novel relapse score. The gene signature comprised 60 
genes for ER-positive and 16 genes for ER-negative samples without any overlaps of 
genes was developed (Wang et al., 2005). 
E-GEOD-7390: This study was designed to independently validate the E-GEOD-
2034 study on a cohort from the TRANSBIG Consortium (Desmedt et al., 2007). 
Gene expression profiling of 198 fresh frozen samples of lymph node-negative 
breast cancer patients was carried out at Bordet Institute, Brussels, Belgium. This 
confirmed the performance of the 76-gene signature published earlier to be a good 
predictor for 5-years distance metastasis and overall survival in a so called ‘good 
profile’ group compared to a 10-years group.          
E-TABM-158: This dataset was designed to explore the association of genomic 
copy number abnormalities in aggressive early-stage breast cancer patients using 
gene expression profiling along with clinical outcomes. A 66-gene signature was 
developed which had altered copy numbers in sub categories of breast cancer and 
was found to be a potential therapeutic target (Chin et al., 2006). 
Table 2 is a summary of the breast cancer datasets selected for validation of 
the Stepwise-ANN findings. 
 
3.3.3 Stepwise ANN 
 
An in-house developed Stepwise-ANN algorithm (Lancashire et al., 2009), 
was used for the prediction of ER status in samples from the E-GEOD-20194 breast 
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cancer dataset. All 22283 probesets were used as input variables for training the 
ANN to predict ER status. The training was performed with a momentum of 0.5 and 
learning rate of 0.1. The complete stepwise ANN coupled with back propagation of 
error algorithm including randomised sample partitioning (60% for training, 20% for 
testing and remaining 20% for validation) with MCCV strategy was iterated for 10 
independent iterations (or runs). The predictive performance and errors, for each 
input variable across all samples, were recorded for each independent loop (complete 
run of predictive model) and for each subset of samples under training, test and 
validation. The rank order of the genes under each iteration was based on their Mean 
Square Error (MSE) values. Minimum Average Test Error (ATE) was used for short 
listing the predicting genes for ER status. 
 
 
Table 2: Summary of breast cancer datasets considered for validation. 
GEO ID 
Total no. 
of probes 
Total no. 
of samples 
Class 
ER-positive     ER-negative 
E-GEOD-2034 22283 286 209 77 
E-TABM-158 22215 118 75 43 
E-GEOD-7390 22283 198 134 64 
 
Summary of breast cancer datasets considered for validating Stepwise-ANN findings. 
Datasets are selected from Gene Expression Omnibus (GEO) library.   
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3.4 Results and Discussions 
3.4.1 Stepwise ANN consistency 
 
  The in-house Stepwise-ANN implementation for predicting IHC ER status of 
breast cancer samples from microarray dataset E-GEOD-20194 yielded consistent 
results across 10 independent iterations of learning. The top ranked probe with 
predictive performances and errors from all 10 individual iterations are summarized 
in Table 3. The mean training performance of the single gene was found to be 
90.45%. The validation subset of samples showed a mean performance of 89.45% 
with error rate of 11.70% indicating robustness and consistent performance across 
ten independent iterations of analysis.  
 
Table 3: Summary of Stepwise-ANN outcome. 
Run Probe ID 
Gene 
Symbol 
Training 
Performance 
Test 
Performance 
Validation 
Performance 
Training 
Error 
Test 
Error 
Validation 
Error 
1 205225_at ESR1 0.9042 0.8929 0.8909 0.1149 0.1102 0.1179 
2 205225_at ESR1 0.8982 0.8929 0.8909 0.1175 0.1165 0.1187 
3 205225_at ESR1 0.9102 0.9107 0.9091 0.1174 0.1178 0.1181 
4 205225_at ESR1 0.9072 0.9107 0.8909 0.1065 0.1071 0.1120 
5 205225_at ESR1 0.9042 0.8929 0.8909 0.1122 0.1142 0.1160 
6 205225_at ESR1 0.9042 0.9286 0.8909 0.1173 0.1111 0.1250 
7 205225_at ESR1 0.9042 0.9018 0.8909 0.1068 0.1088 0.1083 
8 205225_at ESR1 0.9042 0.8929 0.8909 0.1085 0.1128 0.1184 
9 205225_at ESR1 0.9042 0.9110 0.9090 0.1130 0.1120 0.1150 
10 205225_at ESR1 0.9042 0.9107 0.8909 0.1156 0.1110 0.1208 
 MEAN 0.9045 0.9045 0.8945 0.1130 0.1122 0.1170 
 SD 0.0029 0.0119 0.0076 0.0043 0.0033 0.0045 
 
Summarization of Stepwise-ANN classification for ER status. Top ranked gene from ten 
independent iterations was selected based on minimum averaged test errors recorded 
under each loop. 
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The cross examination of performances under all ten independent analysis was 
also found to be consistent with standard deviation of 0.76% and 0.45% in 
performance and error rates respectively in the validation subset of samples 
indicating reproducibility of the model performance. 
The top ranked probe found to be highly associated with the IHC ER status 
prediction in the samples was 205225_at, coding for the gene ESR1, the ERα subunit 
of the receptor. ESR1 was found to be highly associated with the ER class prediction 
in all the random sample subset segregations indicating consistent marker selection 
for class prediction and parameterisation capacity of the ANN model. 
Furthermore, the performance of Stepwise-ANN was investigated with respect 
to errors generated in test and validation subsets of sample segregation under 
independent runs. Figure 8 illustrates the performance of Stepwise-ANN for 
classification of samples for ER status. The overall averaged error generated by 
Stepwise-ANN under 10 independent models in test subset was found to be of range 
0.097 to 0.115 and in validation subset was found to be of range 0.113 to 0.125. The 
error generated by ranked 1 probeset (205225_at representing ESR1 gene) under 5 
independent repeats of Stepwise-ANN comprising 10 independent models each was 
also investigated. The test errors generated was found to be in range from 0.1048 to 
0.1111 and validation errors was found to be in range from 0.11 to 0.12. The 
performance of Stepwise-ANN was investigated with respect to validation subset 
under 5 independent repeats comprising 10 independent models and was found to be 
in range from 0.8945 to 0.9027. Hence, the Stepwise-ANN performance was found 
to be consistence across independent models and independent repeats also.   
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Figure 8: ANN model performance consistency. (a) Test and Validation subset errors 
generated by ANN under 10 independent models. (b) Error encountered by ranked 1 
predictive probeset under Test and Validation subset at 5 independent repeats of ANN 
model. (c) Validation subset performance of 10 independent models and 5 independent 
repeats of ANN. 
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3.4.2 Classification accuracy of Stepwise-ANN 
 
The ability of a predictive model to effectively classify the unseen data would 
largely depend on the nature of the learned pattern from the seen data used for the 
training. The stepwise ANN model used was found to efficiently classify all the 278 
samples from the dataset used with an accuracy of 87.72% with a single gene model. 
By considering actual and predicted classes of samples, the class prediction accuracy 
was confirmed with 95.09% of sensitivity (true positive rate; ability to identify 
positive cases) and 77.19% specificity (true negative rate; ability to identify negative 
cases) respectively yielding to the overall prediction accuracy of 87.72%. 
The ROC curve was found to be in the upper left quadrant of the graph 
representing an efficient model for class prediction. The Area Under Curve (AUC) 
or Receiver Operating Characteristic (ROC) area under stratified sample subsets was 
also found to be 93.02% for training (N=166), 91.70% for test (N=56) and 93.46% 
for validation (N=56) subset with random MCCV strategy implied. The prediction 
accuracy was found to be 90.45% in training, 90.45% in test and 89.45% in 
validation subset of the samples, confirming the efficiency of the predictive model 
and the classification ability of the Stepwise-ANN towards the unseen data. Table 4 
shows the classification accuracy and ROC area for ER class prediction. 
 
3.4.3 Top100 probe list for ER status from Stepwise-ANN 
 
The Stepwise-ANN with consistent high performance in all the 10 independent 
predictive models generated a list of best predictive markers for the ER class from 
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the features and samples given for training. The MSE values from the testing subset 
of samples were used for the generation of rank order. The gene with the minimum 
error value in all the predictive models was given the highest rank and so on. Here, 
for the sake of simplicity, the 100 top genes were selected for further analysis and 
information mining to justify findings (Table 5). The top 100 genes were found to 
have high statistical significance having p-values in below 4.49X10
-3
. Hence, the top 
ranked 100 probes were considered for further analysis. 
 
Table 4: Sensitivity, Specificity, Classification accuracy and ROC analysis. 
True 
Positive 
True 
Negative 
False 
Positive 
False 
Negative 
Sensitivity Specificity Accuracy 
155 88 26 9 95.09% 77.19% 87.72% 
 
 
 
 
 
 
 
Tabulation of classification accuracies recorded by Stepwise-ANN for all samples 
selected during random stratification of samples into training, test and validation 
subsets. Sensitivity and specificity of the predictive model is also represented in terms 
of true and false positivity and negativity. Receiver operating Characteristic (ROC) 
curve analysis and ROC area under curve values represents models accuracy. 
 
 Training 
samples 
Test 
samples 
Validation 
samples 
Sample size 166 56 56 
Prediction accuracy (%) 90.45 90.45 89.45 
ROC area 0.9302 0.9170 0.9346 
Receiver Operating Characteristic curve 
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Table 5: Summary of top ranked 100 genes from stepwise ANN. 
Rank 
Order 
Probe set 
ID 
Gene 
Symbol 
p-value Regulation 
 
Rank 
Order 
Probe set 
ID 
Gene 
Symbol 
p-value Regulation 
1 205225_at ESR1 4.49E-05 Up 
 
51 203749_s_at RARA 2.29E-03 Up 
2 209603_at GATA3 8.98E-05 Up 
 
52 219197_s_at SCUBE2 2.33E-03 Down 
3 212956_at KIAA0882 1.35E-04 Up 
 
53 204881_s_at UGCG 2.38E-03 Up 
4 214164_x_at FLJ20151 1.80E-04 Up 
 
54 204798_at MYB 2.42E-03 Down 
5 215867_x_at CA12 2.24E-04 Up 
 
55 205355_at ACADSB 2.47E-03 Down 
6 209602_s_at GATA3 2.69E-04 Up 
 
56 218259_at KIAA1243 2.51E-03 Down 
7 214440_at NAT1 3.14E-04 Up 
 
57 206754_s_at CYP2B6 2.56E-03 Up 
8 204508_s_at FLJ20151 3.59E-04 Up 
 
58 219414_at CLSTN2 2.60E-03 Down 
9 209604_s_at GATA3 4.04E-04 Up 
 
59 203929_s_at MAPT 2.65E-03 Down 
10 203963_at CA12 4.49E-04 Up 
 
60 203144_s_at KIAA0040 2.69E-03 Down 
11 218195_at FLJ12910 4.94E-04 Up 
 
61 204623_at TFF3 2.74E-03 Down 
12 212960_at KIAA0882 5.39E-04 Down 
 
62 216381_x_at AKR7A3 2.78E-03 Down 
13 209173_at AGR2 5.83E-04 Up 
 
63 208615_s_at PTP4A2 2.83E-03 Down 
14 210735_s_at CA12 6.28E-04 Up 
 
64 205354_at GAMT 2.87E-03 Down 
15 203628_at IGF1R 6.73E-04 Up 
 
65 200711_s_at SKP1A 2.92E-03 Down 
16 211712_s_at ANXA9 7.18E-04 Up 
 
66 222125_s_at PH-4 2.96E-03 Down 
17 218976_at JDP1 7.63E-04 Up 
 
67 204863_s_at IL6ST 3.01E-03 Down 
18 212196_at IL6ST 8.08E-04 Up 
 
68 213419_at APBB2 3.05E-03 Down 
19 205009_at TFF1 8.53E-04 Up 
 
69 203256_at CDH3 3.10E-03 Up 
20 202089_s_at LIV-1 8.98E-04 Up 
 
70 213712_at ELOVL2 3.14E-03 Down 
21 205696_s_at GFRA1 9.42E-04 Up 
 
71 205597_at C6orf29 3.19E-03 Down 
22 218211_s_at MLPH 9.87E-04 Up 
 
72 201983_s_at EGFR 3.23E-03 Down 
23 205862_at GREB1 1.03E-03 Up 
 
73 35666_at SEMA3F 3.28E-03 Down 
24 200670_at XBP1 1.08E-03 Up 
 
74 203928_x_at MAPT 3.32E-03 Up 
25 212496_s_at KIAA0876 1.12E-03 Down 
 
75 212148_at PBX1 3.37E-03 Down 
26 202088_at LIV-1 1.17E-03 Down 
 
76 205472_s_at DACH 3.41E-03 Up 
27 209623_at MCCC2 1.21E-03 Down 
 
77 219913_s_at CRNKL1 3.46E-03 Up 
28 218807_at VAV3 1.26E-03 Up 
 
78 201754_at COX6C 3.50E-03 Down 
29 204667_at FOXA1 1.30E-03 Up 
 
79 205081_at CRIP1 3.55E-03 Down 
30 215729_s_at TONDU 1.35E-03 Up 
 
80 212446_s_at LASS6 3.59E-03 Down 
31 212195_at IL6ST 1.39E-03 Up 
 
81 221710_x_at FLJ10647 3.64E-03 Down 
32 210652_s_at C1orf34 1.44E-03 Down 
 
82 41660_at CELSR1 3.68E-03 Down 
33 217838_s_at RNB6 1.48E-03 Down 
 
83 204497_at ADCY9 3.73E-03 Up 
34 205186_at DNALI1 1.53E-03 Up 
 
84 203627_at IGF1R 3.77E-03 Down 
35 208682_s_at MAGED2 1.57E-03 Up 
 
85 200810_s_at CIRBP 3.82E-03 Down 
36 209460_at NPD009 1.62E-03 Up 
 
86 208873_s_at DP1 3.86E-03 Up 
37 221765_at UGCG 1.66E-03 Down 
 
87 212099_at RHOB 3.90E-03 Down 
38 212442_s_at LASS6 1.71E-03 Down 
 
88 212151_at PBX1 3.95E-03 Down 
39 211000_s_at IL6ST 1.75E-03 Down 
 
89 208617_s_at PTP4A2 3.99E-03 Down 
40 212492_s_at KIAA0876 1.80E-03 Down 
 
90 214404_x_at PDEF 4.04E-03 Down 
41 219051_x_at MGC2601 1.84E-03 Down 
 
91 218806_s_at VAV3 4.08E-03 Down 
42 206401_s_at MAPT 1.89E-03 Up 
 
92 212441_at KIAA0232 4.13E-03 Down 
43 209459_s_at NPD009 1.93E-03 Down 
 
93 204862_s_at NME3 4.17E-03 Down 
44 212638_s_at WWP1 1.98E-03 Up 
 
94 205066_s_at ENPP1 4.22E-03 Up 
45 201508_at IGFBP4 2.02E-03 Down 
 
95 220192_x_at PDEF 4.26E-03 Down 
46 215552_s_at ESR1 2.06E-03 Up 
 
96 212637_s_at WWP1 4.31E-03 Down 
47 210085_s_at ANXA9 2.11E-03 Down 
 
97 209696_at FBP1 4.35E-03 Up 
48 205471_s_at DACH 2.15E-03 Up 
 
98 40148_at APBB2 4.40E-03 Down 
49 201826_s_at CGI-49 2.20E-03 Down 
 
99 209443_at SERPINA5 4.44E-03 Down 
50 214552_s_at RAB5EP 2.24E-03 Up 
 
100 206469_x_at AKR7A3 4.49E-03 Down 
 
Tabulation of top 100 ranked gene probes found associated with ER status class 
prediction through in-house developed Stepwise-ANN analysis. The average of test 
subset error for each gene under each independent 10 iterations of stepwise analysis was 
considered for ranking. The probes with minimum error is ranked highest in the table.   
 
The probe 209603_at representing GATA3 gene appeared at second rank 
position for ER classification. The same gene was found to have another two probes 
on the array as 209602_at and 209604_s_at appearing in rank positions 6 and 9 
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respectively. The GATA3 genes codes for the transcriptional factor belonging to the 
GATA family. The gene is located at chromosome 10p15 in humans. They are 
responsible in the regulation of T cells (Marine and Winoto, 1991), inner ear (Milo et 
al., 2009), adrenal gland and brain with central nervous system in mouse (Zhao et al., 
2008). GATA3 is also found to be responsible for self-renewal of hematopoietic stem 
cells (Buza-Vidas et al., 2011). Wilson et al 2008 have confirmed the reciprocal 
association of GATA3 gene with the ER α gene from their meta-analysis study using 
microarrays (Wilson and Giguere, 2008). GATA3 was found to be a prognostic 
marker (Mehra et al., 2005), and associated with hormonal responsiveness in breast 
cancer (Fang et al., 2009). 
Another important gene found to be associated with ER status in the breast 
cancer samples was CA12. CA12 represents the Carbonic anhydrases gene which is a 
member of zinc metalloprotiens family that catalyses the reversible hydration 
reaction of carbon dioxide. The gene is located at 15q22.2 in humans. CA12 is found 
up regulated in renal cells (Tureci et al., 1998). They have been found to have a role 
in oestrogen metabolism and are good prognostic factor for invasive breast 
carcinoma (Watson et al., 2003). The stepwise-ANN identified three probes as 
215867_x_at, 203963_at and 210735_s_at at ranks 5
th
, 10
th
 and 14
th
 respectively. 
To address the issue of probability of occurrence of any gene by random 
chance, we considered ranking each probeset based on their ATE values and p-value 
based on rank position with respect to all 22283 probesets. 
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Furthermore, the heat map of the top 100 predictive genes (Figure 9) was done. 
The predictive genes considered were able to classify samples clearly. The 
expression pattern revealed genes having distinct regulation in samples. Some genes 
were also found to be having contrasting expression pattern compared to others 
potentially segregating samples into different sub groups of breast cancer. 
 
3.4.4 Comparison of ANN result with original study 
 
In the original study by Liu et al using E-GEOD-20194, different machine 
learning algorithms such as Recursive Feature Elimination of Supervised Vector 
Machines and Gradient and Sequential forward method of Leave-one-out supervised 
machine learning algorithms were compared for predicting the complete pathological 
response using Naïve bayes classier. Liu et al has mentioned that the lack of 
commonality between the markers was expected due to the difference in the classier 
algorithms used to signify the effect of the feature selection method on the dataset. In 
justification for the lack of inconsistency, the Liu et al study suspects that the pre-
filtering methods used for the data generation was independent on the learning 
methods, thus representing the weakness of filtering method which ignores the 
involvement of features in the data. Moreover, a discrepancy among the top ranked 
gene from the different classier used was observed and accepted (Liu et al., 2009). 
We compared our results with the original study using E-GEOD-20194 breast 
cancer data set. A total of 9 genes overlapped with the genes reported by Liu et al    
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Figure 9: Heat map of the top 100 predictive genes. The heat map represents a 
dendogram of hierarchically clustered genes. The rows of heat map represents 
expression of genes (variants of the same genes are symbolized by alphabetical suffix) 
across corresponding samples in columns. Each cell is colorized based on the level of 
expression of that gene in that sample.  
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with our top 100 ER-associated genes from Stepwise-ANN method. These overlap 
genes are EGFR (201983_s_at), ESR1 (205225_at), IL6ST (211000_s_at and 
212195_at), MAPT (203929_s_at), DACH (205471_s_at), GATA3 (209602_s_at), 
GREB1 (205862_at), and SERPINA5 (209443_at). Due to the unavailability of 
predictive performances of each genes from Liu et al., the rank order of genes could 
not be compared with our study. 
 
3.4.5 ER-class prediction comparison between protein and 
gene expression based classification 
The conventional protein expression based classification of samples through 
IHC method incorporates higher false positive rates due to inherent lower sensitivity 
and specificity of the technique (Gown, 2008). Upon classification of samples for ER 
status (IHC) provided by dataset using Stepwise-ANN method, a total of 34 samples 
were misclassified with 87.72% classification accuracy using a single high predictive 
gene at rank one. The sensitivity and specificity of the assay was found to be 95.09% 
and 77.19% respectively.  
To improve the classification accuracy, the samples were classified based on 
the ESR1 gene expression values, since the ESR1 gene coding ERα receptor was the 
best predictive gene for ER classification. The expression profile of the ESR1 gene 
across all 278 samples was considered for a median expression level based 
classification. Any sample’s ESR1 expression below the median value was 
considered to be ER-negative and those greater being ER-positive. The same 
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Stepwise-ANN model was applied to predict the ESR1 gene expression based 
classification of the samples. The misclassification of samples was reduced to 25 
with an improved classification accuracy of 90.97%. The sensitivity and specificity 
was also improved to 96.31% and 83.33% respectively. Promisingly, the false-
positive samples were decreased from 26 to 5 which could be clinically beneficial to 
patients with endocrine and hormonal therapy. Figure 10 is the schematic 
representation of ER and ESR1 expression distribution in samples. Table 6 is the 
ANN model performance for ER (protein) and ESR1 (gene) expression based 
classification. 
 
 
 
Figure 10: Population distribution of samples with IHC and gene expression based 
ER classification. Population distribution chart of breast cancer samples under protein 
by IHC and gene expression  based ER classification. The prediction output values are 
normalised. 
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Table 6: Stepwise-ANN performance for ER (protein) and ESR1 (gene) expression based 
classification. 
 
TP TN FP FN Sensitivity Specificity Accuracy 
ER 
(protein) 
155 88 26 9 95.09% 77.19% 87.72% 
ESR1 
(gene) 
181 88 5 4 96.31% 83.33% 90.97% 
 
The classification accuracy of the ANN model compared with respect to ER (protein) 
and ESR1 (gene) based classification measured in terms of sensitivity and specificity. 
TP = True Positive, FP = False Positive, TN = True Negative, FN = False Negative.  
 
 
3.4.6 Investigation of probe variants 
 
The HG U-133A array used in our study was found to contain multiple probes 
for particular genes. These were typically used for the internal calibration processes 
of the array among which some were house-keeping genes (for example, hum_alu_at 
representing human albumin gene). They may represent mutational variants of the 
wild type and different isoforms of the same genes, and some of the probes may 
correspond to a single protein or to particular polypeptides of the same protein. 
Furthermore, the difference in expression profile of these probe variants may also 
due to the degradation of mRNA in patient tumour samples.  
 
3.4.6.1 Rank positions 
 
The investigation of the top 100 predictive probesets for ER classification 
showed a total of 18 genes having multiple probesets. Among them, there were two 
Chapter 3: CLASSIFICATION OF OSTROGEN RECEPTOR  STATUS IN A BREAST CANCER 
MICROARRAY DATASET USING ARITIFICIAL NEURAL NETWORKS 
84 
 
probesets representing the ESR1 gene, 205225_at and 215552_s_at, which were 
found to be at rank 1 and 45 respectively. The stepwise-ANN also identified three 
probesets of CD12 as 215867_x_at, 203963_at and 210735_s_at at ranks 5
th
, 10
th
 
and 14
th
 respectively. The GATA3 gene was found to have three different probesets 
209603_at, 209602_s_at and 209604_s_at positioned at 2
nd
, 6
th
 and 9
th
 ranks. Table 7 
is the tabulation of rank positions of repeated probes of the same gene found in the 
top 100 predictive probesets for ER classification using the Stepwise-ANN method. 
The appearance of multiple probes of the same gene at high rank order justifies that 
different probes of the same gene have similar ability to classify patterns for ER 
classes. It also shows that predictive models of ANN were efficient enough to 
recognize the similar expression pattern among the gene’s probe variants. 
  
3.4.6.2 Population distribution charts 
 
Population distribution is the schematic representation of expression values of 
a genes or probe across samples to determine the expression profile patterns. The 
probe variants of the ESR1 gene from the top 100 predictive probes for ER 
classification shows varied expression profiles across ER-positive and ER-negative 
samples i.e., the ranked number one, 205225_at probe shows a clear segregation of 
ER-positive and ER-negative samples, whereas the other probe, 215552_s_at at rank 
46, classifies samples with a lower rate (Figure 11(a)). This suggests that the 
appearance of probes of the same gene at lower rank order contains higher 
classification error compared the higher ranked probes. On the other hand, different 
probes of the same gene were found to have a differential expression in ER-positive  
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Table 7: List of repeated probes for gene found in top 100 Stepwise-ANN. 
Rank Input ID 
Accession 
number 
Gene 
symbol 
Gene name 
68 213419_at U62325 APBB2 
amyloid beta (A4) precursor protein-binding, family B, member 2 
98 40148_at U62325 APBB2 
60 216381_x_at AL035413 AKR7A3 Aldo-keto reductase family 7, member A3 (aflatoxin aldehyde 
reductase) 100 206469_x_at NM_012067 AKR7A3 
17 211712_s_at BC005830 ANXA9 
Annexin A9 
48 210085_s_at AF230929 ANXA9 
10 203963_at NM_001218 CA12 
Carbonic anhydrase XII 
13 210735_s_at BC000278 CA12 
50 205471_s_at AW772082 DACH1 
dachshund homolog 1 (Drosophila) 
69 205472_s_at NM_004392 DACH1 
1 205225_at NM_000125 ESR1 
estrogen receptor 1 
45 215552_s_at AI073549 ESR1 
4 214164_x_at BF752277 FLJ20151 
 
7 204508_s_at BC001012 FLJ20151 
2 209603_at AI796169 GATA3 
GATA binding protein 3 5 209602_s_at AI796169 GATA3 
8 209604_s_at BC003070 GATA3 
37 211000_s_at AB015706 IL6ST 
interleukin 6 signal transducer 
64 204863_s_at BE856546 IL6ST 
3 212956_at AI348094 
KIAA0882 
/TBC1D9 
TBC1 domain family, member 9 
12 212960_at BE646554 
KIAA0882 
/TBC1D9 
19 202089_s_at NM_012319 
LIV-1 
/SLC39A6 
solute carrier family 39 (zinc transporter), member 6 
29 202088_at AI635449 
LIV-1 
/SLC39A6 
44 206401_s_at J03778 MAPT 
microtubule-associated protein tau 59 203929_s_at AI056359 MAPT 
72 203928_x_at AI870749 MAPT 
36 209460_at AF237813 NPD009 
 
42 209459_s_at AF237813 NPD009 
86 214404_x_at AI435670 SPDEF 
SAM pointed domain containing ets transcription factor 
94 220192_x_at NM_012391 SPDEF 
66 208615_s_at BF795101 PTP4A2 
protein tyrosine phosphatase type IVA, member 2 
93 208617_s_at AF208850 PTP4A2 
38 221765_at AI378044 UGCG 
UDP-glucose ceramide glucosyltransferase 
55 204881_s_at NM_003358 UGCG 
26 218807_at NM_006113 VAV3 
vav 3 guanine nucleotide exchange factor 
88 218806_s_at AF118887 VAV3 
43 212638_s_at BF131791 WWP1 
WW domain containing E3 ubiquitin protein ligase 1 
96 212637_s_at AU155187 WWP1 
 
The probe variants present in top 100 genes selected by Stepwise-ANN method. A 
total of 18 genes with multiple probe IDs were found to be associated with ER status 
in the array used. The ranks are sorted based on alphabetical order of gene symbols. 
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Figure 11: Population distribution of ESR1 and APBB2 probe variants. Schematic 
representation of population distribution of expression values of ESR1 probes across the 
total population of samples. (a) The probe variants of ESR1 in ER-positive and ER-
negative samples show a clear difference in the pattern of expression. (b) The probe 
variants of APBB2 in ER-positive and ER-negative samples show a clear difference in 
the pattern of expression. Both the probes show an opposite expression profile among 
the samples. 
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and ER-negative samples. For example, the two probes of APBB2 (Amyloid beta 
(A4) precursor protein-binding, family B) gene, 213419_at ranked 68
th
 and 40148_at 
ranked at 98
th
 positions, showed a clear contrasting expression pattern among the 
ER-positive and ER-negative samples. 213419_at had a higher expression profile in 
ER-positive samples, whereas, 40148_at was found to have an increased expression 
in ER-negative samples (Figure 11(b)). 
 
3.4.7 Gene Ontology of the top 100 probes 
 
 An investigation of the involvement of ER-associated genes in disease 
formation and prognosis may provide information regarding the molecular or 
functional pathway of ER-associated genes. It may also identify biomarkers 
associated with ER and its functionality. To investigate the ontological information 
of the genes predictive for the ER class, the top 100 probes selected from the 
Stepwise-ANN model were submitted to an online open access gene-protein 
interaction database called Panther (Thomas et al., 2003). The advantage of using 
the Panther database for the mining of ontological information was that all these 
genes were found to be present and updated in the Panther database when accessed 
on 1
st
 of November 2011. 
 
3.4.7.1 Molecular function 
 
 The ontological information regarding the molecular functions associated with 
the ER-associated top 100 genes from Stepwise-ANN model were found to be 
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dominated by the catalytic activity (40.31%), DNA binding activity (27.69%), and 
transcriptional regulatory activity (13.31%). Other molecular functions shared by the 
ER-associated genes were enzyme regulatory function, and with receptor activity 
function. The molecular ontology is represented in Figure 12 and detailed 
information in Table 8. 
 
3.4.7.2 Biological function 
 
The biological functionality of the ER-associated genes was dominated by 
metabolic processes (19.76%), developmental process (17.37%), cellular process 
(11.38%) and cell communication (10.78%). Other functions such as cell cycle, 
immune response, system process, cell adhesion, cell component organisation, 
apoptosis, transport, stimulus response, reproduction, precursor and homeostatic 
functions were also found. The biological ontology is represented in Figure 13 and 
detailed information in Table 8. 
 
3.4.7.3 Pathways 
The top 100 genes found associated with the ER status by the Stepwise-ANN 
were also investigated for ontological pathways (Figure 14) and found to be involved 
in various pathways concerning with the cell cycle, immune responses in terms of B-
cell and T-cell activation and regulation, nucleotide metabolism and synthesis, 
Vitamin-D metabolism and Want signalling pathways. Promisingly, the gene IL6ST 
was found to be involved in immune response and genes such as E-cad and P-cad 
were found to be highly involved in Catherin signalling pathway. 
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Figure 12: Molecular functional ontology information of ER-associated genes. 
Molecular functional ontology information of top 100 ER-associated genes from 
Stepwise-ANN model. The genes are grouped based on their molecular function along 
with the percentage of distribution. 
 
 
 
Figure 13: Biological functional ontology information of ER-associated genes. 
Biological functional ontology information of top 100 ER-associated genes from 
Stepwise-ANN model. The genes are grouped based on their biological function along 
with the percentage of distribution. 
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Table 8: Detailed ontological information of ER-associated genes from Stepwise-ANN model. 
Ontology Genes involved 
MOLECULAR FUNCTIONS 
Binding 
GATA3, TFF1, KIAA0876, RNB6, RARA, SEMA3F, DP1, 
SOX11, VAV3, IL6ST, CRNKL1, KIAA0882, ANXA9, MLPH, 
FOXA1, MAPT, TFF3, CIRBP 
Catalytic 
CYP2B6, GATA3, PTP4A2, AKR7A3, CRNKL1, MCCC2, 
KIAA0882, UGCG, CIRBP, CA12, ENPP1, FBP1, SKP1A, 
NME3, WWP1, ADCY9, AGR2, EGFR, ACADSB, CRIP1, NAT1 
Enzyme regulation VAV3, KIAA0882, MLPH, SERPINA5 
Ion Channel AKR7A3 
Receptor Activity RARA, IL6ST, DP1, CDH3, CELSR1, CDH3, EGFR, ESR1 
Structural molecular Activity RNB6, MAPT, DNALI1, CRIP1 
Transcriptional Regulators GATA3, KIAA0876, RARA, DP1, SOX11, CRNKL1, FOXA1 
Transport Activity DP1, NAT1 
BIOLOGICAL FUNCTIONS 
Apoptosis DP1, MAPT, MAGED2, MYB, EGFR, CRIP1 
Cell cycle 
DP1, JDP1, PTP4A2, FOXA1, CIRBP, MYB, SKP1A, PDEF, 
EGFR, ESR1 
Cell Adhesion 
SEMA3F, CDH3, CLSTN2, MAGED2, CELSR1, IGFBP4, CDH3, 
EGFR 
Cell communication 
RARA, SEMA3F, TFF1, IL6ST, VAV3, ANXA9, FOXA1, TFF3, 
CDH3, CLSTN2, CELSR1, IGFBP4, PDEF, CDH3, EGFR, ESR1, 
CRIP1, NAT1 
Cell component organization FOXA1, KIAA0882, MAPT, CDH3, CELSR1, CDH3, CRIP1 
Cell process 
GATA3, RARA, SEMA3F, CRNKL1, IL6ST, ANXA9, FOXA1, 
KIAA0882, CIRBP, MAPT, TFF3, CDH3, CELSR1, PDEF, 
WWP1, CDH3, EGFR, KIAA1243, CRIP1, DP1, JDP1, PTP4A2, 
RARA, RNB6, SEMA3F, TFF1, IL6ST, VAV3, ANXA9, FOXA1, 
KIAA0882, CIRBP, MAPT,TFF3, CDH3, CLSTN2, MAGED2, 
MYB, SKP1A, CELSR1, IGFBP4, PDEF, CDH3, DNALI1, EGFR, 
ESR1, CRIP1, NAT1 
Homeostasis AGR2 
Immune response 
JDP1, SEMA3F, TFF1, IL6ST, VAV3, TFF3, PDEF, EGFR, 
XBP1, CRIP1 
Metabolic Process 
CYP2B6, DP1, GATA3, JDP1, KIAA0876, PTP4A2, RARA, 
AKR7A3, CRNKL1, MCCC2, ANXA9, FOXA1, UGCG, CIRBP, 
DP1, CA12, ENPP1, FBP1, MYB, SERPINA5, SKP1A, NME3, 
PDEF, WWP1, ADCY9, AGR2, EGFR, XBP1, ESR1, ACADSB, 
CRIP1, NAT1 
Precursor generation CYP2B6, ACADSB 
Reproduction KIAA0876, CIRBP, MAGED2, EGFR, ESR1 
Stimuli response JDP1, IL6ST, VAV3, PDEF, CRIP1 
System Process 
VAV3, FOXA1, CIRBP, APBB2, CDH3, CDH3, ESR1, CRIP1, 
NAT1 
Transport ANXA9, KIAA0882, MLPH, DP1, NAT1 
Unknown GO list  
FLJ20151, AL050025, FLJ12910, H05812, AW242916, LIV-1, 
AL049265, C1orf34, TONDU, PD009, BG289001, MGC2601, 
CGI-49, AI424243, KIAA0040, PH-4, C6orf29, BF508639, 
AL049381, FLJ10647, BF967998, AI263909, AI658534, 
AI830698 
The ontological information about the biological processes carried out on top 100 ER-
associted genes. The genes were grouped according to their molecualr and biological 
functions.  
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Adrenaline and noradrenaline biosynthesis (P00001) 
Alzheimer disease-presenilin pathway (P00004) 
B cell activation (P00010) 
Bupropoin degradation (P05729) 
Cadherin signaling pathway (P00012) 
Cytoskeletal regulation by Rho GTPase (P00016) 
De novo purine biosynthsis (P02738) 
De novo pyrimidine deoxyrybonucleotide biosyntheis (P02739) 
De novo pyrimidine ribonucleotide biosynthesis (P02740) 
EGF receptor signaling pathway (P00018) 
Endothelin signaling pathway (P00019) 
GABA-B receptor II signaling pathway (P05731) 
Heterotrimeric G-protein signaling pathway (P00026) 
Inflammation mediated by chemokine and cytokine signaling pathway (P00031) 
Insulin/IGF pathway-protein kinase B signaling cascade (P00033) 
Interleukin signaling pathway (P00036) 
PDGF signaling pathway (P00047) 
PI3 kinase pathway (P00048) 
T cell activation (P00053) 
TGF-beta signaling pathway (P00052) 
Ubiquitin proteaoome pathway (P00060) 
Vitamin D metabolism and pathway (P04396) 
Wnt signaling pathway (P00057) 
      
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: Pathway ontology information of ER-Associated genes. Pathway ontology of information of top 100 ER-associate 
genes from Stepwise-ANN model. The genes are grouped based on the pathway. 
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3.4.8 Cross validation with other breast cancer datasets 
 
The findings from the Stepwise-ANN model of the E-GEOD-20194 dataset, 
were compared with three other breast cancer datasets namely E-GEOD-2034 
(Wang et al., 2005), E-TABM-158 (Chin et al., 2006) and E-GEOD-7390 
(Desmedt et al., 2007). To validate the findings, an investigation of predictive 
performance and rank position of predictive genes was compared between the 
breast cancer datasets. 
To validate the predictive performance, the ER class prediction was 
performed using the Stepwise-ANN model by considering standardised settings 
(described earlier in Chapter 2. Section 2.7). The classification accuracy and ROC 
area were investigated for comparison. Among the datasets considered for cross 
validation, the classification accuracy of the rank one predictor for ER 
classification in E-GEOD-20194 dataset was found to be highest (90.97%) 
followed by E-TABM-158 (89.74%), E-GEOD-2034 (89.51%) and E-GEOD-
7390 (87.30%). The investigation was extended to study the ROC area for 
validation subset of samples, and was found to be highest in E-GEOD-20194 
(93.58%) followed by E-GEOD-2034 (92.11%), E-GEOD-7390 (88.08%) and E-
TABM-158 (80.99%). The detailed findings are tabulated in Table 9 and Figure 
15.  
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Table 9: Stepwise-ANN classification performance in breast cancer datasets. 
Dataset TP TN FP FN 
Sensitivity 
(%) 
Specificity 
(%) 
Accuracy 
(%) 
ROC 
area (%) 
E-GEOD-2034 190 66 11 19 90.90 85.71 89.51 92.11 
E-TABM-158 73 32 11 1 98.64 74.41 89.74 80.99 
E-GEOD-7390 124 48 15 10 92.53 76.19 87.30 88.08 
E-GEOD-20194 157 95 19 6 96.31 83.33 90.97 93.58 
 
The Stepwise-ANN classification performance in breast cancer datasets considered 
for cross validation. Sensitivity, specificity, classification accuracy and ROC area are 
represented in percentages. TP=True Positive, TN=True Negative, FP= False 
Positive and FN=False Negative.  
 
 
 
Figure 15: ROC Curve analysis of breast cancer datasets. Receiver Operative 
Characteristic (ROC) curve of validation subset of samples from breast cancer 
datasets. The true positivity (Sensitivity) was compared with False positivity 
(1=Specificity). 
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To investigate the consistency of the Stepwise-ANN in selecting efficient 
predictive markers across the breast cancer datasets, we considered the rank 
position of the predictive markers. The ranking of each probes was assigned with 
respect to the averaged error recorded in the test subset of samples. Then, the top 
10 predictive probes were selected after cumulative ranking of each probe across 
the datasets used for cross validation. The rank position of the 10 highly 
predictive probes were checked across the datasets used. Table 10 is the tabulation 
of rank position of the 10 best predictive probes across breast cancer datasets. 
 
Table 10: Rank position of top 10 probes across breast cancer datasets. 
Gene 
Symbol 
Probe ID 
Rank order of genes in breast cancer datasets 
p-value 
E-GEOD-2034 E-TABM-158 E-GEOD-7390 E-GEOD-20194 
ESR1 205225_at 4 1 1 1 1.63E-17 
GATA3 209603_at 3 2 7 2 3.42E-16 
GATA3 209604_s_at 1 4 9 8 1.17E-15 
TBC1D9 212956_at 6 14 2 3 2.05E-15 
CA12 214164_x_at 8 7 6 4 5.47E-15 
CA12 215867_x_at 7 13 4 6 8.89E-15 
GATA3 209602_s_at 2 10 22 5 8.95E-15 
CA12 203963_at 17 5 19 10 6.57E-14 
TBC1D9 212960_at 31 3 11 12 4.99E-14 
DNAJC12 218976_at 34 12 16 16 4.25E-13 
 
The rank position of top 10 probes across breast cancer datasets. The probes are 
selected based on the averaged predictive performances across datasets. p-value 
represents the statistical significance of the probe cumulated across all datasets 
studied. 
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The probe representing the ESR1 gene (ERα) was found to be at the top rank 
in 3 out of 4 datasets studied. The rank position of probes did not differ much 
across the datasets since the top 10 probes were all under the rank order of 35. 
The rank position and p-value of the probe ranking also confirmed the consistency 
of the Stepwise-ANN findings across the datasets. 
 
3.5 Conclusion 
 
The Stepwise-ANN, an in-house developed algorithm, showed the ability to 
identify the most significant gene signature from the E-GEOD-20194 breast 
cancer microarray data. We applied random cross-validation on the data to obtain 
the unbiased top 100 genes from the dataset. We used a predictive ANN model 
coupled with back-propagation of errors algorithm to perform a thorough search 
on the entire gene population to ensure that the most significant gene subset was 
always selected by our model. 
The Stepwise-ANN model was able to produce a consistent high 
performance with mean training, testing and validation subsets being 90.45%, 
90.45% and 89.45% respectively in all the 10 independent iterations of the 
predictive models. Furthermore, the Stepwise-ANN model showed a high 
classification accuracy of 90.97%. The sensitivity and specificity analysis showed 
96.31% and 83.33% respectively signifying the reliability of the findings. The 
consistency and reproducibility of the model was further demonstrated by the 
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listing of a single gene most associated with the ER-class at every independent 
iteration. 
The gene ESR1, coding for ERα subunit was found to be directly associated 
with the ER-status in the breast cancer, validating the feature selection capability 
of the Stepwise-ANN. The ESR1 gene which is highest ranked by the ANN shows 
that it is a strong predictor of ER status in breast cancer.  
From this model, nine other contenders associated genes; EGFR, ESR1, 
IL6ST (X2), MAPT, DACH, GATA3, GREB1, IL6ST and SERPINA5 were found 
to overlap with the original study of Liu et al (LiuQ 2009).  
Interestingly, the Stepwise-ANN model was efficient enough to pull out the 
differences between the expression profiles of close variants of the same gene, 
some being similar in expression profile and some with contrasting expression 
profiles across the ER-positive and ER-negative samples. 
The consistency of the Stepwise-ANN in selecting the most predictive 
marker for ER-class was investigated and proved in three different breast cancer 
datasets in terms of classification performance of the model and rank position of 
probes.  
  A part of this chapter is published in the International Conference on 
Machine Learning and Cybernetics (ICMLC), 2011 with an article entitled 
“ESTROGEN RECEPTOR STATUS PREDICTION FOR BREAST CANCER 
USING ARTIFICIAL NEURAL NETWORK” (Dhondalay et al., 2011) 
(Annexure 1). This peer reviewed paper of the bespoke methodology and findings 
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on the E-GEOD-20194 dataset, emphasised the implementation of the in-house 
developed Stepwise ANN method for ER classification on a larger cohort (>200) 
of samples. 
  
Chapter 4: OSTROGEN RECEPTOR NETWORK INFERENCE WITH ARTIFICIAL NEURAL 
NETWORKS 
 
98 
 
Chapter 4 
OESTROGEN RECEPTOR NETWORK 
INFERENCE WITH ARTIFICIAL NEURAL 
NETWORKS  
(using pre-identified ER-associated markers by Stepwise-ANN approach) 
 
 
Chapter abstract: The overall functionality of a cell at any given time is governed 
by the complex interactions among its molecules. A conventional approach using 
knocking out a molecule of interest to investigate the physiological and functional 
alterations in the biological behaviour of a disease is tiresome and time 
consuming. To circumvent this, computational network inferencing approaches 
have been found to be promising. In this study, we have attempted to investigate 
the interactions between ER-associated markers utilising an ANN based gene-
gene network inferencing approach. The ANN-based network inference identified 
breast cancer associated markers such as FOXA1, GATA3, CA12 and others with 
ER status specificity. Clinical validation of ER-associated marker, VAV3 was 
found insignificant with clinicopathological markers, breast cancer specific 
markers and clinical outcome in patients. On the other hand, DACH1 was found to 
be an independent prognostic marker for disease free survival and distance 
metastasis in clinical samples.          
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4.1 Introduction 
 
One characteristic of a biological cell at a given time is the complex 
interaction of its various elements such as DNA, RNA, proteins and small 
molecules (Alberts et al., 2002). It is a major goal of functional genomics to 
explain the functional interactions between genomic and proteomic functional 
elements in a cellular pathway or network (Hieter and Boguski, 1997). The vital 
challenge in biomedicine is the need to establish the relationship between the 
physiological processes and the action of interacting contenders within a disease.  
Traditionally the interaction of a single biological element is determined 
by knocking out the particular gene or molecule of interest and studying the 
physiological and functional changes arising that could be attributed to the 
knockout using a reductionist approach (Van Regenmortel, 2004). However, 
biology is more complex than this and biological networks consist of hundreds or 
thousands of potential interactions. To test all of these experimentally for even a 
single pathway would involve multiple knockout studies taking an enormous 
amount of time to achieve. To circumvent this, bioinformaticians have developed 
computational algorithms which predict and infer interactions and the relation 
between contender markers. 
4.2 Network Inference 
 
Network inference is a field of computational systems biology which 
predicts and infers biological network by employing algorithms wherein the 
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interactions among the contender of the system are logically connected to each 
other representing the behaviour of the system (D'Haeseleer et al., 1999). The 
simplest network in systems graph is a pairwise relation between Nodes (called 
vertices) through Edges (called links). The nodes of cellular system may be genes, 
mRNA, proteins and/or other molecules. Edges are comprised of links between a 
source node and a target node representing the relation between the nodes. 
Depending on the availability of information, edges can have positive or negative 
values (representing activation or inhibition), weights (quantifying confidence 
levels), strength, and/or reaction speeds. 
The advent of high throughput post genomic technologies has enabled the 
cumulative study of thousands of biological molecules at a time. Network 
inference methods using high-throughput data depend on probing for patterns of 
partial correlation or conditional probabilities that indicate causal influence at any 
given time or across multiple times (Hayete et al., 2007).  
There are generally five types of biological networks that are widely 
inferred by using computational algorithms. They are;  
 Gene-gene interaction networks wherein the correlational association of 
expression between genes are investigated using experimental microarray data 
as inputs (Basso et al., 2005, Hartemink, 2005). 
 Protein-protein interaction networks wherein the mere association of a protein 
with other proteins is exploited without consideration of the functional and 
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conformational changes brought about by the association (Vazquez et al., 
2003).  
 Transcriptional regulatory networks exploit the fact that DNA (gene) 
transcribes to RNA (mRNA) which is then translated to protein. Some studies 
have utilised mRNA expression levels from microarray experiments as inputs 
in the networks to predict the target gene (Gutierrez-Rios et al., 2003). For 
example, the chromatin immune precipitation (ChIP) method explores 
transcriptional factors governing other gene’s expression (Wang et al., 2007). 
 Signal transduction network wherein amino acid modifications such as 
phosphorylation, dephosphorylation, methylation or ubiquitylation 
(representing activation or inactivation status of a protein) are of prime 
importance (Steffen et al., 2002). The signalling networks are also complicated 
by the fact that post-transcriptional and post-translational modifications may 
alter the concentration of involved or resultant protein (Beck et al., 2006), 
requiring complex and refined statistical intervention.  
 Metabolic interaction networks use measurement of the concentration of 
metabolites from experimental setups as inputs for the algorithms (Mahadevan 
and Palsson, 2005), wherein metabolites act as nodes and clubbing the 
information of enzyme kinetics and energy conversions has facilitated 
inference of complex interactions (Craciun et al., 2013). 
Recently, a number of computational methods have been established for 
inferring gene regulatory networks using Bayesian networks (Beal et al., 2005, 
Husmeier, 2003), differential equations (Chen et al., 2005, de Jong, 2002) and 
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optimization techniques (Tsai and Wang, 2005), in several organisms such as 
Saccharomyces cerevisiae (Xu et al., 2004), and Drosophila (Sun et al., 2003). 
Moreover, efforts from bioinformatics has been directed to the development and 
use of various network inference algorithms focussing on the linearity of datasets 
(D'Haeseleer et al., 1999), with target-regulator pair methods to predict functional 
interactions (Arkin et al., 1997).  
The cDNA microarray data with its added advantage of thousands of genes 
in single experimental setup serves as an ideal platform for investigating ER-
associated genes. In the past, several investigators have employed various 
machine learning methods for prediction and have struggled to overcome the 
problem of non-linearity of biological microarray datasets. Gruvberger et al has 
utilised ANNs to predict ER-associated gene signature in breast cancer patients 
(Gruvberger et al., 2001). However, an investigation of contribution of each 
contenders for prediction and the association of genes with respect to each other 
and was not attempted, until Lemetre et al proposed a novel method for 
quantifying interactions between predictive genes using ANN (Lemetre et al., 
2009). 
4.3 Aims and Objectives 
 
 To identify the importance of ER-associated genes in breast cancer 
disease, through an investigation of the contribution between ER-
associated genes  using ANN. 
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 To investigate the interactions in ER stratified (ER+ and ER-) samples in 
order to understand why ER dependent subgroup of breast cancer have 
varied response to treatment 
 To visualise the constructed interaction network models. 
 To corroborate the findings in published literature. 
 To validate ER-associated markers in clinical breast tumour samples. 
 
4.4 Methodology 
4.4.1 Gene-Gene Interaction analysis 
 
The pre-identified top 100 genes from the Stepwise-ANN method were 
applied to an ANN based gene-gene network inference algorithm developed by 
Lemetre et al. (Lemetre et al., 2009). This approach utilizes a feed forward back 
propagation algorithm to predict the expression level of a given probe from the 
other 99 probes in the set. The model is trained to optimum performance on 
unseen data using the Monte Carlo cross validation strategy. It is then 
parameterized to determine a weighting of the link from input probe to output 
probe. This link has both a sign and a magnitude. This process is repeated for the 
remaining 99 probes setting each probe as the output generating a total of 100 
models. 
The parameterizations of each of these models are then integrated to 
produce an interaction matrix. The 100 strongest interactions (representing the top 
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1% of interactions) were then selected for visualization. Using this multifactorial 
nonlinear ANN based inference approach has an advantage over simple linear 
regression based approaches in that the interaction may be nonlinear and that bi-
directionality can be modelled. 
 
4.4.2 Visualisation of network models 
 
For the visualization of the gene interactions in this study, we have used a 
free standalone Cytoscape Ver 2.7.3 software (http://www.cytoscape.org), as 
mentioned in Chapter 2, Section 2.8.6. The genes are represented as nodes and the 
interaction intensities as edges, presented in either positive (green) or negative 
(red) with the magnitude of interaction represented by the width of the edge.  The 
directionality is given from source to target and represented by arrows. The 
thickness of the edge was maintained proportional to the intensity of interactions 
by using a rescaling method of weights based on minimum and maximum values 
to squeeze the dimensionality of the edges to create more generalized models. 
 
4.5.3 Clinical validation of ER-associated markers: 
 
Tissue microarray sections of primary operable breast carcinoma patients 
from the Nottingham Tenovous Breast Cancer unit at the Nottingham NHS 
Hospital, collected between 1988 to 1998, were used to investigate the expression 
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of ER-associated markers by Immunohistochemistry. The patients were of age 
from 27 to 70 years with a median age being 55 years. The optimization of 
optimal antibody concentration and method was successfully carried out on tissue 
microarray of formalin fixed paraffin-embedded tissue sections. 
4.5.3.1 Immunohistochemistry reagents: 
 
Chemicals Supplier 
Absolute Ethanol  VWR 
Citric acid Sigma 
DPX mountant Sigma 
Hydrochloric acid Fischer Scientific 
Magnesium chloride Fischer Scientific 
Sodium chloride Fischer Scientific 
Sodium hydroxide Fischer Scientific 
Tris anhydrate Sigma 
Tween 20 Sigma 
Xylene Acros organics 
 
IHC reagents Supplier Catalogue No. 
Anti-VAV3 antibody; polyclonal, raised in goat Abcam ab21208 
Anti-DACH1 antibody; polyclonal, raised in rabbit Sigma HPA012672 
Secondary anti-goat antibody, biotintylated DAKO  
Secondary anti-rabbit antibody, biotintylated DAKO  
IHC staining kit DAKO REAL
™
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Preparations: 
 10mM Sodium citrate buffer [pH 6.0]: Dissolve 2.1g of Citric acid in about 
900ml of distilled water. Add 25ml of 1M Sodium hydroxide. Make up the 
volume to 1000ml with distilled water simultaneously adjusting the pH to 6.0 
with 1M Sodium chloride or 1M Hydrochloric acid. 
 
 Tris Buffered Saline (TBS) [pH 7.6]: Dissolve 21g of Tris and 6g of Sodium 
chloride in about 900ml of distilled water. Make up the volume to 1000ml with 
distilled water simultaneously adjusting the pH to 7.6 with 1M Sodium 
chloride or 1M Hydrochloric acid. 
 
 1% acid alcohol solution: Add 70% Ethanol (70ml absolute Ethanol in 30ml 
of distilled water) and 1ml of concentrated Hydrochloric acid. 
 
 Blueing solution: Dissolve a pinch of magnesium chloride crystals in distilled 
water.  
 
 
4.5.3.2 Immunohistochemistry protocol: 
 
 Melt the sections on a hot plate or in a hot air oven at 58-600C for 10 minutes. 
Dewaxing: 
 Dewax the sections in Xylene  2 times for 10 minutes each. 
 Pass through 3 changes of absolute Ethanol for 1 minute each. 
Rehydration: 
 Wash the slides in tap water for 1 minute. 
Antigen Retrieval: 
 Load the sections into a plastic tray and place in a plastic sandwich box holding 
850 ml of 10mM Sodium citrate (pH 6.0) buffer. 
Chapter 4: OSTROGEN RECEPTOR NETWORK INFERENCE WITH ARTIFICIAL NEURAL 
NETWORKS 
 
107 
 
 Place the box into the microwave and place the lid on the box so that there is a 
gap for steam to escape. 
 Turn on the microwave and set it to 80% for 23 minutes. Press START. 
 Periodically check the level of the citrate buffer so that the buffer level should 
not fall below the level of the slides. 
 When the time has elapsed, remove the box from the microwave. 
 Carefully lower the slide rack into a bowl of cold running water, in the sink. 
 Leave for 20 minutes. 
 Meanwhile, wash the container and clean the microwave for future use. 
Washing: 
 Incubate the sections in 0.1%Tween 20 in TBS at room temperature (RT) for 
20 minutes. 
 Incubate the sections in TBS at RT for 3 minutes. 
 Drain and wipe round sections. 
Blocking: 
 Carefully layer the sections with Peroxidase Block (H2O2 Blocking solution) 
[1:50] and incubate for 5 minutes at RT. 
 Drain the sections and wash in TBS for 5 minutes at RT with agitation. 
 Drain and wipe round the sections. 
Primary Antibody: 
 Carefully load the sections with Primary antibodies and incubate for 30 
minutes at RT 
 Drain the sections and wash in TBS for 5 minutes at RT with agitation. 
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 Drain and wipe round the sections. 
Secondary Antibody: 
 Carefully load the sections with Secondary antibodies and incubate for 30 
minutes at RT. 
 Drain the sections and wash in TBS for 5 minutes at RT with agitation. 
 Drain and wipe round the sections. 
Peroxidase Conjugation: 
 Carefully load the sections with Streptavidin (Peroxidase) conjugate reagent 
and incubate for 30 minutes at RT. 
 Drain the sections and wash in TBS for 5 minutes at RT with agitation. 
 Drain and wipe round the sections. 
Chromogen Addition: 
 Carefully load the sections with freshly prepared DAB Chromogen reagent and 
incubate for 10 minutes at RT. 
 Drain the sections and wash in tap water for 5 minutes at RT. 
Counter Staining: 
 Counterstain the slides with Haematoxylin by immersing the rack slides for 5 
minutes. 
 Wash well in running tap water. 
Acid Alcohol Treatment and Blueing: 
 Dip in 1% acid alcohol for 15-30 seconds. 
 Wash well in running tap water. 
 Dip in Blueing Solution for 5-10 seconds. 
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 Wash well in running tap water. 
Dehydration: 
 Pass the slides through 3 changes of Ab. Ethanol for 2 minutes each. 
 Pass the slides through 2 changes of Xylene for 2 minutes each. 
Mounting: 
 Mount the slide with DPX mountant with a coverslip. 
 After proper drying, visualise under the light microscope.  
 
4.5.3.3 Univariate and Multivariate statistical analysis 
The protein expression of ER-associated markers and their association with 
other categorical biomarkers was studied by Chi square test to produce 
contingency tables by using SPSS 16.0 statistical software (SPSS Inc, Chicago, 
IL, USA) Normal cytoplasmic staining with presence or absence of tumour 
associated membranous staining was categorically scored as positive or negative 
irrespective of staining intensity. A Kaplan Meier plot with a log rank test was 
used to assess disease free survival, breast cancer specific survival and time for 
metastasis formation. The number of months from diagnosis to invasive local 
recurrence, local lymph node or distant relapse was defined as the disease free 
survival. Patients who died from reasons other than breast cancer were censored 
during the survival analysis. A Mantle Cox log rank test compares survival rates. 
Independent prognostic effect of variables was evaluated by multivariate Cox 
proportional hazard regression with 95% confidence interval. A p-value of <0.05 
was considered to be significant. 
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4.5 Results 
4.5.1 ER interactomes 
 
In the gene-gene interaction model developed by considering the top 100 
genes associated with ER-status in a total (278) population of samples is depicted 
in the Figure 16. For simpler visualization of the complex network model 
generated, the model with only top 100 interactions is shown here. The nodes are 
represented as light blue or pink according to their up-regulated or down-
regulated status in the microarray dataset considered. The edges were scaled 
according to their minimum and maximum values to give a more generalized 
pattern of the interactions and to reduce the bias.  
The genes with multiple connecting edges (of weights >5) with other genes 
are termed as Hubs in this study. The top 100 gene-gene interaction model 
generated showed FOXA1 and GATA3 as being the positive hubs with multiple 
edges joining with other genes, whereas CDH3, TONDU, EGFR and SOX11 
appeared to be negative hubs. It was interesting to note that some edges had 
bidirectional links with other genes representing multiple associations with the 
gene or gene variants. It was also interesting to note that some edges had multiple 
regulations suggesting the involvement of genes in reciprocal regulation or feed-
back regulation with each other. Some genes were even found to be having self- 
regulatory effects such as DACH1, MAPT and GATA3. This phenomenon may be 
because genes such as GATA3 act as transcriptional regulators for other genes and 
so are self- regulatory. 
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Figure 16: Positive and negative interactions. Interaction  model of top 100 positive and negative interactions in breast cancer 
samples. The genes are represented as nodes and the interaction intensities as thickness of edges with directionality from source to 
target gene.  The light blue and pink nodes represents up-regulation and down-regulation respectively. The green and red edges 
represents positive and negative interactions respectively. 
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4.5.2 ER-Positive and ER-Negative interactomes 
 
In the later part of the study, we were interested in looking at the gene-gene 
interaction models when the samples were stratified based on their ER-status. 
Hence, a gene-gene interaction analysis was carried out on a separate cohort of 
ER-Positive (114 samples) and ER-Negative samples (164 samples). 
When the network inference was undertaken on the different ER status 
groups, the network interaction model (top 100 interactions) showed some 
interesting results. In the interaction model from ER-Positive samples (Figure 17), 
the genes CDH3, SOX11, EGFR were found to be highly negatively regulated by 
other genes. The highest negative regulation was noticed between CDH3 and 
SOX11. DACH, SERPINA5, ANXA9 and TFF3 formed the major positively 
regulated hubs. The highest positive interaction was found to be self-regulation of 
DACH. RARA was found to be acting as an ambiguous hub with both positive and 
negative interactions. 
In the gene-gene interaction network model from ER-Negative samples 
(Figure 18), VAV3, GAMT, ANXA9 appeared as positive hub. The negative hubs 
were again found to be CDH3, SOX11 and TONDU. This demonstrate the 
consistency of negatively regulated genes among ER-Positive and ER-Negative 
samples. 
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Figure 17: Interactions in ER-Positive samples. Interaction  model of top 100 positive and negative interactions in ER-Positive 
breast cancer samples. The genes are represented as nodes and the interaction intensities as thickness of edges with directionality 
from source to target gene. The light blue and pink nodes represents up-regulation and down-regulation respectively. The green and 
red edges represents positive and negative interactions respectively.  
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Figure 18: Interactions in ER-Negative samples. Interaction  model of top 100 positive and negative interactions in ER-Negative 
breast cancer samples. The genes are represented as nodes and the interaction intensities as thickness of edges with directionality 
from source to target gene. The light blue and pink nodes represents up-regulation and down-regulation respectively. The green and 
red edges represents positive and negative interactions respectively. 
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 The potential markers having multiple interactions from/with other genes 
act as hubs in these gene-gene interaction models. Further stratification of the 
samples based on the ER status and an investigation for markers acting as 
interacting hubs, identified a total of 17 potential hubs by considering a top one 
hundred interactions under each category of the samples. A list of 17 potential 
markers for the ER status group samples is tabulated in Table 11. The above 
results are published in IEEE-EMBS International Conference on Biomedical and 
Health informatics (Dhondalay et al., 2012) (Annexure 2).  
 
Table 11: ER-associated gene-gene interaction hubs. 
 
ER 
(278 samples) 
ER-Positive samples 
(114 samples) 
ER-Negative samples 
(164 samples) 
Positive 
Interactions 
FOXA1 ANXA9 ANXA9 
GATA3 DACH1 C6orf29 
 MGC2601 COX6C 
 RARA GAMT 
 SERPINA5 IGFBP4 
 TFF3 IL6ST 
  NME3 
  VAV3 
Negative 
Interactions 
CHD3 CHD3 CHD3 
SOX11 SOX11 SOX11 
TONDU EGFR TONDU 
 
Summary of interactions acting as hubs in ER total sample population and ER 
status stratified samples. Hubs where found to be with multiple links converging or 
diverging at particular gene when taken as nodes in gene-gene interaction models. 
Red representing negative, Green representing positive and yellow represents 
ambiguous interaction hubs. 
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4.5.3 Clinical validation of ER-associated markers 
 
Patient Selection and Tissue Microarray preparation: 
Primary operable breast carcinoma sample, aged 70 or less, were selected 
from patients presenting at the Nottingham Breast Cancer Unit from 1988 to 1998 
for Tissue MicroArray (TMA) preparation from Nottingham Tenovous series with 
additional biomarker data (Habashy et al., 2010).  
For comparison of observed heterogeneity for VAV3 (N=739) and DACH1 
(N=993) expression, paraffin processed TMA blocks were constructed from tissue 
core sampling from periphery avoiding areas of necrosis. A well characterised 
series was selected with information of patients’ clinical and pathological data of 
age, tumour size, histologic type, mitotic index, lymph node status and 
histological grade, NPI and vascular invasion. Information regarding the tissue 
protein expression for relevant tumour biomarkers, pathological markers and 
follow up data about local, regional and distant metastasis with survival outcome 
was also present. Maintained on a prospective basis was information regarding 
disease free survival (DFS), distant metastasis (DM) and breast cancer specific 
survival (BCSS).  
 
4.5.3.1 VAV3 protein expression: 
 
Sections stained for anti-VAV3 primary antibody (ab21208, Abcam), raised 
in goat and anti-goat biotinylated secondary antibody (DAKO), were used for 
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a b c d 
immunohistochemistry. The negative control section was stained with an 
inappropriate antibody for CD68 of the same immunoglobulin class. Figure 19 
shows the variation of VAV3 intensities classified as negative, weak, moderate 
and strong staining. 
 
 
Figure 19: VAV3 protein expression by IHC. Immunohistochemical staining of 
Grade III invasive ductal carcinomas showing cytoplasmic staining for VAV3 
expression.. VAV3 staining intensities as (a) negative, (b) weak (c) moderate and (d) 
strong staining pattern (x200). 
 
 
4.5.3.1 Association with clinicopathological markers 
 
Clinicopathological markers such as patient age, tumour size, tumour stage, 
tumour grade, tumour type, NPI, distance metastasis, Metastatic recurrence, 
vascular invasion, cellular proliferation as mitosis and menopausal status were 
investigated for association with VAV3 by using a Chi-square test. As a result, in 
the whole series of breast cancer patients compared for clinical parameters with 
VAV3, no significant association was found corresponding to any factor for the 
categories of negative and positive for VAV3 staining. Table 12 is the summary 
of the Chi-square test of VAV3 protein expression compared with 
clinicopathological markers of patients.  
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Table 12: VAV3 expression association with clinicopathological markers. 
Marker 
VAV3 Negative VAV3 Positive 
Chi-Square 
(χ2) 
p-value No. of 
cases 
% 
No. of 
cases 
% 
Age 
 
 
 
 3.686 0.946 
<40  51 6.9 51 6.9   
40 - 50 210 28.5 211 28.7   
51-60 251 34.1 250 34.0   
>60 251 30.40 224 ( 30.4   
Tumour Size 
 
 
 
 1.604 0.206 
<1.5cm 366 49.7 366 49.7   
>1.5 but < 2cm 370 50.3 370 50.3   
Tumour Stage 
 
 
 
 0.567 0.666 
1 461 62.6 462 62.4   
2 208 28.2 209 28.4   
3 68 9.2 68 9.2   
Tumour Grade 
 
 
 
 0.195 0.827 
1 115 15.6 115 15.6   
2 242 32.9 242 32.9   
3 379 51.5 379 51.5   
Nottingham Prognostic Index 
 
 
 
 0.16 0.763 
Poor 131 17.8 131 17.8   
Moderate  393 53.4 394 53.5   
Good 212 28.8 211 28.7   
Distant Metastasis 
 
 
 
 0.06 0.898 
No metastasis 508 69.9 508 69.9   
Metastasis present 219 30.1 219 30.1   
Recurrence 
 
 
 
 0.15 0.901 
No recurrence 423 59.0 423 59.0   
Recurrence present 294 41.0 294 41.0   
Vascular Invasion 
 
 
 
 0.932 0.337 
Negative 399 54.9 398 54.7   
Probable 103 14.2 104 14.3   
Definite 225 30.9 225 30.9   
Tumour Type 
 
 
 
 9.527 0.464 
Ductal - NST 429 59.3 429 59.3   
Lobular 66 9.1 66 9.1   
Tubular and tubular mixed 144 19.9 144 19.9   
Medullary 24 3.3 24 3.3   
Other special types (a) 11 1.5 11 1.5   
Mixed NST and Lobular (b) 44 6.1 44 6.1   
DCIS 3 0.4 3 0.4   
MISCA 2 0.3 2 0.3   
Mitosis 
 
 
 
 0.466 0.667 
1 23 32.9 231 32.9   
2 149 21.2 148 21.1   
3 322 45.9 323 46.0   
Menopause 
 
 
 
 0.38 0.846 
Premenopause 270 36.7 270 36.7   
Postmenopause 466 63.3 466 63.3   
 
VAV3 expression association with clinicopathological markers of 
tumour tissue. Sample distribution Multivariate Chi-square test along 
with p-values are indicated.  
Chapter 4: OSTROGEN RECEPTOR NETWORK INFERENCE WITH ARTIFICIAL NEURAL 
NETWORKS 
 
 
119 
 
 
 
4.5.3.1.1 Association with breast cancer markers 
 
The association of VAV3 protein expression with breast cancer related 
markers was investigated. A detailed list of breast cancer markers and Chi-square 
with statistical significance are tabulated in Table 13. VAV3 showed no 
significant association with hormonal makers such as ER, PgR, AR, Her2, Her3 
and Her4; or immunological markers such as CK5/6, CK7/8, and CD71. VAV3 
was also not significantly related to other breast cancer related markers such as 
ALCAM, CA9, cyclin D1, DGP4B5, ERBB2, HERCEPT, muc1, p16, p27, TK1, 
VEGF, FOXA1, p53, REGR, TFF1 and EGFR. Interestingly, VAV3 was found to 
be significantly associated with E-cadherin, PELP1, FHIT and BUC11 with p-
values of 0.01, 0.007, 0.003 and 0.000 respectively.   
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Table 13: VAV3 expression association with breast cancer markers. 
Markers 
VAV3 Negative VAV3 Positive Chi-Square 
(χ2) 
p-value 
No. of cases % No. of cases % 
ALCAM 
    
0.345 0.564 
Negative 14 77.8 4 22.2 
  
Positive 36 70.6 15 29.4 
  
AR 
    
0.084 0.772 
Negative 170 70.8 70 29.2 
  
Positive 286 69.8 124 30.2 
  
BUC11 Cyt 
    
17.08 0.000* 
0 14 46.7 16 53.3 
  
1 49 58.3 35 41.7 
  
2 87 75.0 29 25.0 
  
3 44 81.5 10 18.5 
  
c-myc 
    
0.913 0.341 
Negative 39 73.6 14 26.4 
  
Positive 126 66.7 63 33.3 
  
CA 9 
    
3.117 0.078 
Negative 158 70.5 66 29.5 
  
Positive 17 89.5 2 10.5 
  
CD 71 
    
0.154 0.696 
Negative 55 67.1 27 32.9 
  
Positive 132 69.5 58 30.5 
  
CK 5/6 
    
0.32 0.572 
Negative 392 68.8 178 31.2 
  
Positive 172 71.7 68 28.3 
  
CK 7/8 
    
0 0.984 
Negative 7 70.0 3 30.0 
  
Positive 483 69.7 210 30.3 
  
Cyclin D1 
    
0.896 0.347 
Low 72 68.6 33 31.4 
  
Moderate 43 72.9 16 27.1 
  
High 26 76.5 8 23.5 
  
DGP4B5 
    
2.2982 0.872 
Negative 215 69.1 96 30.9 
  
Positive 14 63.6 8 36.4 
  
Mod. Positive 9 52.9 8 47.1 
  
Str. Positive 35 74.5 12 25.5 
  
E-cadherin 
    
6.679 0.010* 
Negative 161 63.6 92 36.4 
  
Positive 317 73.0 117 27.0 
  
EGFR 
    
0.652 0.42 
Negative 340 69.8 147 30.2 
  
Positive 89 73.6 32 26.4 
  
ER 
    
0.034 0.853 
Negative 147 69.3 65 30.7 
  
Positive 332 70.0 142 30.0 
  
ERBB2 
    
0.082 0.775 
Negative 301 69.4 133 30.6 
  
Positive 176 70.4 74 29.6 
  
(Continued) 
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(Table 13 continued) 
Markers 
VAV3 Negative VAV3 Positive Chi-Square 
(χ2) 
p-value 
No. of cases % No. of cases % 
FHIT     9.011 0.003* 
Negative 67 58.8 47 41.2   
Positive 365 73.0 135 27.0   
FOXA1 
    
3.526 0.071 
Negative 168 64.9 91 35.1 
  
Positive 173 72.4 66 27.6 
  
HER2 
    
1.188 0.590 
1 224 70.0 96 30.0 
  
2 13 59.1 9 40.9 
  
3 36 67.9 17 32.1 
  
HER3 
    
1.797 0.181 
Negative 32 62.7 19 37.3 
  
Positive 382 71.7 151 28.3 
  
HER4 
    
0.049 0.826 
Negative 78 69.0 35 31.0 
  
Positive 335 70.1 143 29.9 
  
HERCPT 
    
0.527 0.469 
Negative 410 69.3 182 30.7 
  
Positive 75 72.8 28 27.2 
  
MUC 1 
    
1.792 0.182 
Negative 20 83.3 4 16.7 
  
Positive 225 70.5 94 29.5 
  
P 16 
    
1.034 0.311 
Negative 72 63.2 42 36.8 
  
Positive 103 69.1 46 30.9 
  
P 27_50 
    
0.909 0.342 
Negative 50 74.6 17 25.4 
  
Positive 130 68.4 60 31.6 
  
P53 
    
0.035 0.852 
Negative 326 70.1 139 29.9 
  
Positive 152 69.4 67 30.6 
  
PELP1 
    
8.222 0.007* 
Low 51 60.7 33 39.3 
  
Moderate 226 66.3 115 33.7 
  
Strong 60 81.1 14 18.9 
  
PgR 
    
0.029 0.866 
Negative 210 69.1 94 30.9 
  
Positive 262 69.7 114 30.3 
  
RERG 
    
0.345 0.558 
Negative 237 66.9 117 33.1 
  
Positive 101 69.7 44 30.3 
  
TFF1 
    
0.001 0.981 
Negative 155 69.2 69 30.8 
  
Positive 152 69.1 68 30.9 
  
TK1 
    
3.432 0.064 
Negative 122 62.9 72 37.1 
  
Positive 153 71.5 61 28.5 
  
VEGF 
    
3.011 0.084 
Negative 12 57.1 9 42.9 
  
Positive 58 76.3 18 23.7 
  
VAV3 protein expression association with breast cancer markers. 
Significant associations are labelled with *. 
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4.5.3.1.2 Association with clinical outcome of patients 
 
A multivariate Mantle-Cox regression analysis with minimal and maximal 
cut–off for 95% of confidence interval revealed that VAV3 was significantly 
associated with tumour stage and tumour grade for breast cancer specific survival, 
recurrence survival time and distance metastasis in breast cancer patient outcomes 
when the VAV3 expression absence against weak, moderate and strong staining 
intensities were considered. Table 14 summarizes the hazard ratio of VAV3 for a 
patient’s outcome prediction. 
 
Table 14: Mantle-Cox regression analysis of VAV3 for predicting patient outcome. 
  
Variable p-value 
Hazard 
Ratio 
Lower 
95 % CI 
Upper 
95% CI 
Breast cancer 
specific survival 
Tumour size 0.230 1.258 0.865 1.83 
Tumour stage 0.000* 1.894 1.408 2.547 
Tumour grade 0.000* 1.983 1.408 2.547 
Recurrence 
survival time 
Tumour size 0.150 1.23 0.928 1.631 
Tumour stage 0.000* 1.734 1.334 2.254 
Tumour grade 0.010* 1.398 1.083 1.805 
Distance 
metastasis 
Tumour size 0.198 1.242 0.893 1.728 
Tumour stage 0.000* 2.079 1.558 2.774 
Tumour grade 0.001* 1.675 1.234 2.275 
 
Prediction of patient outcome using VAV3 expression by Mantle-Cox 
regression analysis. CI = Confidence Interval. The significant 
associations are indicated with *. 
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4.5.3.2 DACH1 protein expression 
 
Four micron thick formalin fixed paraffin-processed TMA and full face 
sections were subjected to microwave antigen retrieval in citrate buffer (pH 6.0), 
and then immunohistochemically stained with a goat polyclonal antibody against 
DACH1 (Sigma HPA012672) using a streptavidin biotin technique (Dako, 
Cambridge, UK). The DACH1 antibody was optimised at a working dilution of 
1:250. Sections were counterstained in haematoxylin and mounted using DPX 
mounting medium. Negative controls comprising omission of the primary 
antibody or substitution with an inappropriate primary antibody of similar 
immunoglobulin class was used. 
The immunohistochemically stained TMA sections were scored by 
observers blinded to the clinicopathological features of tumours and patients’ 
outcome. Nuclear staining intensity and the percentage of cells stained was 
assessed in unequivocal malignant epithelium using the H-score (histochemical 
score)(McCarty et al., 1985). Staining intensity was scored from 0, 1, 2 or 3 and 
the percentage of positive cells at each intensity subjectively estimated to produce 
a final score in the range 0–300 as depicted in Figure 20.  DACH-1 H-score data 
was categorised using an H-score ≥200 to define positivity based on the histogram 
of frequencies. Damaged tissue cores and those that did not contain invasive 
carcinoma were censored.   
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Figure 20: DACH1 protein expression by IHC. Immunohistochemical staining of 
Grade III invasive ductal carcinomas showing nuclear staining for DACH1 
expression. DACH1 staining intensities as (a) negative as 0 (b) weak as 1 (c) 
moderate as 2 and (d) strong staining pattern as 3 for H-score. 
 
 
4.5.3.2 Association with clinicopathological markers 
 
To test the clinical relevance in breast cancer, the association of the DACH1 
protein with clinicopathology features was investigated in a well characterised 
patient cohort. The median age of the patients was 55 years (range 27-70). 
Nuclear DACH1 protein expression was significantly increased in post-
menopausal patients with lobular and tubular cancer types but in contrast, was 
rarely seen in patients with medullary cancer. DACH1 expression showed no 
significant association with tumour size, tumour stage, development of metastasis, 
tumour recurrence, or vascular invasion. DACH1 expression was significantly 
increased in tumours of low grade, good NPI and candidacy for hormonal therapy 
(Table 15).  
a b c d 
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Table 15: Association of DACH1 protein expression with clinicopathological markers. 
 
Association of DACH1 protein expression with clinicopathological 
markers of breast cancer patients. Statistical significant associations 
are indicated with *.  
Clinical Parameter 
DACH1 absent DACH1 present Chi-square 
(χ2) 
p-value 
N % N % 
Age group     12.505 0.006* 
<40 40 10.31 35 5.79   
40-50 128 32.99 176 29.09   
51-60 124 31.96 197 32.56   
>60 96 24.74 197 32.56   
Menopause     8.912 0.003* 
Premenopausal 174 44.85 214 35.37   
Postmenopausal 214 55.15 391 64.63   
Tumour Size     2.283 0.131 
≤1.5 cm 178 46.23 307 51.17   
>1.5 cm 207 53.77 293 48.83   
Tumour Stage     0.413 0.813 
1 241 62.27 362 60.23   
2 112 28.94 183 30.45   
3 34 8.79 56 9.32   
Tumour Grade     69.335 <0.001* 
1 35 9.09 134 22.33   
2 94 24.42 226 37.67   
3 256 66.49 240 40.00   
Nottingham Prognostic Index     22.571 <0.001* 
Good  75 19.48 200 33.28   
Moderate 233 60.52 309 51.41   
Poor 77 20.00 92 15.31   
Tumour type     57.194 <0.001* 
Ductal - Non Specific Type (NST) 260 68.60 314 53.04   
Lobular (Classical and variants) 28 7.39 85 14.36   
Tubular & Tubular mixed 50 13.19 136 22.97   
Medullary 20 5.28 3 0.51   
Special type (Mucinous, Cribriform 
and Invasive papillary) 
4 1.06 14 4.36   
Mixed NST with Lobular and 
special types 
17 4.49 40 6.76   
Distant metastasis formation     0.349 0.555 
Absent 268 69.43 425 71.19   
Present 118 30.57 172 28.81   
Tumour recurrence     0.078 0.780 
Absent 231 60.63 353 59.73   
Present 150 39.37 238 40.27   
Vascular invasion     5.345 0.069 
Negative 222 57.81 325 54.53   
Probable 33 8.59 80 13.42   
Definite 129 33.59 191 32.05   
Endocrine Therapy     9.085 0.003* 
Untreated 261 71.12 331 61.41   
Treated 106 28.88 208 38.59   
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4.5.3.2.1 Association with breast cancer markers 
 
Nuclear DACH1 expression was highly significantly increased in patients 
with ER-alpha positive tumours expressing PgR, and epithelial CK18/19 
cytokeratins. Significant positive associations were seen with ‘luminal-like’ 
markers of good prognosis including FOXA1 and RERG. In contrast, highly 
significant inverse associations were found with luminal markers indicating poor 
prognosis including CD71 and TK1 (Table 16 showing association with other 
biomarkers). 
Supporting its association with good prognosis, tumour’s DACH1 
expression significantly correlated with low cell proliferation (MIB1) and the 
functional apoptosis marker Bcl2. Low DACH1 frequency and expression was 
seen in tumours bearing markers of poor prognosis including the basal-like 
markers CK14/5/6 and EGFR, as well as the HER2 and p53 positivity. 
 
4.5.3.2.2 Association with clinical outcome of patients 
 
Nuclear DACH1 positivity showed a significant association in predicting 
cancer specific survival (χ2=11.96, p<0.001), disease free interval (χ2=15.33, 
p<0.001), tumour recurrence (χ2=16.49, p<0.001) and distant metastasis 
(χ2=16.31, p<0.001) over 5 years post diagnosis (Figure 21). However, the level 
of significance lessened for predicting cancer specific survival (χ2=2.31, p=0.13),  
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Table 16: Association of DACH1 protein expression with breast cancer markers. 
Markers 
DACH1 absent DACH1 present Chi-square 
(χ2) 
p-value 
N % N % 
ER     142.867 <0.001* 
Absent 181 49.45 78 13.66   
Present 185 50.55 493 86.34   
PgR     55.671 <0.001* 
Absent 212 58.56 191 33.69   
Present 150 41.44 376 66.31   
CK18     54.282 <0.001* 
Absent 86 24.86 39 7.21   
Present 260 75.14 502 92.79   
CK19     5.786 0.016* 
Absent 50 13.51 50 8.61   
Present 320 86.49 531 91.39   
HER2     6.595 0.010* 
Absent 311 83.38 524 89.12   
Present 62 16.62 64 10.88   
E-cadherin     0.853 0.356 
Absent 145 40.06 213 37.04   
Present 217 59.94 362 62.96   
EGFR     6.371 0.012* 
Absent 249 76.62 425 83.66   
Present 76 23.38 83 16.34   
CK5/6     66.158 <0.001* 
Absent 267 71.97 534 91.75   
Present 104 28.03 48 8.25   
CK14     11.671 0.001* 
Absent 304 82.83 518 90.40   
Present 63 17.17 55 9.60   
p53     33.999 <0.001* 
Absent 227 62.71 457 80.04   
Present 135 37.29 114 19.96   
MIB1     28.563 <0.001* 
Absent 59 29.95 154 54.61   
Present 138 70.05 128 45.39   
BCL2     10.510 0.001* 
Absent 21 19.63 21 7.89   
Present 86 80.37 245 92.11   
FOXA1       26.495 <0.001* 
Absent 178 62.9 174 43.0   
Present 105 37.1 231 57.0   
TFF1         1.563 0.211 
Absent 133 53.6 174 48.5   
Present 115 46.4 185 51.5   
CD71         25.926 <0.001* 
Absent 90 32.4 220 51.9   
Present 188 67.6 204 48.1   
TK1         9.172 0.002* 
Absent 94 41.6 183 54.6   
Present 132 58.4 152 45.4   
PELP1(170)         0.375 0.540 
Absent 250 87.4 369 85.8   
Present 36 12.6 61 14.2   
RERG         4.291 0.038* 
Absent 214 78.7 306 71.7   
Present 58 21.3 121 28.3   
 
Association of DACH1 with breast cancer biomarkers. N=number of 
samples. Statistically significant p-values are indicated with *.  
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disease free interval (χ2=1.75, p=0.17), tumour recurrence (χ2=2.11, p=0.15) and 
distant metastasis (χ2=3.74, p=0.053) over 10 years. 
The effect of endocrine therapy on the ability of DACH1 to predict breast 
cancer specific survival using Kaplan-Meier modelling was considered. DACH1 
positivity was associated with good survival in patients treated with tamoxifen 
(χ2=8.30, p=0.004) and in addition, also showed a strong trend in patients not 
receiving tamoxifen (χ2=3.7, p=0.055).    
The predictive independence of DACH1 was tested using multivariate Cox 
regression models. DACH1 remained an independent predictor of specific 
survival (Hazard ratio (HR))=0.69, p=0.012, 95% CI=0.52 – 0.92) when hormonal 
treatment was considered, but not when tumour grade (HR=1.006, p=0.97, 95% 
CI=0.77 – 1.31) was taken into account. 
 
Figure 21: Association of DACH1 protein expression with clinical outcome of 
patients. Association of DACH1 protein expression with clinical outcome of 
patients using Kaplan-Meier plots for 5 year post-diagnostic for (a) Survival, (b) 
Recurrence and (c) Distant metastasis. 
DACH1 
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DACH1 
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DACH1 
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DACH1 
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DACH1 
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DACH1 
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(a) (b) (c) 
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4.6 Discussion 
 
The aim of this chapter was to investigate the interactions between ER-
associated genes in breast cancer microarray dataset, utilising an ANN-based 
network inference method. The analysis was successful in quantifying the 
interactions. Promisingly most of the interacting hubs recorded were found to be 
relevant with respect to breast cancer or tumorigenesis process of disease 
progression i.e., FOXA1, GATA3, CA12 and CDH3. Surprisingly, when 
comparing the interacting hubs identified from the total population of sample 
without ER stratification and after stratification, there were some distinct 
observations noticed. We could notice that the negative hubs were found to be 
more consistent than the positive hubs. Below are some of the most prominent 
genes found to be highly interacting with others and their literature corroboration.  
 
4.6.1 Literature validation of ER-associated markers 
 
FOXA1: 
The forkhead box A1, FOXA1 gene is localised on 14q21.1. The gene codes 
for a protein which is a forkhead class of DNA binding proteins acting as 
transcriptional activators. FOXA1 is involved in embryonic development, 
differentiation and tissue specific gene expression regulation (Lupien et al., 2008). 
FOXA1 binding with consensus sequences on DNA and interacting with histones, 
brings about relaxation of chromatin and facilitates enhancer or promoter site 
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availability to other transcriptional regulators (Taube et al., 2010). Supporting our 
findings, FOXA1 is found to be involved in ESR1-mediated transcription 
(Hurtado et al., 2011). Specifically in breast cancer, FOXA1 is necessary for 
ESR1-NKX2-1 promoter binding (Minoo et al., 2007), ESR1-induced repression 
of RPRM (Malik et al., 2010), and also facilitates apoptosis by repressing BCL2 
expression (Song et al., 2009). Furthermore, FOXA1 has also been considered as a 
prognostic indicator (Habashy et al., 2008), of disease-free survival in luminal A 
subtype in breast cancer (Badve et al., 2007).            
From ANN-based interaction inferencing, the FOXA1 gene which appeared 
as a positive hub in total samples, was not found to be an hub in ER-stratified 
samples. This suggests that FOXA1 expression is controlled by other genes. 
Conformingly, FOXA1 expression was found to be directly dependent on GATA3 
expression in ER positive samples (Albergaria et al., 2009). Furthermore, the 
reason FOXA1 is unable to act as interacting hub during sample stratification may 
be because of the expression pattern of the gene itself. FOXA1 was found to have 
an up regulated expression in both ER-Positive and ER-Negative samples with 
mean expression of 10.52 and 8.44 respectively. The population distribution of 
FOXA1 revealed that there was clear step-function in the expression pattern of the 
FOXA1 that hindered an active classification of samples due to lack of learning of 
the pattern by the Stepwise-ANN. 
GATA3: 
The GATA3 gene, encodes a protein belonging to GATA family of 
transcription factors and is found to be vital for T-cell development since it binds 
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to 5´-AGATAG-3´ consensus sequence of enhancer of T-cell receptor α and β 
(Wei et al., 2011). GATA3 is related with Barakat syndrome which is 
characterised by hypothyroidism, renal dysplasia and sensorineural deafness 
(Zahirieh et al., 2005), and rheumatoid arthritis (Kawashima and Miossec, 2005). 
In breast cancer, GATA3 expression is associated with ER (Hoch et al., 
1999), and exhibits coregulatory activity with ESR1 (Eeckhoute et al., 2007). In 
non-invasive (MCF-7) and in invasive (MDA-MB-231) breast cancer cell lines, 
GATA3 is found to be associated with a reversal of epithelial to mesenchymal 
transition, thus inhibiting metastasis (Yan et al., 2010). GATA3 as a marker of 
hormonal response (Fang et al., 2009), is found to be a prognostic marker in TMA 
meta-analysis (Mehra et al., 2005). Even though, GATA3 has a strong association 
with ESR1, it lacks prognostic value independently (Voduc et al., 2008), but 
serves as a prognostic indictor in hormone-negative tumours along with FOXA1 
(Albergaria et al., 2009). Supporting to this, in our ANN-based interaction 
inference model, GATA3 is found to positively interact with FOXA1 in the breast 
cancer samples. 
CA12: 
CA12, a transmembrane carbonic anhydrase isoform is activated in response 
to low oxygen as a marker of hypoxia (Wykoff et al., 2001). CA12 regulates intra 
and extracellular pH and is an important therapeutic molecule targetable by 
carbonic anhydrase inhibitors (Pastorekova et al., 2008). Hypoxia inducible 
growth factor brings about a change in cellular expression programme by 
activating genes involved in angiogenesis, anaerobic glycolysis, deadhesion and 
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invasion. This potentiates aggressive, metastatic spread and poor response to 
therapy in tumour cells. Hypoxia through physiological stress causes 
accumulation of acidic products and induction of CA12 expression in breast 
cancer cells (Wykoff et al., 2000). 
In breast tumour cells, cellular response to hypoxia is mediated by Hypoxia 
Inducible Factor 1 (HIF1) whose expression is indicative of poor prognosis. In a 
study by Tureci el at., 77 out of 103 ER positive breast cancer patients showed 
CA12 expression associated with negative EGFR, absence of necrosis and low 
grade of tumor (Tureci et al., 1998). In another study, 84% DCIS, and 71% 
invasive breast cancers show CA12 expression with low grade and good prognosis 
(Potter and Harris, 2003). Tumors positive for CA12 showed lower relapse rate, 
better survival and better prognosis in invasive breast cancer (Watson et al., 
2003).  
IGFBP4: 
The insulin like growth factor binding protein (IGFBP) 4 belongs to Insulin 
like growth factor system consists of two peptides (IGF I & II),  two receptors 
(IGF IR & IIR) which are homologous to each other and pro-insulin (Douglas et 
al., 2010), six insulin like growth factor binding proteins (1-6) and four insulin 
like growth factor binding protein related peptides. The mechanism of action of 
IGFBP4 involves binding with IGF I & II and then bringing about a change in 
their biological activity (Durai et al., 2006). Over expression of IGFBP4 inhibits 
cell cycle proliferation and induces apoptosis. Reduced expression of IGFBP4 
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increases the availability of IGF I, affects vascular growth response and presents 
anti-proliferative action which is important in cancer biology. 
In breast cancer IGF I and II act as potent mitogens stimulating growth. In a 
study by Douglas et al., on breast cancer patients, inhibited binding of IGF to 
IGFR1 indicating that IGF I and II stimulated breast cancer cell growth (Douglas 
et al., 2010). In ER α positive breast cancers, estradiol combines with IGF to 
promote cell growth through ligand independent activation of ER occurring by 
activation of MAPK phosphorylation (Wood and Yee, 2000). IGFBP4 is also one 
of the highly expressed genes in the ER-Positive group with tamoxifen failure 
compared to the control study group (Vendrell et al., 2008). IGFBP4 high 
expression was found in the nucleus and cytoplasm in breast tumour cells. The 
raised nuclear expression was induced by estrogen which stimulated ER positive 
breast cancer cell growth (Yoshida et al., 2004). IGFBP4 formed an independent 
prognostic factor of disease free survival in ER positive breast cancer patients 
having a high IGFBP4 expression (Mita et al., 2007).  
CDH3: 
The placental (P)-cadherin 3, CDH3 gene encodes a calcium dependent cell-
cell adhesion glycoprotein consisting of five extracellular repeats, a 
transmembrane and a highly conserved cytoplasmic trail peptide. CDH3 is 
localised at 16q22.1 within six cadherin cluster. CDH3 expression is highly 
associated with differentiation of lung carcinoma cells (Shimoyama et al., 1989). 
Imai et al., found CDH3 to be having tumour antigen-specific immunotherapy 
potential in colorectal and pancreatic cancers (Imai et al., 2008).  
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In breast cancer, P-cadherin inhibits invasion and metastasis functioning as 
a pro-adhesive and anti-invasive molecule (Paredes et al., 2004). Moreover, P-
cadherin indicates poor prognosis in patients due to hypomethylation of its 
promoter region (Paredes et al., 2005). 
VAV3: 
The VAV3 oncogene is a member of the VAV family of guanine nucleotide 
exchange factors associated with nucleotide free-state of guanocine 
triphosphatase, cytoskeleton rearrangement and transcriptional alterations. The 
VAV family consists of 3 members; VAV, VAV2 and VAV3 present on 
chromosome 19, 9 and 1 respectively in humans. Among the members, the VAV 
gene is expressed in the hematopoietic cells causing stimulation of Interleukin-2. 
VAV2 expression is ubiquitous and VAV3 has a broader expression profile 
(Moores et al., 2000).  In the case of the VAV3 gene, the zinc finger domain region 
increases VAV3’s binding and activation ability (Bustelo, 2001). Movilla et al., 
has confirmed VAV3’s participation in protein tyrosine kinase pathway (Movilla 
and Bustelo, 1999). 
VAV3 also causes androgen receptor transactivation by PI3K/AKT pathway 
and thus plays an important role in cancer development and progression (Dong et 
al., 2006). In tumour cells, activation and hypersensitivity is mediated by 
PI3K/AKT signalling which causes progression and antiestrogen resistance in 
breast cancer cells. Overexpression of the VAV3 protein is noticed in poorly 
differentiated tumours. The SH2, PH and DH domains of VAV3 interact with the 
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receptor protein tyrosine kinase, PIP3 and ERα respectively thus potentiating 
regulation of cell differentiation cell growth and ERα activation (Lee et al., 2008). 
Through our immunostaining of VAV3 in the 739 TMAs from Nottingham 
Tenovous Series of breast cancer patients, we did not observe association of 
VAV3 protein expression with any clinicopathological markers and patient 
clinical outcome. But we did find VAV3 significantly associated with cell 
adhesion marker E-cadherin (p=0.010), luminal markers FHIT (p=0.003) and 
PELP1 (p=0.007).  
DACH1: 
The Drosophila DACH gene, is a member of the retinal determination gene 
network family of nuclear proteins. It plays an important role in the development 
of Drosophila eye and limb, and regulates cell fate programming by encoding a 
chromatin associated protein (Hammond et al., 1998). In humans, DACH1 
expression is associated with breast, ovary, renal, and gastric carcinomas. 
In breast cancer, DACH1 plays a vital role. DACH1 physically associates 
with ERα to inhibits ER ligand dependent activity and DACH1 expression 
correlates with ERα (Popov et al., 2009). DACH1 inhibits cellular migration and 
metastasis by inhibiting interleukin-8 (Wu et al., 2008). Moreover, DACH1 is 
associated with cell fate determination and cellular proliferation by inhibiting 
cyclin D1 activity,  wherein cyclin D1 acts as a check point for transition from the 
G1 to S phase of the cell cycle (Wu et al., 2006). Many cancer cells over express 
cyclin D1 which correlates with their DACH1 expression (Nan et al., 2009). 
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Cellular proliferation and migration in hormone dependent breast and prostate 
cancer repressed by DACH1 (Popov et al., 2009). DACH1 expression is found to 
be greater in normal cells compared to metastatic cells in breast cancer TMA 
samples (Wu et al., 2008). Reduced DACH1 and increased FOX expression can 
cause deregulation of the genes associated with tumorigenesis (Zhou et al., 2010). 
Through our ANN based interaction modelling method in ER-positive 
samples, we found DACH1 to be one of the positive hubs and positively 
interacting with other ER associated genes. On the contrary, DACH1 did not 
appear as an interacting hub in ER-negative samples by network inference as well 
as immunostaining methods, supporting its relevance with ER positivity.  
Immunostaining for DACH1 has revealed significantly reduced expression 
in invasive cancer compared to normal breast epithelium. DACH1 expression was 
also found inversely proportional to mitosis and cyclin D1 expression in breast 
cancer patient samples (Wu et al., 2006). More recently, DACH1 expression is 
also correlated with reduced expression of IL-8 and other related chemokines, 
thus inhibiting cellular migration and invasion in MCF10A cells (Wu et al., 2008); 
as well as in endometrial cancers (Nan et al., 2009). It is known that DACH1 
homozygous deletion stimulates tumorigenesis in glioma cells (Watanabe et al., 
2011). Furthermore, it is also found that DACH1 overexpression represents poor 
prognosis in ovarian cancers (Liang et al., 2012). 
Significant association of DACH1 with cellular proliferative markers such 
as MIB1 and Bcl2 in our studies is supported with the fact that DACH1 
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suppresses cellular proliferation, growth and survival through TGF-beta signalling 
pathway by binding with Smad4 (Wu et al., 2003), and DNA synthesis inhibition 
by DACH1 in breast epithelial cells (Wu et al., 2006). Contrastingly,  DACH1 
loses its tumour suppressor activity in cancer cells grown with IGF-1 (DeAngelis 
et al., 2011). 
The hormonal responsiveness of DACH1 in breast cancer patients was also 
confirmed by significant association of DACH1 expression with ER (also through 
our DACH1 interactome), PgR and HER2. Moreover, the resistance in anti-EGFR 
treatment using Cetuximab is also found (DeAngelis et al., 2011). But with 
respect to tamoxifen treatment, DACH1 was significantly associated with good 
prognosis.  
Through immunostaining of the DACH1 protein, we investigated DACH1 
protein expression association in 993 samples from the Nottingham Tenovous 
series TMA. DACH1 protein expression was significantly associated with 
clinicopathological factors such as age (p=0.006), menopause status (p=0.003), 
tumour grade (p=<0.001), tumour type (p=<0.001), NPI (p=<0.001) and 
endocrine treatment (p=0.003). DACH1 protein expression was also significantly 
associated with breast cancer markers such as hormonal markers ER (p=<0.001) 
and PR (p=<0.001); HER2 (p=0.010); growth factor EGFR (p=0.012); 
immunological markers CK5/6 (p=<0.001), CK14 (p=0.001), CK18 (p=<0.001) 
and CK19 (p=0.016); cell cycle marker p53 (p=<0.001); cellular proliferation 
markers MIB1 (p=<0.001) and BCL2 (p=0.001); luminal markers FOXA1 
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(p=<0.001), CD71 (p=<0.001), TK1 (p=0.002) and RERG (p=0.038). DACH1 
was found to be an independent predictor of specific survival (HR=0.69, p=0.012) 
with hormonal therapy. 
4.7 Summary and Conclusion 
 
Breast cancer is a complex and heterogenous disease, ER protein alone is 
unable to provide extensive information for biology of breast cancer. However, 
ER-associated genes and their contribution towards the ER phenotype in the 
breast cancer may provide sufficient information. To investigate the interaction 
among ER-associated genes, an ANN-based gene-gene network inferencing 
method was adopted. This inference method was successful in quantifying the 
interaction magnitudes depending on the weights used to predict the expression of 
the target gene from the source gene expression. The representation of genes as 
nodes and interaction as edges enabled the visualisation of the network models. 
Positive weights representing positive regulation and negative weights 
representing negative regulation of interaction was also applied. The directionality 
of interaction was assigned from source to target gene. 
ANN-based network inference analysis of breast cancer sample expression 
profile was helpful in identification of interacting hubs. There were quite distinct 
differences in interacting hubs between the total breast cancer samples and ER-
status based stratified samples. The ANN method was found to be promising in 
pulling out most of the breast cancer associated genes such as FOXA1, GATA3, 
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CDH3, CA12 successfully and inferring involvement of them in breast cancer 
development and disease prognosis.  
Clinical validation of the DACH1 protein expression in breast tumour 
tissues suggested that DACH1 could act as an independent predictor for breast 
cancer specific survival with hormonal therapy.  
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Chapter 5 
SYSTEMS BIOLOGY OF ER RELATING TO 
BREAST CANCER 
 
 
Chapter abstract: The systems biology approach to modelling biological system 
comprises a dynamic interconnection of elements. In the case of complex diseases 
such as breast cancer, investigation of cross-talk between components of ER (ERα 
and ERβ) might give information on disease aggressiveness and prognosis. To 
investigate contenders of ER system and cross talk between them, in this study we 
have identified and utilised ESR1 (coding for ERα) and ESR2 (coding for ERβ) 
predictive markers with ANN-based modelling approaches. The bespoke ANN-
based network inference algorithm was also used for construction of interactomes of 
ESR1 and ESR2. Simulation of the ER system from known interacting molecules of 
ESR1 and ESR2 using ANN-based network inference revealed close association 
between ER-associated markers such as PGR, AR, EGFR, FOXA1 and RARA, 
validating biological relation between ER and PR along with AR. ER system 
simulation also validated ERBB2 cluster as a separate entity apart from ER and PGR. 
5.1 Introduction 
 
Systems biology is a science dealing with the study of biology and medicine 
incorporating computational mathematical approaches to model biological systems 
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through prerequisite understanding of how the elements are interconnected or 
interrelated, in both a structural and dynamic way (Kitano, 2002b, Kitano, 2002a). 
Broadly, there are two approaches adopted by researchers to understand the 
interconnections. 
 Pathway-centric approaches are governed by the associated pathway of the 
marker or a process studied. Apart from primitive single-pathway models, 
recently the cross-talk between the kinase inhibitors influencing the migration of 
cells with overexpression of Her2 in mammary epithelial cells was investigated 
adopting a multi-pathway model (Lee et al., 2006). 
 Interactomic approaches are the consideration of all possible cross-talk or 
interactions of the marker of study with protein-DNA or protein-protein 
associations (Rual et al., 2005). 
There has been an exponential increase in the application of ‘systems biology 
approaches’ from nearly one hundred reported publications in 2000 to over one 
thousand in 2012 in NCBI’s PubMed library. Examples of their successful 
applications include: - Drug discovery (Cho et al., 2006); predicting oncogenes and 
molecular perturbations in B-cell lymphoma (Mani et al., 2008); neurodegenerative 
disorders such as multiple sclerosis and Alzheimer’s (Goni et al., 2008); for pathway 
modelling and discovery (Bosl, 2007). These dealt with various aspects of disease 
and effective treatment discovery.   
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5.1.1 Systems biology in breast cancer 
 
It is currently accepted that breast cancer is not a single disease, but instead it 
is a highly heterogenous disease, with complex pathology. It shows dysregulation of 
multiple pathways governing cellular proliferation, differentiation, migration and 
death. It could arise from multi-pathway dysregulation. In addition Perou et al. has 
formulated “intrinsic subtypes of breast cancer” identifying 5 distinct tumour types 
and a normal breast-like group, to predict patient relapse, overall survival and 
response to endocrine and chemotherapy (Caldas and Aparicio, 2002, Perou, 2011, 
Perou et al., 2000).   
Predicting clinical outcome in patients is very necessary but highly 
challenging. There are two computational algorithms that have been developed to 
predict the clinical outcome in patients using patterns of gene expression data 
available, namely Mammaprint
®
 and OncotypeDX RS
®
 (Kaklamani, 2006, 
Slodkowska and Ross, 2009). Gene expression profiling using DNA microarray has 
contributed considerably to our understanding of complex pathways (Itadani et al., 
2008), thus can promisingly help us to understand the molecular heterogeneity of 
breast cancer formation, progression and recurrence. 
Recently there has been an increase in biomarker identification using genome-
wide expression profile analysis (Golub et al., 1999, Ramaswamy and Perou, 2003). 
This has enabled researchers to attempt systems biology approaches in breast cancer. 
Chuang et al. have investigated markers associated with breast cancer metastasis by 
using protein network-based methods. Here individual markers having differential 
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expression between metastasis groups were considered as sub-networks of a protein-
protein interaction network rather than as conventional individual markers (Chuang 
et al., 2007). Furthermore, Faratian et al. has proposed a novel cell signalling kinetic 
model to identify the role of PTEN in trastuzumab resistance in breast cancer 
(Faratian et al., 2009). 
Even though systems biology approaches have seen significant applications, 
current published approaches possess some limitations. In the majority of the studies, 
investigators have considered only a small subset of highly predictive or highly 
discriminative markers associated with their question, later extending their studies to 
validation of findings based on Gene Ontology pathway-based analysis (Chuang et 
al., 2007). One of the prime hurdles to pathway-based analysis is the absence of 
information for the majority of human genes in relation to a given pathway. 
Furthermore, the overlapping of genes with other different pathways makes 
interpretation highly challenging. 
In the case of complex diseases such as breast cancer, little information is 
known about predictive and prognostic markers. Even less is known about the cross-
talk between the ER counterparts such as ERα (coding gene ESR1) and ERβ (coding 
gene ESR2). Knowledge of the interaction between ESR1 and ESR2 could be 
beneficial for determining more contenders of aggressive disease. 
Discovery of biomarkers in the ER pathway holds promise for finding new 
druggable targets potentially inhibiting ER. Use of reductionist approaches through 
knock out techniques to characterise the functionality of biomarkers is a time and 
effort consuming task. Moreover, the functionality is a complex result of collective 
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influence of all the possible contenders at the same time and space in a biological 
system. Hence, non-reductionist computational approaches to systems biology have 
the potential to represent the complexity of biological system.  
ANNs have been shown to be able to deal with the non-linearity in biological 
datasets, making them successful in class prediction (Lancashire et al., 2009), 
finding markers of biological relevance. For example ER class prediction 
(Dhondalay et al., 2011) and gene-gene network inferencing in breast cancer 
(Dhondalay et al., 2012, Lemetre et al., 2009). From a computational viewpoint, 
systems biology has inspired network modelling approaches promising need-
oriented methodologies specific to data associated with given question (Kreeger and 
Lauffenburger, 2010). In this study, ANN is used for application in systems biology. 
5.2 Aims and objectives 
 
 As both the components of ER system i.e., ERα (ESR1) and ERβ (ESR2) play 
an important role in determining the aggressiveness of disease, the first aim 
of work is the identification of predictive markers of ESR1 and ESR2. 
 
 Following this, the investigation of cross-talk between ESR1-associated and 
ESR2-associated markers through ANN-based network inferencing method 
highlights the influence of associated markers on overall ER system. 
 
 Finally, ANN-based network inference contenders are validated with known 
contenders of ER system.   
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5.3 Materials and methods 
 
5.3.1 Breast cancer microarray dataset 
 
The E-GEOD-20194 dataset (Shi et al., 2010), a pre-normalised cDNA 
microarray breast cancer dataset developed on the HG-U133A platform, was 
obtained from EMBL-EBI database library (http://www.ebi.ac.uk/arrayexpress). The 
dataset consisted of 22283 probesets across 278 primary breast cancer samples. The 
samples were classified based on the median expression values of ESR1 and ESR2 
probes as positive for samples having expression values greater than median values 
and as negative for samples having expression values lesser than median values of 
the population. 
 
5.3.2 ANN architecture and model development 
 
Selection of predictive markers: 
A Stepwise-ANN coupled with back-propagation of error algorithm  as 
described earlier (Lancashire et al., 2009), was used to predict ESR1 and ESR2 class. 
All available 22283 probesets from the array were used as single input variables for 
training each model. The algorithm parameters consists of momentum of 0.5, 
learning rate of 0.1 and 3000 epochs with a threshold window of 1000. The models 
were subjected to MCCV partition as 60% for training, 20% for testing and 
remaining 20% for validation. The whole process was repeated for 10 independent 
iterations. The probesets were selected based on the predictiveness of each probeset 
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by considering averaged error in the test subset of samples. From this ranking, 100 
highly predictive probesets were selected for network inferencing. 
 
Network inference algorithm: 
 
The 100 highly predictive probesets for ESR1 and ESR2 derived from the 
stepwise-ANN method were analysed to model interactions by a gene-gene network 
inference algorithm (Lemetre et al., 2009). Here, the expression of a given probeset 
was predicted one at a time from all the other probesets iteratively i.e., 99 used to 
predict 1. The samples are subjected to MCCV strategy to optimise performance on 
unseen data in training. Weights of the trained models were used to determine the 
magnitude network. Once all probes had been considered as output, a matrix of 
interactions was produced. The weight of the link with respect to input and output 
probes is determined along with sign and magnitude. This complete process was 
repeated 10 times independently to develop a generalised models and averaged 
across all 10 to increase consistency and averaged accuracy. All interactions with 
ESR1 and ESR2 were selected to construct ESR1 and ESR2 interactomes 
respectively.  
 
Visualisation of network interactomes: 
As described earlier in Chapter 2 (Section 2.8.6), we have utilised Cytoscape 
Ver 2.7.3 software to visualise the interactome models of both ESR1 and ESR2. In 
the interaction models, the genes were represented as nodes and the interaction 
intensities as edges. The directionality of the edges as an arrow is maintained from 
source to target. The edges were either positive (green) or negative (red) along with 
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the magnitude of interaction as the thickness of the edges. The thickness of edge was 
scaled based on minimum and maximum interaction values across all interactions to 
squeeze the dimensionality of edges to create more generalized models. 
 
5.3.3 ESR1 and ESR2 interactome simulation and validation 
 
All previously reported (known) interactions of ESR1 and ESR2 were pooled 
from both genomic and proteomic interaction databases namely; VEGA (Vertebrate 
Genome Annotation database) (Wilming et al., 2008), Ensemble from Welcome 
Trust Sanger Institute, Uniprot KB (UniProtein Knowledgebase), HPRD (Human 
Protein Reference Database) (Peri et al., 2003), HGNC (HUGO Gene Nomenclature 
Committee)  (www.genenames.org), OMIM  (Online Mendelian Inheritance in Man) 
from John Hopkins University, Entrez gene, GeneBank and RefSeq from National 
Centre for Biotechnology Information, STRING (Szklarczyk et al., 2011), MINT 
(Molecular INTeraction database) (Chatr-aryamontri et al., 2007) and Gene Cards 
(www.genecards.org). The BioGRID (Biological General repository for Interaction 
Datasets) platform was used to merge interactions from the above mentioned 
databases (Breitkreutz et al., 2003). 
 
5.3.4 ER system simulation 
 
Both, the ERα (ESR1) and ERβ (ESR2) subunits were considered and 
combined to construct a simulation of the ER system. After merging 438 interactions 
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of ESR1 and 422 interaction of ESR2, a total of 412 unique molecules were 
considered to be within the putative ER system. The gene expression profiles of all 
412 genes were selected from the E-GEOD-20104 breast cancer microarray dataset. 
As described earlier, an ANN gene-gene network inference method was used for 
network modelling and simulation. 10 independent model simulations of 412 genes 
across 278 samples were performed for the generalisation of models. 
5.4 Results: 
 
5.4.1 ESR1 and ESR2 predictive markers 
 
A bespoke Stepwise-ANN based predictive modelling approach (Chapter 2, 
section 2.7) was used to identify predictive probes for ESR1 and ESR2 gene 
expression-based classification. The probes were ranked based on the averaged error 
developed by the probe in the test subset of samples. Table 17 and Table 18 are the 
tabulation of the top 100 predictive probes for ESR1 and ESR2 classification. 
 
5.4.2 ESR1 and ESR2 interactomes 
 
The ESR1 and ESR2 interactome network inference model was created using 
the expression profile of top 100 highly predictive probesets from the ESR1 and 
ESR2-based classification model separately. From the bespoke ANN-based network 
inference algorithm (Chapter 2, Section 2.8), out of 9100 potential interactions 
computed from 100 predictive probesets of ESR1 and ESR2, only 75 unique  
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Table 17: The top 100 predictive probes for ESR1 classification. 
Rank 
Order 
Probeset ID 
Gene 
Symbol 
p-value 
 
Rank 
Order 
Probeset ID 
Gene 
Symbol 
p-value 
1 205225_at ESR1 4.49E-05 
 
51 205597_at SLC44A4 2.29E-03 
2 204623_at TFF3 8.98E-05 
 
52 201983_s_at EGFR 2.33E-03 
3 219414_at CLSTN2 1.35E-04 
 
53 212195_at IL6ST 2.38E-03 
4 205186_at DNALI1 1.80E-04 
 
54 209696_at FBP1 2.42E-03 
5 218806_s_at VAV3 2.24E-04 
 
55 212441_at KIAA0232 2.47E-03 
6 219051_x_at METRN 2.69E-04 
 
56 205472_s_at DACH1 2.51E-03 
7 209459_s_at ABAT 3.14E-04 
 
57 41660_at CELSR1 2.56E-03 
8 204508_s_at CA12 3.59E-04 
 
58 204863_s_at IL6ST 2.60E-03 
9 209623_at MCCC2 4.04E-04 
 
59 219197_s_at SCUBE2 2.65E-03 
10 205354_at GAMT 4.49E-04 
 
60 210735_s_at CA12 2.69E-03 
11 214440_at NAT1 4.94E-04 
 
61 218211_s_at MLPH 2.74E-03 
12 208615_s_at PTP4A2 5.39E-04 
 
62 206469_x_at AKR7A3 2.78E-03 
13 203963_at CA12 5.83E-04 
 
63 212496_s_at JMJD2B 2.83E-03 
14 218259_at MKL2 6.28E-04 
 
64 214404_x_at SPDEF 2.87E-03 
15 200670_at XBP1 6.73E-04 
 
65 209602_s_at GATA3 2.92E-03 
16 205471_s_at DACH1 7.18E-04 
 
66 210085_s_at ANXA9 2.96E-03 
17 212638_s_at WWP1 7.63E-04 
 
67 213419_at APBB2 3.01E-03 
18 218976_at DNAJC12 8.08E-04 
 
68 208617_s_at PTP4A2 3.05E-03 
19 204862_s_at NME3 8.53E-04 
 
69 212151_at PBX1 3.10E-03 
20 205066_s_at ENPP1 8.98E-04 
 
70 212196_at IL6ST 3.14E-03 
21 219913_s_at CRNKL1 9.42E-04 
 
71 204914_s_at SOX11 3.19E-03 
22 201826_s_at SCCPDH 9.87E-04 
 
72 217838_s_at EVL 3.23E-03 
23 205355_at ACADSB 1.03E-03 
 
73 204881_s_at UGCG 3.28E-03 
24 209460_at ABAT 1.08E-03 
 
74 212148_at PBX1 3.32E-03 
25 215867_x_at AL050025 1.12E-03 
 
75 200711_s_at SKP1A 3.37E-03 
26 201754_at COX6C 1.17E-03 
 
76 212446_s_at LASS6 3.41E-03 
27 218195_at C6orf211 1.21E-03 
 
77 203928_x_at MAPT 3.46E-03 
28 208682_s_at MAGED2 1.26E-03 
 
78 203749_s_at RARA 3.50E-03 
29 204798_at MYB 1.30E-03 
 
79 216381_x_at AKR7A3 3.55E-03 
30 215729_s_at VGLL1 1.35E-03 
 
80 212956_at TBC1D9 3.59E-03 
31 221710_x_at C1orf78 1.39E-03 
 
81 209603_at GATA3 3.64E-03 
32 214164_x_at CA12 1.44E-03 
 
82 205862_at GREB1 3.68E-03 
33 35666_at SEMA3F 1.48E-03 
 
83 200810_s_at CIRBP 3.72E-03 
34 212492_s_at JMJD2B 1.53E-03 
 
84 203628_at IGF1R 3.77E-03 
35 205081_at CRIP1 1.57E-03 
 
85 206754_s_at CYP2B6 3.81E-03 
36 221765_at UGCG 1.62E-03 
 
86 203929_s_at MAPT 3.86E-03 
37 201508_at IGFBP4 1.66E-03 
 
87 209604_s_at GATA3 3.90E-03 
38 210652_s_at C1orf34 1.71E-03 
 
88 208873_s_at REEP5 3.95E-03 
39 213712_at ELOVL2 1.75E-03 
 
89 211000_s_at IL6ST 3.99E-03 
40 209173_at AGR2 1.80E-03 
 
90 220192_x_at SPDEF 4.04E-03 
41 212442_s_at LASS6 1.84E-03 
 
91 212960_at TBC1D9 4.08E-03 
42 214552_s_at RABEP1 1.88E-03 
 
92 218807_at VAV3 4.13E-03 
43 205696_s_at GFRA1 1.93E-03 
 
93 203627_at IGF1R 4.17E-03 
44 212637_s_at WWP1 1.97E-03 
 
94 212099_at RHOB 4.22E-03 
45 205009_at TFF1 2.02E-03 
 
95 202089_s_at SLC39A6 4.26E-03 
46 204667_at FOXA1 2.06E-03 
 
96 211712_s_at ANXA9 4.31E-03 
47 203256_at CDH3 2.11E-03 
 
97 203144_s_at KIAA0040 4.35E-03 
48 209443_at SERPINA5 2.15E-03 
 
98 222125_s_at PH_4 4.40E-03 
49 204497_at ADCY9 2.20E-03 
 
99 215552_s_at ESR1 4.44E-03 
50 206401_s_at MAPT 2.24E-03 
 
100 202088_at LIV_1 4.49E-03 
 
Tabulation of top 100 ranked gene probes found associated with ESR1 classification 
using Stepwise-ANN analysis. The average of test subset error for each gene under each 
independent 10 repetitions was considered for ranking. The probes with minimum error 
is being ranked highest in the table.   
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Table 18: The top 100 predictive probes for ESR2 classification. 
Rank 
Order 
Probeset ID Gene symbol p-value 
 
Rank Probeset ID 
Gene 
symbol 
p-value 
1 211119_at ESR2 4.49E-05 
 
51 216187_x_at AF222691 2.29E-03 
2 r2_Ec_bioD_3_at K01391 8.98E-05 
 
52 220222_at PRO1905 2.33E-03 
3 CreX_3_at K01391 1.35E-04 
 
53 220385_at JPH2 2.38E-03 
4 r2_P1_cre_3_at K01391 1.80E-04 
 
54 208448_x_at IFNA16 2.42E-03 
5 CreX_5_at K01391 2.24E-04 
 
55 211835_at AJ225093 2.47E-03 
6 222207_x_at LOC389517 2.69E-04 
 
56 215593_at AK023918 2.51E-03 
7 BioDn_5_at K01391 3.14E-04 
 
57 204428_s_at LCAT 2.56E-03 
8 r2_Ec_bioD_5_at K01391 3.59E-04 
 
58 215320_at LOC645961 2.60E-03 
9 216707_at AL162044 4.04E-04 
 
59 215179_x_at PGF 2.65E-03 
10 BioDn_3_at K01391 4.49E-04 
 
60 206899_at NTSR2 2.69E-03 
11 203716_s_at DPP4 4.94E-04 
 
61 213586_at CDKN2D 2.74E-03 
12 220804_s_at TP73 5.39E-04 
 
62 220601_at C16orf70 2.78E-03 
13 222086_s_at WNT6 5.83E-04 
 
63 213155_at WSCD1 2.83E-03 
14 203948_s_at MPO 6.28E-04 
 
64 216789_at AK026439 2.87E-03 
15 219699_at LGI2 6.73E-04 
 
65 206320_s_at SMAD9 2.92E-03 
16 211788_s_at TREX2 7.18E-04 
 
66 210324_at C8G 2.96E-03 
17 hum_alu_at K01391 7.63E-04 
 
67 206820_at HRBL 3.01E-03 
18 210344_at OSBPL7 8.08E-04 
 
68 206148_at IL3RA 3.05E-03 
19 219796_s_at MUPCDH 8.53E-04 
 
69 219011_at PLEKHA4 3.10E-03 
20 216646_at L11372 8.98E-04 
 
70 211030_s_at SLC6A6 3.14E-03 
21 r2_Ec_bioB_5_at K01391 9.42E-04 
 
71 206865_at HRK 3.19E-03 
22 207685_at CRYBB3 9.87E-04 
 
72 210879_s_at RAB11FIP5 3.23E-03 
23 216617_s_at MAG 1.03E-03 
 
73 214637_at OSM 3.28E-03 
24 207377_at I_4 1.08E-03 
 
74 205314_x_at SNTB2 3.32E-03 
25 216957_at USP22 1.12E-03 
 
75 221921_s_at CADM3 3.37E-03 
26 207288_at FLJ13330 1.17E-03 
 
76 216796_s_at AK026847 3.41E-03 
27 211314_at CACNA1G 1.21E-03 
 
77 217669_s_at AKAP6 3.46E-03 
28 210565_at GCGR 1.26E-03 
 
78 206328_at CDH15 3.50E-03 
29 216790_at AK026465 1.30E-03 
 
79 220611_at DAB1 3.55E-03 
30 216116_at NCKIPSD 1.35E-03 
 
80 220818_s_at TRPC4 3.59E-03 
31 217715_x_at BE045142 1.39E-03 
 
81 208088_s_at CFHR5 3.64E-03 
32 215140_at AL109667 1.44E-03 
 
82 222356_at FLJ32069 3.68E-03 
33 205183_at HNRPD 1.48E-03 
 
83 206013_s_at ACTL6B 3.72E-03 
34 BioB_5_at K01391 1.53E-03 
 
84 216572_at FOXL1 3.77E-03 
35 r2_P1_cre_5_at K01391 1.57E-03 
 
85 221406_s_at MSH5 3.81E-03 
36 206657_s_at MYOD1 1.62E-03 
 
86 215652_at AK024382 3.86E-03 
37 215861_at RP4_724E16.2 1.66E-03 
 
87 208494_at SLC6A7 3.90E-03 
38 211915_s_at TUBB4Q 1.71E-03 
 
88 219642_s_at PEX5L 3.95E-03 
39 208560_at KCNA10 1.75E-03 
 
89 216204_at COMT 3.99E-03 
40 208354_s_at SLC12A3 1.80E-03 
 
90 39650_s_at KIAA0435 4.04E-03 
41 210122_at PRM2 1.84E-03 
 
91 211225_at FUT5 4.08E-03 
42 216630_at AL110190 1.88E-03 
 
92 208331_at BPY2 4.13E-03 
43 211604_x_at HAP1 1.93E-03 
 
93 215996_at GNAI2 4.17E-03 
44 214780_s_at MYO9B 1.97E-03 
 
94 211461_at CSPG4LYP1 4.22E-03 
45 205902_at KCNN3 2.02E-03 
 
95 220152_at C10orf95 4.26E-03 
46 216900_s_at CHRNA4 2.06E-03 
 
96 222198_at AA447740 4.31E-03 
47 BioB_3_at K01391 2.11E-03 
 
97 215628_x_at AL049285 4.35E-03 
48 220071_x_at CEP27 2.15E-03 
 
98 211398_at FGFR2_G 4.40E-03 
49 r2_Ec_bioB_3_at K01391 2.20E-03 
 
99 214715_x_at ZNF160 4.44E-03 
50 206647_at HBZ 2.24E-03 
 
100 206270_at PRKCG 4.49E-03 
 
Tabulation of top 100 ranked gene probes found associated with ESR2 classification 
using Stepwise-ANN analysis. The average of test subset error for each gene under each 
independent 10 repetitions was considered for ranking. The probes with minimum error 
is being ranked highest in the table.   
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interactions (8 negative and 67 positive) for ESR1 and 85 unique interactions (85 
negative) for ESR2 were identified after removing non-significant and multiple 
interactions. Figure 22 and Figure 23   represents the ESR1 and ESR2 interactome 
developed from the ANN-based network inference algorithm respectively. 
 
5.4.3 Modelling known ER pathway elements using ANN 
 
Modelling of both components of the ER system, i.e., ESR1 and ESR2 was 
achieved by considering possible interacting molecules from the in silico interaction 
databases. 438 interacting molecules with ESR1 and 422 interacting molecules with 
ESR2 were derived from in silico curated information using BioGRID and 
GeneCards databases. A complete list of interacting molecules with ESR1 
(Appendix 1) and ESR2 (Appendix 2) are tabulated. After removing duplicate and 
repeated interactions, 698 interacting molecules from both ESR1 and ESR2 were 
identified (Appendix 3). All the probes representing the interacting molecules were 
identified. The gene expression profile of each of them across 278 samples (from E-
GEOD-20194) dataset were selected and input into the ANN-based interaction 
inference algorithm. Ten independent interaction models yielded 169390 interactions 
making complex inferences. Pre-selection of strongest 100 positive and 100 negative 
interactions were considered for simple visualisation and inferencing. Figure 24 
represents the ER system (ERα and ERβ) interaction models simulated by the ANN-
based network inference method. 
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Figure 22: ESR1 interactome from ANN. ESR1 interactome using ANN network 
inference method. The interactome is constructed by selecting all interactions with 
ESR1 in total (278) samples from E-GEOD-20194 microarray dataset. The arrows of 
edges indicate the direction of interaction from source to target. The green edges 
represents positive interactions and red representing negative interactions. The thickness 
of edges are scaled based on the population of interactions.  
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Figure 23: ESR2 interactome from ANN. ESR2 interactome using ANN network 
inference method. The interactome is constructed by selecting all interactions with 
ESR2 in total (278) samples from E-GEOD-20194 microarray dataset. The arrows of 
edges indicate the direction of interaction from source to target. The red edges 
represents negative interactions. The thickness of edges are scaled based on the 
population of interactions. 
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Figure 24: ER system (ERα and ERβ) interaction simulation by ANN-based network interaction inference. The simulation is 
done on gene expression profile of unique molecules from E-GEOD-20194 breast cancer microarray dataset. The arrows of edges 
indicate the direction of interaction from source to target. The green edges represents positive interactions and red representing 
negative interactions. The thickness of edges are scaled based on the population of interactions. The pink nodes are overlapping genes 
from predictive gene sets of ESR1 and ESR2. The interaction model is constructed by selecting strongest100 positive and 100 negative 
interactions for simple visualisation. 
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For validation of interactions, the genes were compared with the predictive 
gene sets of ESR1 and ESR2 by taking 100 highly predictive genes for the 
respective classes. Upon comparing, 17 genes were found to be overlapping with 
the predictive genes. These are; Androgen Receptor (AR), Basic Transcription 
Factor 3 (BTF3), EGFR, Erythroblastic leukemia viral oncogene homolog 2 
(ERBB2/HER2/neu), ESR1, FOXA1, Guanine Nucleotide binding protein (G-
Protein) alpha 12 (GNA12), Insulin-like Growth Factor 1 (IGF1), IGF1R, Mitogen 
Activated Protein Kinase 14 (MAPK14), MYOD1, PGR, RARA, TFF1, Tripartite 
motif containing 24 (TRIM24), VAV3 and XBP1. 
5.5 Discussion 
 
Aiming to identify predictive probes responsible for ESR1 and ESR2 
classification and to investigate the cross-talk between the predictive probes, we 
have used ANN-based predictive modelling and network inferencing approaches.   
ERα (ESR1) and ERβ (ESR2) are components of the ER system, both 
playing a role in mammary development, female reproduction and in the breast 
cancer progression system. Investigation of each and every component of the 
system is necessary for a complete understanding and functionality of the system 
as a whole. The functionality of ESR1 and ESR2 could depend on the collective 
functionality of the interacting molecules within it. In an attempt to investigate the 
interacting molecules, here computational determination of the interacting 
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molecules is achieved by considering the predictive markers for the respective 
components of the ER system.  
ESR1(ERα) interactome: 
Among the 7 genes () found overlapping in the ESR1 interactome with the 
genes cumulated from various interaction datasets, all were found to be directly or 
indirectly related in breast cancer. This proves the ANN’s predictability with 
respect to ESR1. Supporting this, EGFR upon transactivated by estradiol, is found 
to be negatively associated with ER expression in breast cancer (Levin, 2003). As 
a result of bidirectional cross-talk between ER and EGFR, in breast cancer 
patients with antiestrogen resistance, the loss of ESR1 expression is linked to 
overexpression of EGFR (Hoffmann and Sommer, 2005). The FOXA1 
transcription factor is a member of the ER signalling pathway and is found to be 
strongly correlated with the luminal subtype of breast cancer and prognosis 
(Habashy et al., 2008). FOXA1 is also associated with ESR1 expression regulation 
and ductal morphogenesis in mammary cells (Bernardo et al., 2010). Upon 
activation of the IGF1R pathway by ERα, IGF1R overexpression is found to be 
associated with ESR1 in primary breast cancer and lymph node metastasis (Koda 
et al., 2003). RARA and ERα shows a feed-back mechanism wherein, RARA 
competitively binds to the ERE region affecting the transactivation of ERα (Song 
et al., 1998), and as a result, ERα is found to induce overexpression of RARA in 
MCF-7 breast cancer cell line (Laganiere et al., 2005), TFF1 expression is 
induced by estradiol and plays a transcriptional role in breast cancer (Sun et al., 
2005). Chen et al. in their study have found TFF1 as one among the other 20 
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differentially expressed ER-related genes in breast cancer samples through 
microarray (Chen et al., 2011). VAV3 is a guanine nucleotide exchange factor 
protein found to be an oncogene, and its overexpression aberrantly enhances ERα 
activity, thus playing a role in breast cancer development and progression (Lee et 
al., 2008). XBP1 being a member of stress signalling pathway, is involved in the 
impairment of cell cycle regulation associated with breast carcinogenesis (Andres 
and Wittliff, 2011). 
ESR2 (ERβ) interactome: 
ESR2 interactome validation showed one gene overlapping i.e., MYOD1. 
MYOD1 encodes a nuclear protein belonging to the helix-loop-helix family of 
transcription factors, responsible for myogenic initiation and regulation of muscle 
cell differentiation and regeneration (Maguire et al., 2012). MYOD1 is found to 
exhibit anti-proliferative effect in MCF-7 breast cancer cell lines (Chen et al., 
2010). Furthermore, MYOD1 along with ERβ is found to attenuate ERα-mediated 
BRCA2 expression (Jin et al., 2008a). 
The ESR2 interactome of the ER system is computationally distinct from 
ERα. This is due to the fact that the predictive genes of ESR2 are separate from 
ESR1 and is amplified by the pre-selection of only 100 highly predictive probes. 
A broader consideration of predictive probes may be beneficial for finding 
commonalities between the ESR1 and ESR2 subsets.  
Although the in silico interaction database was useful in identifying 
interacting molecules with ESR1 and ESR2, the information was found to be 
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incomplete. For example; the GATA3 transcription factor was not found 
interacting with either ESR1 or ESR2. This is in spite of the fact that, the 
association of GATA3 with ESR1 (Voduc et al., 2008), and the association of 
FOXA1 and GATA3 in breast cancer is well documented (Albergaria et al., 2009). 
Moreover, the interaction information was often repeated under different physical 
or experimental setups. Furthermore, text mining approaches used to generate 
interaction information in databases may look at mere mentioning of molecules in 
text. On the other hand, in spite of lower overlapping of molecules, the ANN 
network inferencing model was successful in identifying biological relevant 
interactions. 
ER system simulation: 
Simulation of the ER system by combining ESR1 and ESR2 interacting 
molecules in an ANN-based network inference method was able to pull out some 
of the ER-associated genes missed by considering individual components. Even 
though the filtering of the top100 positive and negative interaction was applied, 
the interaction network was complex. Apart from the ESR1 interacting molecules 
such as RARA, EGFR, FOXA1, VAV3, TFF1, IGF1R, XBP1 and the ESR2 
interacting molecule MYOD1 previously found, other molecules were also found 
to be associated with ER and/or breast cancer.   
ESR1 encodes the ERα subunit and acts as a transcription factor for ER-
associated genes. PGR encodes for the PR which plays a central role in 
establishment and maintenance of pregnancy (Gadkar-Sable et al., 2005). PR 
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being able to directly bind to DNA and regulate target gene transcription, acts as a 
biomarker in breast development, tumorigenesis, progression and clinical outcome 
in luminal and basal tumour subtype along with ER (Kimura et al., 1988). 
ERBB2, also known as Her2/neu is also another prognostic marker in breast 
cancer along with ER and PR.  
AR is found to be directly associated with growth in breast cancer cell lines. 
Apart from being over-expressed in breast tumour cells, AR is found to be 
associated with good clinical prognosis in ER-positive post-menopausal women 
and acts as a secondary biomarker for clinical outcome (Hu et al., 2011). TRIM24 
protein mediates transcriptional control of nuclear receptors including ER and 
RARA. TRIM24 also plays a role in overexpression of ligand-dependent 
transcription activation of AR and ESR1. TRIM24/TIF-1α is a negative regulator 
of transcription factors and its overexpression is associated with poor prognosis 
and worse survival in breast cancer (Chambon et al., 2011). IGF1 shares similar 
functionality to IGF1R, as discussed previously (Chapter 4, Section 4.6.1). 
GNA12 as a member of the G proteins, acting as a modulator or transducer in 
transmembrane signalling. Upon activation by ligand-receptor binding, these 
proteins initiates secondary messenger signalling cascades linked to cellular 
regulatory processes. Along with polycystin-1, GNA12 shares a binding region 
which is necessary for apoptosis regulation (Yu et al., 2010). MAPK14 also called 
as p38, encodes a protein of family MAP kinases which are involved in cellular 
processes such as proliferation, differentiation, and transcription regulation. 
MAPK14 have been found to be have a role in various cancers such as lung, colon 
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ovarian and even in breast. In breast cancer, cross-talk between ER, HER2 and 
p38 have proved to contribute to tamoxifen resistance (Gutierrez et al., 2005). 
BTF3 forming a complex with RNA polymerase IIB is responsible for 
transcription initiation and regulates transcription in pancreatic cancer 
(Kusumawidjaja et al., 2007). In breast tumour cells, BTF3 is found to interact 
with NH2-terminal of ESR1 to initiate transcription of ER-associated genes 
(Green et al., 2007). 
Even though filtering of the top 200 (100 positive and 100 negative) 
interactions which is 0.11% of total 169390 interactions, the ANN-based network 
inference algorithm was able to pull out distinctive interactions emphasising the 
prominent interactions across all interacting molecules. Most importantly, the 
interaction network clustered around ESR1 and PGR together with other genes 
such as AR, EGFR, FOXA1, TFF1, XBP1, VAV3 and RARA, making them 
separated from ERBB2 which is clinically valid. Other genes like GNA12, 
MAPK14, BTF3, IGF1 and TRIM24 would be involved in the basic functionality 
of breast cancer as MAPK14 is a transducer of many signalling pathways and 
TRIM24 is associated with transcription initiation. 
 
5.6 Conclusion 
 
A Stepwise-ANN method for predictive probesets of ESR1 and ESR2 were 
found to be biologically relevant with overlapping of markers from curated 
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databases. Construction of the interaction network using ANN-based network 
inferencing method was informative in determining the causal interaction and 
quantitative measurement of interactions computationally.  
The ANN-based network inferencing method for ESR1 was supported by 
the interactions of ESR1 with ER-associated expression of FOXA1, VAV3 and 
TFF1.   
The ER system pathway simulation using ANN-based network inference 
method was found to be biologically relevant by clustering interactions among the 
genes PGR, AR, EGFR, FOXA1, VAV3, TFF1. The systems biology approach to 
ER could be extended at the cost of complexity of the interactions. 
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Chapter 6 
NON-REDUCTIONAL SYSTEMS BIOLOGY 
APPROACH TO ESR1 WITH BROADER 
CONSIDERATION AND RELATIONSHIP 
TO PGR AND ERBB2 
 
 
Chapter abstract: Breast cancer with varied clinically responsive subtypes 
represents a complex system. The behaviour of the system is governed by the cross-
talk between the components of the system such as ER, PR and Her2. 
Computationally, the identification of predictive markers of the component system 
would benefit understanding of the behaviour of the system. In this study, we have 
adopted ANN-based predictive modelling to identify predictive markers in a non-
reductional approach and network inferencing method to investigate the cross-talk 
between markers. Subsequent interactomes are also constructed and later combined 
to represent a systems biology of breast cancer. Our results identified a closed 
relation between ESR1 and PGR interactomes with sharing of predictive markers, 
suggesting them as links between the systems. The ERBB2 system showed a discrete 
network among its predictive markers and was found to be a separate entity with 
very few connections with the ESR1 system.  
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6.1 Introduction 
 
6.1.1 ER, PR and Her2 
 
Breast cancer is a complex disease comprising of distinct biological subtypes 
with a diverse spectrum of molecular, pathological and clinical features exhibiting 
different prognostic and therapeutic implications. The former classification of breast 
cancer patients is solely based on ER expression and is less discriminatory in terms 
of prognosis. Furthermore, the independent prognostic and predictive role of 
Progesterone receptor (PR/PGR) expression has been a subject of controversy and it 
is well known that the PR gene is regulated by the oestrogen pathway (Clarke et al., 
2005). Even though, further sub-classification of patients based on PR and Human 
epidermal growth factor receptor 2 (ERBB2/ErbB-2/HER2/neu) expression has 
provided enhanced discrimination, a complete characterisation of clinically 
beneficial breast cancer patients is ever expanding. Recently, researchers have 
focussed their efforts on identifying additional biomarkers for therapeutic guidance. 
Current identification and investigation of the functionality of biomarkers is 
extensively based on conventional knock-down approaches wherein a single marker 
is investigated at a time. Correlation of a marker with respect to the known 
parameters is studied using linear methods. As the number of parameters increases, 
there is a considerable increase in the complexity of the system being studied and 
this makes it extremely difficult and challenging to analyse using the conventional 
reductionist approaches. A major drawback of current reductionist approach is the 
time taken to model such systems, as a single marker is investigated at a time. 
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Furthermore, as biological systems consists of various molecules acting at a single 
time instance, a lack of information of the cumulative effect and complex interaction 
among molecules over time widens the gap making interpretation of the whole 
system extremely unfeasible and complex.  
 
6.1.2 Non-reductional systems biology approach 
 
A Non-reductional or additive approach is about putting together rather than 
taking apart i.e., integration rather than reduction. In prior chapters, the addition of 
markers was predetermined or restricted to the markers of the study utilising only the 
top 100 associated to a given question. This poses a potential bias from a systems 
biology view. Alternatively, scanning of predictive markers  associated with a given 
marker across the whole genome overcomes the bias of predetermined or restricted 
addition. This may benefit the information concerned in biological systems. 
Computationally, this non-reductionist approach is a serial addition of highly 
predictive markers to their primary marker. The subsequent construction of a 
pathway or network facilitates the study of a pathway with markers derived from the 
whole probeset. 
6.2 Aims and objectives 
 
 To identify predictive probes for median-based gene expression classification 
for ESR1, PGR and ERBB2.  
 To apply a non-reductionist approach to ESR1 interactome using ANN. 
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 To expand the approach to the PGR and ERBB2 interactomes.  
 To investigate the common markers across the ESR1, PGR and ERBB2 
interactomes. 
 
6.3 Materials and methods 
 
6.3.1 Predictive gene identification using stepwise-ANN 
 
The E-GEOD-20194 microarray dataset, consisting of 22283 probes developed 
on HG-U133A Affymetrix array across 278 primary breast cancer, was chosen for 
the computational predictive gene identification. 
The stepwise-ANN algorithm, mentioned earlier in Chapter 2 (Section 2.7), 
was used for identification of predictive genes for ESR1, PGR and ERBB2. Briefly, 
the classification of samples for training was based on the median-based gene 
expression levels. The algorithm was trained with 60% of total samples and tested on 
another 20%. A 20% fraction of sample was used for validation of prediction using a 
Monte Carlo Cross Validation strategy coupled in a stepwise-ANN with back-
propagation of error algorithm. The prediction models were trained with a 
momentum of 0.5 and learning rate of 0.1 with 3000 epochs. The complete algorithm 
was iterated to generate 10 independent predictive models and predictiveness across 
matched probes was averaged for accurate prediction for each probe. The predictive 
rank was assigned based on the error generated by a test subset of samples for every 
probe.   
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6.3.2 Non-reductionist approach 
 
 A non-reductionist approach is a serial addition of markers to the primary 
markers, thereby increasing the complexity of the network. In this chapter, we have 
adopted gene-median expression based classification using a stepwise-ANN to 
identify predictive markers. The level of complexity is increased by scanning the 
entire genome for top 10 predictive markers every time i.e., at initial level, top 10 
predictive markers are identified and later extended to the another level by 
identifying the top 10 additional markers for the earlier identified ones. A schematic 
representation of this non-reductional approach is depicted in Figure 25. 
  
 
Figure 25: Schematic representation of non-reductional approach. Non-reductional 
approach initiate with identification of predictive markers for a particular question or 
system. Then serial addition of predictive markers for prior identified markers is carried 
out. There by exponentially increasing the number of markers identified from 10 to 100 
in two step additive approach. 
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In this chapter, we have addressed serial additional of predictive markers for 
breast cancer components such as the ESR1 (coding for ERα), PGR (coding for PgR) 
and ERBB2 (coding for Her2) genes. A median expression based classification was 
used to identify the top 10 predictive genes for these systems separately. Later, the 
entire genome was scanned for predictive genes for the prior identified genes in a 
serial additive manner. This increases the level of complexity in an exponential form 
from 10 to 100 markers. Due to the exponential increase in the number of markers, 
here, for convenient and simple inferencing, two additive levels are carried out.  
 
6.3.3 ANN interaction network inferencing 
 
An ANN-based interaction network inferencing algorithm (discussed in 
Chapter 2 Section 2.8) was used to decipher the interconnections between the 
predictive genes. Briefly, the algorithm iteratively predicts every gene’s expression 
as target by considering the remaining gene’s expressions as inputs, until all the 
genes are considered as targets as well as providing possible interactions for that 
gene. At every step, the weights are recorded representing a relation the relationship 
between input and target. The algorithm is run for ten independent iterations and 
weights averaged. The weights are then scaled based in minimum and maximum 
values to generalise the weights across all genes.  
  The interaction models based on weights are created in Cytoscape Ver 2.7.3 
software (www.cytoscape.org). Figure 26 is a schematic overview of non-reductional 
systems biology approach used in this chapter.  
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Figure 26: Overview of non-reductional systems biology approach. The 
identification of markers for ESR1, PGR and ERBB2 is done separately using Stepwise-
ANN predictive modelling method till second level of 100 marker identification (top 10 
of top 10s). Later these markers are subjected to ANN-based network inferencing 
whereby construction of ESR1, PGR and ERBB2 interactomes is carried out to 
represent systems biology approach.  
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6.4 Results 
 
6.4.1 Non-reductional ESR1 Interactome 
 
 Non-reductional interactome of ESR1 (yellow node) was constructed taking 
the top ten most predictive genes for median-based gene expression classification of 
ESR1. Figure 27 is a ESR1 non-reductional interactome. Blue nodes represent the 
first level of predictive genes whilst the associated pink nodes are the second level 
predictive genes for the level one marker. 
 Genes such as GATA3, CA12, NAT1, TBC1D9 and others were found to be 
highly predictive for ESR1 gene expression based classification. All of the first level 
predictive genes were found to be predictive for others, forming highly 
interconnected edges, suggesting a clustered and mutual interaction among them. 
Genes such as XPBP1 and LIV_1 were found to be predictive for more than two 
genes, representing epicentres of the network. The highest negative interaction was 
TBC1D9 to DNALI1 and the highest positive interaction was found to be between 
GATA3 and FOXA1.  
 
6.4.2 Extension to PGR and ERBB2 interactomes 
 
A non-reductional interactome of PGR and ERBB2 (yellow nodes) were also 
constructed taking the highly predictive ten genes from median-based gene 
expression classification of PGR and ERBB2 respectively, represented as blue nodes. 
All pink nodes are the second level predictive genes of earlier genes.  
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Figure 27: Non-reductional ESR1 interaction model. The genes are represented as 
nodes and interactions as edges. The directionality of interactions is represented as 
arrows, from source to target. The positive and negative interactions are represented as 
Green and Red edges respectively. Blue nodes are the first level predictive genes of 
ESR1 and act as primary genes for second level predictive genes. 
 
In the PGR (yellow node) non-reductional interactome (Figure 28), genes such 
as SCUBE2, MAPT and IL6ST was found to be highly interactive with other 
predictive genes of PGR. When compared with ESR1, the PGR interactome was less 
compact suggesting a scattered network of genes. The highest negative interaction 
was found to be between PTGER3 and MYBL2 and highest positive interaction was 
from PTGER3 to STC2.  
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In the ERBB2 (yellow node) non-reductional interactome (Figure 29), the 
interactions were much more scattered and less clustered compared to the ESR1 and 
PGR interactomes. Gene GRP65 formed a distinct cluster of its predictive genes 
totally isolated from the others. The highest negative interaction was found to be 
between PSMD3 and PPARBP and the highest positive interaction was between 
ERBB2 and SPDEF.  
 
 
Figure 28: Non-reductional PGR interaction model. The genes are represented as 
nodes and interactions as edges. The directionality of interactions is represented as 
arrows, from source to target. The positive and negative interactions are represented as 
Green and Red edges respectively. Blue nodes are the first level predictive genes of 
PGR and act as primary genes for second level predictive genes.   
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Figure 29: Non-reductional ERBB2 interaction model. The genes are represented as 
nodes and interactions as edges. The directionality of interactions is represented as 
arrows, from source to target. The positive and negative interactions are represented as 
Green and Red edges respectively. Blue nodes are the first level predictive genes of 
ERBB2 and act as primary genes for second level predictive genes. 
 
 
6.4.3 Cumulative ESR1, PGR and ERBB2 non-reductional model 
 
The cumulative interactomes of ESR1, PGR and ERBB2  (yellow nodes) is 
shown in Figure 30. The first level predictive genes of ERS1, PGR and ERBB2 are 
represented with green, orange and blue nodes respectively. The interactions are 
represented as edges with arrows indicating the directionality of interaction from 
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Figure 30: Cumulative ESR1, PGR and ERBB2 non-reductional systems model. Non-reductional systems model comprising ESR1, 
PGR and ERBB2 interactomes. Genes are represented as nodes and interactions as edges. Yellow nodes are the starting points of 
interactomes. First level predictive markers of ESR1, PGR and ERBB2 are represented with green, orange and blue nodes respectively. 
All other secondary markers are represented with pink nodes. The directionality of interactions is represented with arrows from source to 
target. 
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source to target. A complete list of predictive genes for ESR1, PGR and ERBB2 
interactomes are listed in Table 19. 
The genes AGR2 and FOXA1 were found to be the only linking genes between 
the ESR1 and ERBB2 interactomes. However, extensive bridging genes were found 
between the ESR1 and PGR interactomes. The gene GPR65, a predictive gene for 
ERBB2, and its predictive genes remained as an isolated cluster from rest of the 
genes. It was promising to get ESR1 and PGR interactomes highly connected sharing 
many interlinks, but the ERBB2 interactome was clustered distinctly.   
 
6.5 Discussion 
 
This chapter describes to the identification of predictive markers for ESR1, 
PGR and ERBB2, using a non-reductional systems biology approach for these 
predictive markers in an serial additive manner. 
ANNs were found to be efficient machine learning method for classification of 
samples and predictive gene selection. The application of this method for systems 
biology parse is established in this study. The construction of interactomes with an 
additive or non-reductionist approach for predictive markers using a stepwise-ANN 
is extensively investigated in this study. The ANN-based network inferencing 
approach is well established and documented (Dhondalay et al., 2011, Lemetre et al., 
2009).  
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Table 19: Predictive gene list of ESR1, PGR and ERBB2 non-reductional interactomes. 
 
 Predictive gene list of ESR1 non-reductional interactome  
           
RANK 1 2 3 4 5 6 7 8 9 10 
 
CA12 GATA3 TBC1D9 AL050025 NAT1 C6orf211 IGF1R DNALI DNAJC12 SLC39A6 
1 AL050025 ESR1 GATA3 CA12 CA12 ESR1 ESR1 GATA3 ESR1 LIV_1 
2 GATA3 CA12 ESR1 GATA3 ESR1 GATA3 IGFBP4 CA12 TBC1D9 ESR1 
3 ESR1 TBC1D9 CA12 ESR1 GATA3 TBC1D9 GATA3 ESR1 GATA3 NAT1 
4 NAT1 AL050025 SLC39A6 TBC1D9 AL050025 XBP1 GREB1 TBC1D9 NAT1 TBC1D9 
5 TBC1D9 DNALI1 NAT1 NAT1 TBC1D9 CA12 CA12 AL050025 SLC39A6 CA12 
6 XBP1 NAT1 AL050025 XBP1 SLC39A6 SLC2A3P1 TBC1D9 XBP1 CA12 GATA3 
7 GAMT FOXA1 XBP1 DNALI ABAT SLC39A6 SLC39A6 ANXA9 AL050025 XBP1 
8 DNALI1 JMJD2B C6orf211 GAMT DNALC12 NAT1 DNALI ADCY DNALI FOXA1 
9 MLPH VAV3 WWP1 MLPH LIV_1 AL050025 ADCY9 TBC1D9 GREB1 AL050025 
10 C10orf116 UGCG DNALI1 C10orf116 IL6ST WWP1 LIV_1 SLC39A6 LIV_1 DNALC12 
           
 
Predictive gene list of PGR non-reductional interactome 
 
           
RANK 1 2 3 4 5 6 7 8 9 10 
 
PTGER3 NPY1R ABAT HMGA1 ZMYND10 MEIS3P1 MAPT MYBL2 SCUBE2 IL6ST 
1 SCUBE2 GJA1 ESR1 MYBL2 C9orf116 IL6ST TBC1D9 CEP55 ESR1 ESR1 
2 MAPT ELOVL2 GATA3 CDC20 TBC1D9 MAPT ESR1 UBE2C NAT1 TBC1D9 
3 PGR SCUBE2 DNAJC12 SLC7A5 MRPS14 C1orf78 PGR CDC20 IL6ST CA12 
4 STC2 PGR TBC1D9 RRM2 LRRC48 CA12 IL6ST STK6 GAMT NAT1 
5 MYBL2 IGF1R CA12 SCUBE2 CA12 PGR SCUBE2 CENPN AL050025 GATA3 
6 IL6ST MAPT NAT1 RRM2 CCDC48 C16orf45 CA12 MAD2L1 CA12 DNALI1 
7 HMGA1 C4orf18 IL6ST CENPN RBKS HMGA1 ERBB4 KIF20A SLC7A8 XBP1 
8 CENPN STC2 XBP1 MCM10 PGR SCUBE2 PTGER3 PRC1 C10orf116 ABAT 
9 C11orf60 PFKP AL050025 CEP55 SEMA3B LRIG1 NAT1 AURKA DNALI1 MAPT 
10 ERBB4 IL6ST AGR2 IL6ST ANXA9 MRPS14 JMJD2B FOXM1 ABAT AL050025 
           
 Predictive gene list of ERBB2 non-reductional interactome  
           
RANK 1 2 3 4 5 6 7 8 9 10 
 
MAPRE2 GPR65 STRAD3 U06715 SLC9A3R1 MLPH SPDEF KIA0100 PERLD PSMD3 
1 PLCG2 HCLS1 ERBB2 CYB561 SPDEF LASS6 KIAA0100 ERBB2 PERLD1 CYB561 
2 TAF4B EVI2A PERLD1 CANT1 CANT1 SPDEF ERBB2 SPDEF ERBB2 RECK 
3 IL16 LY86 PSMD3 EPN3 KRT18 CA12 DAPP1 SUPT6H STARD3 SCD5 
4 TBC1D4 CYBB GRB7 SLC3A3R1 SLC43A3 NME3 SUPT6H PSMD3 MLPH U06715 
5 SLC2A14 RASSF2 U06715 TJP3 DCXR FOXA1 PSMD3 DAPP1 GRB7 OPHN1 
6 HN1L IRF8 GSDML SMARCD2 AU150943 AGR2 NMT2 CANT1 PSMD3 ACLY 
7 QKI CD48 PPARBP CUEDC1 EPN3 RHO TMEM97 DNPEP SPDEF K01391 
8 MFNG PRKCB1 TCAP SPDEF LASS6 TFF1 TNFAIP1 TMEM97 CANT1 SH3GL3 
9 MSL3L1 WAS MSL BCL11A HSPC009 TFF3 DNPEP LASS6 DDR1 PPARBP 
10 CD83 BIN2 PCBP2 OPTN SYNGR2 GATA3 QKI NMT2 DNPEP CLTC 
 
Predictive gene list of ESR1, PGR and ERBB2 non-reductional interactomes. The 
primary predictive genes for each category are listed in bold grey highlighted boxes 
and the rank order of their predictive genes are listed underneath.    
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  The primary predictive genes from the ESR1 non-reductional interactome 
was considered promising due to the fact that the genes such as GATA3, NAT1, 
CA12, IGF1R had been reported to play role with ER and/or in breast cancer, as 
previously discussed in chapter 3 and 4. They were also found to be highly 
predictive for ESR1 classification. Additionally, ESR1 appearing as predictive 
gene for all primary genes suggest a close interaction and association of ESR1 
with other predictive genes. The gene DNALI1 (Dynein, axonemal, light 
intermediate chain 1) is an homolog of Chlamydomonas p28 gene and the actual 
function of it in human is unclear, but is found to be down regulated in breast 
carcinomas (Parris et al., 2010). The gene SLC39A6, coding for a zinc transporter 
protein is found to be associated in breast cancer and even found to be 
overexpressed in meta-analysis of microarray datasets (Srour et al., 2008). A 
positive interaction of SLC39A6 with another zinc transporter, LIV_1 was found to 
be supporting the functionality and role in breast cancer. Furthermore, the relation 
of GATA3 with FOXA1 was found to be positively associated with ESR1. The 
complete characterisation of gene C6orf211 and AL050025 mRNA clone 
sequence could lead to more information about their functionality in breast cancer. 
The PGR non-reductional interactome was moderately discrete with few 
inter connections between the primary predictive genes. The PGR gene was found 
to be directly associated with MEIS3P1, PTGER2, MAPT, NPY1R and ZMYND10 
genes. MYBL2 (v-myb myeloblastosis viral oncogene homolog (avian)-like 2) is 
a transcription factor involved in cell cycle progression and is often amplified or 
over expressed in many tumours. MYBL2 being associated with tumour 
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progression, is also found to be associated in basal-like breast tumour specific 
transcription regulation in mammary epithelial cells (Thorner et al., 2009). As a 
transcription factor, MYBL2 is found to regulate other breast cancer related genes 
such as BCL2 and TOP2A (Shi et al., 2012). Lower expression of the gene MAPT 
(Microtubule-Associated Protein Tau) has been found to be associated with 
paclitaxel sensitivity in breast cancer samples (Rouzier et al., 2005). Recently, it 
has been found that MAPT protein expression is directly related with ER 
expression (Ikeda et al., 2010). Interleukin 6 signal transducer (IL6ST) gene is 
related to enhanced cellular proliferation in breast cancer and in combination with 
BLC2 alters proliferation or imbalance in apoptosis leading to neoplastic tumour 
development (Garcia-Tunon et al., 2005). Promisingly in the PGR interactome, 
ESR1 was found to be linked with ABAT, SCUBE2, IL6ST and MAPT. 
The ERBB2 non-reductional interactome was also discrete and scattered 
compared to ESR1 and PGR. The primary predictive genes were less 
interconnected suggesting a sparse network of genes in the ERBB2 cluster. Gene 
such as GPR65 were totally isolated from rest of the network implicating distinct 
diverged interactions. The melanophilin (MLPH) gene is associated with bladder 
cancer, but in breast cancer the involvement with ERBB2 is still unclear. The G 
protein-coupled receptor 65 (GPR65) belongs to the family of G proteins which 
are often overexpressed in tumoregenesis associated with apoptosis in ovarian 
cancers (Sin et al., 2004). The per1-like domain 1 (PERLD1) protein involved in 
lipid remodelling process, supporting our findings and is found to be associated 
with Her-2 over-expressive subclass of breast cancer indicating a poor prognosis 
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(Staaf et al., 2010). Furthermore, in gastric tumour cell lines, PERLD1 is found up 
regulated along with ERBB2 (Junnila et al., 2010). STARD3 gene encodes StAR-
related lipid transfer (START) domain containing 3 proteins related to lipid 
trafficking and steroidogenesis with an implication in hormone-receptor-positive 
breast tumours (Andrechek et al., 2003). Furthermore STARD3 is localised with 
ERBB2 on 17q12 in humans (Glynn et al., 2010). The PSMD3 gene encodes 
Proteosome 26S subunit 3 protein is known to regulate cell cycle check points and 
may have role in cell progression and tumorogenesis. SPDEF protein is a 
transcription factor highly expressed in prostate epithelial cells. The over-
expression of SPDEF is also found in breast, brain, lung and ovarian carcinomas. 
In breast cancer, high expression of SPDEF is correlated with poor overall 
survival of patients in ER+ tumours and also to luminal Her-2+ tumours (Sood, 
2009). MAPRE2 gene codes for Microtubule associated protein RP/EB family 
member 2 protein which is responsible for spindle symmetry and polymerisation 
during mitosis associated with cell division and migration. In pancreatic cancers, 
over-expression of MAPRE2 is associated with reduced post-operative survival of 
patients (Abiatari et al., 2009). 
Computational cumulative integration of non-reductional ESR1, PGR and 
ERBB2 interactomes to represent systems biology was an attempt to mimic a 
biological breast cancer scenario. Promisingly ESR1, PGR and ERBB2 formed 
distinct clusters with their predictive genes. Upon integration, parallel to clinical 
findings by other researchers, ESR1 and PGR shared a complex network of 
interactions among their predictive genes. The genes such as IGF1R, TBC1D9, 
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IL6ST, DNALI1 and SCUBE2 acted as bridging genes between the ESR1 and PGR 
clusters indicating the shared functionality of these genes in the ER and PR 
systems. The ERBB2 cluster was distinct and separated from the ESR1 and PGR 
clusters indicating ERBB2 as a separate entity. There were no genes found linking 
ERBB2 and PGR clusters, but this is expected as they have different modalities. 
However, genes such as AGR2, MLPH, GATA3 and FOXA1 were found to link 
the ESR1 and ERBB2 clusters indicating that these genes might be having role in 
regulation of ERBB2 expression by ER. 
Consideration of a two level predictive gene non-reductional additive 
approach even though being limited, was successful in addressing patterns of 
interactions shared by common genes with common functionality. The increase in 
higher level additive approaches poses challenges for computational time 
consumption, network complexity and inferencing.  
6.6 Conclusion 
 
The non-reductional addition of predictive gene approach using ANN is 
promising in highlighting biologically relevant associations or interactions among 
the predictive genes. The construction of additive interactomes of ESR1, PGR and 
ERBB2 were unique in their topology and interaction complexity. ESR1 being 
highly complex, shared genes with the PGR predictive cluster more extensively 
than the ERBB2 cluster. The ERBB2 cluster being sparse and isolated from ESR1 
and PGR represented a biologically different entity.  
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The application of ANNs in systems biology is promising. Development of 
object-oriented algorithms will be beneficial for reducing computational time and 
will provide a standardised methodology for addressing hypothesis driven 
investigations. 
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Chapter 7 
OVERALL SUMMARY AND FUTURE 
WORK 
 
 
Breast cancer being a complex and heterogenous disease, shows a varied 
response to endocrine and hormonal treatment. The steroidal hormone, oestrogen 
plays a vital role in mammary tissue development and prognosis of breast cancer. 
The ER pathway remains unclear, giving an opportunity for the investigation of 
ER-associated markers. Although, prognostic indicators such as ER, PR and Her2 
are well established and documented in breast cancer, efforts in identification of 
novel biomarkers and classification of favourable subgroups have enabled 
molecular subtyping of patients based on their gene expression profiles. Recent 
technological advances in high throughput techniques have facilitated the 
possibility of investigating gene expression profiles of the entire human genome. 
These techniques show promise, but also pose challenges for efficient analysis 
and interpretation of data with respect to their dimensionality, non-linearity and 
multivariate nature. Computational researchers have developed machine learning 
approaches to combat these challenges. One such machine learning approach 
which is gaining recognition in biosciences is Artificial Neural Network (ANN). 
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ANNs are a form of supervised machine learning methods motivated from 
physiological information processing by biological neurons. An in-house 
developed variant of ANN, a stepwise-ANN, has been successfully applied and 
validated in genomic data analysis (Lancashire et al., 2009) and network 
inferencing (Lemetre et al., 2009).  
This thesis demonstrates the application of this ANN in a systems biology 
focussing on the ER systems to provide a novel non-reductional approach in 
systems biology of breast cancer. The studies follow the aims using the ANN; 
 To classify breast cancer microarray samples for ER status. 
 To identify predictive genes associated with ER status. 
 To validate ER-associated markers in clinical breast tumour samples. 
 To investigate cross-talk between ER-associated genes using a ANN-based 
network inference approach. 
 To investigate predictive markers of the ER system (ESR1 coding for ERα and 
ESR2 coding for ERβ). 
 To investigate cross-talk between ER systems associated markers using a 
ANN-based network inference approach. 
 As novelty, to investigate predictive markers in a non-reductional approach in 
systems biology of breast cancer. 
Chapter 3 demonstrated the successful application of stepwise-ANN model 
for ER status classification in breast cancer microarray dataset. The ANN showed 
a consistence classification performance in test and validation subsets of samples 
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with a mean of 90.45% and 89.45% respectively under ten independent runs. The 
classification accuracy of the ANN for ER status was found to be 87.72%. It was 
promising to find the ESR1 gene (coding for ERα) as the best predictor for ER 
status in samples. The classification accuracy of ANN was improved to 90.97% 
when a gene’s median expression based classification was performed for the 
ESR1 gene, with a sensitivity and specificity of 96.31% and 83.33% respectively. 
It was also promising to find breast cancer related markers in the high rank order 
of predictability. The highly predictive 100 markers were investigated for gene 
ontological information and found to be dominated with binding activity and 
metabolic process. Finally, our findings were also validated on the original study 
of dataset and on independent breast cancer datasets. 
Chapter 4 demonstrates the application of the ANN in network inferencing 
to investigate cross-talk between markers. For this study, we have used 100 highly 
predictive markers of ER status derived from a stepwise-ANN method. The ANN 
network inference method identified interaction hubs specific for ER status and 
associated with breast cancer. Markers such as DACH1, TFF3, RARA, EGFR, 
SERPINA5 in ER-positive samples and VAV3, IL6ST, NME3, GAMT in ER-
negative samples. Among the identified interacting hubs, we validated the protein 
expression of VAV3 and DACH1 in clinical breast tumour samples from 
Nottingham Tenovous series. Our finding confirmed that VAV3 was not 
associated with clinicopathological markers, breast cancer specific markers and 
patient outcome. On the other hand, DACH1 was found highly associated with 
clinicopathological markers, breast cancer specific markers and clinical outcome 
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in patients with respect to tumour recurrence and metastasis formation in 5 year 
follow-up data. 
Chapter 5 focussed on the systems biology of ER using the ANN network 
inference approach. To investigate cross-talk in the ER system, we considered 
ESR1 and ESR2 components. Initially the ESR1 and ESR2 interactomes were 
constructed using the top 100 predictive markers specific for ESR1 and ESR2 
status in breast cancer microarray samples. Furthermore, in an attempt to model 
known contenders of the ER pathway, we identified ESR1 and ESR2 interacting 
molecules from in silico interaction databases. The interacting molecules were 
modelled using an ANN-based network inference method. Our finding clustered 
ESR1 and PGR together along with other breast cancer biomarkers such as AR, 
FOXA1, RARA, TFF1 and EGFR, confirming the biological relevance of our 
findings. 
Finally in Chapter 6, a novel non-reductional systems biology approach 
was developed for ESR1 and later extended to PGR and ERBB2. In this study, we 
have utilised predictive markers in a serial additive manner with increasing level 
of markers and complexity. In the first level, 10 predictive markers associated 
with the system were identified. Later, in a second level, 10 predictive markers 
associated with each of the first level markers were added. At every level, the 
predictive marker identification was achieved by considering the gene median 
expression based classification and scanning the entire genome array across all 
samples from dataset. Our finding showed more complex interactions among the 
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ESR1 predictive markers than PGR and ERBB2 markers. Cumulative addition of 
ESR1, PGR and ERBB2 systems to represent a complete biology of breast cancer 
resulted in overlap among the ESR1 and PGR system markers, confirming the 
biological association between the systems. ERBB2 showed no overlap with any 
other systems, suggesting a separate biological entity in breast cancer. 
Overall, in this research work, the ANN model has been successfully 
applied to microarray dataset for the classification of samples based on ER status 
and identification of ER-associated markers. Protein expressions of identified ER-
associated markers, VAV3 and DACH1, have been validated in clinical breast 
tumour tissue samples by immunohistochemistry. The ANN-based network 
inferencing method has been used to investigate the cross-talk in ER system. The 
systems biology approach to ER system is structured in consideration with its 
components, ESR1 and ESR2, as interactomes. Furthermore, to investigate the 
cross-talk between multi-system involvement in breast cancer, as a novelty, the 
integration of ER, PR and Her2 systems have been achieved with respect to ESR1, 
PGR and ERBB2 associated genes in a non-reductional systems biology approach.     
Advantages: 
The non-reductional systems biology approach described here bring 
novelties to existing approaches. One of the main advantages of ANNs in systems 
biology is their ability to efficiently infer cross-talks between the set of markers 
rather than single markers in a pairwise manner.  
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Additionally, a non-reductional systems biology approach, as contrary to 
conventional reductionist approach, gives the advantage of serial addition of 
markers without neglecting the influence of prior markers in an additive approach. 
Furthermore, this novel approach, contrary to most alternatives, the 
potential to be applied to pathway decipherization using several types of data from 
different high throughput platforms of proteomics and metabolomics is possible. 
Limitations: 
Despite the biologically relevant findings, nonetheless, the approach may 
have limitations. Firstly, one of the central limitations may come from the source 
of data itself. Even though we restricted our study to whole genome arrays, the 
interactions can only be relative to all others within the dataset and none of the 
interactions can be complete, because of ever increasing panel of genes in array. 
Another important limitation is the validation of interactions. In spite of 
using well documented multiple in silico interaction databases, some interactions 
of ESR1 with FOXA1 and GATA3 were missing despite being well documented 
and associated with ESR1 and breast cancer. Knowing the fact that only direct 
interactions were considered in the in silico databases considered here, the 
inference of indirect interactions may be considered as an advantage.  
Additionally, preselecting only 100 predictive gene set may impose a 
restricted investigation of contenders involved, highlighting the limitation of the 
method, but not the approach. On the other hand, increasing the gene set number 
Chapter 7: OVERALL SUMMARY AND FUTURE WORK 
 
 
 
187 
 
will proportionally increase the complexity of networks of interactomes and may 
introduce difficulty in inferencing. 
Furthermore, the gene expression levels considered as output in network 
inferencing approach using ANN is modelled for over or under the median 
expression level across whole population of samples i.e., the inputs are used to 
predict the output in a binary fashion at an expense of losing information during 
conversion of continuous data points into discrete output. 
 
FUTURE WORK: 
 As the selection of 100 predictive genes was one among the limitations of 
network inferencing approach, it would be interesting to utilise other statistical 
methods such as principle component analysis to determine the number of 
significant predictive genes to be used with removal of outliers. Adding on to 
this, calculating the percentage of population explained by each gene will also 
be interesting. 
 Development of network topology featuring distance between the nodes is 
another interesting aspect of network inference. The inherent errors 
encountered during prediction of output from the inputs could be exploited to 
localise the nodes correspondingly i.e., the output nodes with higher errors 
could be placed at further distance from source nodes than nodes with lower 
errors. 
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 Development of an algorithm to calculate ‘interaction coefficient’ of nodes 
which could be the product of the number of interactions of a node and the 
cumulative errors encountered across all interactions from the same node. This 
could help in identifying and selection of the most significant node with 
highest interaction coefficient. 
 Further validation is required in order to confirm the findings. Especially, the 
TONDU (or VGLL1) identified as a negative interaction hub in ER-negative 
samples through ANN-network inferencing approach (Chapter 4), requires 
validation in clinical breast tumour samples with the expectation of serving as a 
biomarker in triple negative (adverse clinical responsive) patients. 
 Finally, incorporation of protein-protein interaction information may provide 
more meaningful network inferencing. 
Another aspect for expansion in future work could be in the direction of ER-
beta subunit of ERs. Recently, ER-beta 1 and ER-beta 2 isoforms have been found 
to be clinically important and prognostic indicators in breast cancer studies 
(Speirs, 2008, Speirs et al., 2008, Speirs and Shaaban, 2009, Honma et al., 2008, 
Novelli et al., 2008). The investigation of cross-talk between ER-beta-1 and ER-
beta-2 using ANN-based network inferencing methods could help in 
characterising the role of ER-beta in breast cancer. 
Additionally, as this entire research work was concentrated towards female 
breast cancer, investigations in rare and important male breast cancer is also 
feasible. As indicated by White et. al. that male breast cancer requires more 
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awareness and information (White et al., 2011), the application of ANN based 
classification and network inferencing methods might be helpful in understanding 
the disease. 
Furthermore, using other neural network models such as recurrent neural 
networks and Kohonen self-organising neural networks will be interesting. 
Furthermore, the application of ANN-based network inferencing approach to 
other cancers and disease is believed to have potential in identifying biomarkers 
and contenders of pathway. 
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APPENDIX 1 
 
Curated list of interacting molecules with ESR1 interaction databases: 
Sl. No. Gene Symbol Database Reference 
1 ABCC5 GeneCards I2D: score=0.14 
2 ACTB BioGrid Ambrosino C (2010) 
3 ACTC1 BioGrid Ambrosino C (2010) 
4 ACTN4 BioGrid Khurana S (2011) 
5 ACTR2 BioGrid Ambrosino C (2010) 
6 ACTR3 BioGrid Ambrosino C (2010) 
7 AHR BioGrid Klinge CM (2000) 
8 AHRR BioGrid Klinge CM (2000) 
9 AKAP13 BioGrid Rubino D (1998) 
10 AKT1 BioGrid Campbell RA (2001) 
11 AKT2 BioGrid Sun M (2001) 
12 AP1B1 GeneCards STRING: ENSP00000350199 
13 AR GeneCards I2D: score=1.00 STRING: ENSP00000363822 
14 ARG1 GeneCards I2D: score=0.09 
15 ARHGDIA BioGrid Barone I (2011) 
16 ARHGEF15 GeneCards I2D: score=0.19 
17 ARNT GeneCards I2D: score=1.00 STRING: ENSP00000351407 
18 ASF1A GeneCards EBI-78473,EBI-749553 STRING: ENSP00000229595 
19 ASH2L BioGrid Shi L (2011) 
20 ASPG GeneCards STRING: ENSP00000389003 
21 ATAD2 BioGrid Zou JX (2007) 
22 ATAD3C GeneCards I2D: score=0.22 
23 ATP5J GeneCards STRING: ENSP00000389649 
24 BAG1 BioGrid Zeiner M (1995) 
25 BARD1 BioGrid Dizin E (2010) 
26 BAZ1B BioGrid Kitagawa H (2003) 
27 BCAR1 BioGrid Cabodi S (2004) 
28 BCAS2 GeneCards I2D: score=0.41 STRING: ENSP00000358554 
29 BDNF GeneCards I2D: score=0.98 STRING: ENSP00000414303 
30 BLCAP GeneCards EBI-78473,EBI-3895726 
31 BLOC1S1 BioGrid Mishra SK (2003) 
32 BRCA1 BioGrid Wang C (2005) 
33 BTF3 GeneCards I2D: score=0.70 STRING: ENSP00000369965 
34 C16orf53 GeneCards MINT-7013584 
35 CALM1 BioGrid Garcia Pedrero JM (2002) 
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36 CALM2 GeneCards I2D: score=0.99 
37 CALM3 GeneCards I2D: score=0.99 
38 CAV1 BioGrid Schlegel A (2001) 
39 CBLL1 BioGrid Gong EY (2010) 
40 CCNC BioGrid Kang YK (2002) 
41 CCND1 BioGrid Zwijsen RM (1997) 
42 CCNH BioGrid Talukder AH (2003) 
43 CCNT1 GeneCards I2D: score=0.83 STRING: ENSP00000261900 
44 CDC25B BioGrid Ma ZQ (2001) 
45 CDK11B BioGrid Wang Y (2009) 
46 CDK7 BioGrid Wang Y (2009) 
47 CDK8 BioGrid Wang Y (2009) 
48 CDKN1A BioGrid Maynadier M (2008) 
49 CEBPA BioGrid Boruk M (1998) 
50 CEBPB BioGrid Stein B (1995) 
51 CHD3 BioGrid Okada M (2008) 
52 CHD9 GeneCards I2D: score=0.71 STRING: ENSP00000381522 
53 CHUK GeneCards I2D: score=0.98 STRING: ENSP00000359424 
54 CITED1 BioGrid Yahata T (2001) 
55 COBRA1 BioGrid Aiyar SE (2004) 
56 COL18A1 GeneCards STRING: ENSP00000352798 
57 COL1A2 GeneCards STRING: ENSP00000297268 
58 COPS5 BioGrid Callige M (2005) 
59 CPEB1 GeneCards STRING: ENSP00000414187 
60 CREBBP BioGrid Heery DM (1997) 
61 CRIPAK GeneCards I2D: score=0.44 STRING: ENSP00000323978 
62 CSNK2B GeneCards I2D: score=0.98 STRING: ENSP00000365025 
63 CTNNB1 BioGrid Kouzmenko AP (2004) 
64 CTSD GeneCards STRING: ENSP00000236671 
65 CUEDC2 BioGrid Pan X (2011) 
66 CUL3 BioGrid Byun B (2008) 
67 CUL4B GeneCards I2D: score=0.33 STRING: ENSP00000384109 
68 DAP3 BioGrid Hulkko SM (2000) 
69 DDX17 BioGrid Fujita T (2003) 
70 DDX3X BioGrid Fujita T (2003) 
71 DDX5 BioGrid Fujita T (2003) 
72 DDX54 BioGrid Rajendran RR (2003) 
73 DNM1L GeneCards EBI-78473,EBI-724571 
74 DNTTIP2 BioGrid Bu H (2004) 
75 DSCAM GeneCards STRING: ENSP00000383303 
76 DUT BioGrid Albers M (2005) 
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77 E2F1 BioGrid Liu W (2012) 
78 EBAG9 GeneCards I2D: score=0.12 
79 EGFR GeneCards MINT-6169667  I2D: score=1.00 STRING: ENSP00000275493 
80 EHMT2 BioGrid Purcell DJ (2011) 
81 EIF3I GeneCards I2D: score=0.33 STRING: ENSP00000362688 
82 ELAVL1 GeneCards I2D: score=0.21 
83 EP300 BioGrid Fujita T (2003) 
84 ERBB2 BioGrid Yang Z (2004) 
85 EREG GeneCards STRING: ENSP00000244869 
86 ESR1 BioGrid Ikeda M (2002) 
87 ESR2 BioGrid Monroe DG (2003) 
88 ESRRA GeneCards I2D: score=0.99 STRING: ENSP00000000442 
89 ESRRB GeneCards STRING: ENSP00000261532 
90 ESRRG GeneCards STRING: ENSP00000386171 
91 EXOSC4 GeneCards I2D: score=0.12 
92 EZH2 GeneCards I2D: score=0.35 
93 FHL1 GeneCards I2D: score=0.68 STRING: ENSP00000359724 
94 FHL2 BioGrid Kobayashi S (2004) 
95 FKBP4 BioGrid Nair SC (1996) 
96 FKBP5 BioGrid Nair SC (1996) 
97 FLII BioGrid Jeong KW (2009) 
98 FOS BioGrid Baron S (2007) 
99 FOXA1 GeneCards STRING: ENSP00000250448 
100 FOXL2 GeneCards I2D: score=0.90 STRING: ENSP00000333188 
101 FOXM1 GeneCards STRING: ENSP00000342307 
102 FOXO1 BioGrid Zhao HH (2001) 
103 FOXO3 GeneCards I2D: score=0.98 STRING: ENSP00000339527 
104 FOXO4 BioGrid Schuur ER (2001) 
105 GADD45A BioGrid Yi YW (2000) 
106 GADD45B BioGrid Yi YW (2000) 
107 GADD45G BioGrid Yi YW (2000) 
108 GNA13 GeneCards STRING: ENSP00000400717 
109 GNA14 GeneCards STRING: ENSP00000365807 
110 GNA15 GeneCards STRING: ENSP00000262958 
111 GNAI1 GeneCards I2D: score=0.13 STRING: ENSP00000343027 
112 GNAI2 GeneCards STRING: ENSP00000312999 
113 GNAL GeneCards STRING: ENSP00000334051 
114 GNAO1 GeneCards STRING: ENSP00000262493 
115 GNAZ GeneCards STRING: ENSP00000248996 
116 GNG2 GeneCards STRING: ENSP00000334448 
117 GRB2 GeneCards I2D: score=1.00 STRING: ENSP00000339007 
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118 GRIP1 BioGrid Yi YW (2000) 
119 GSN BioGrid Yi YW (2000) 
120 GTF2B BioGrid Yi YW (2000) 
121 GTF2H1 BioGrid Yi YW (2000) 
122 HAX1 GeneCards EBI-78473,EBI-357001 
123 HDAC1 BioGrid Kawai H (2003) 
124 HDAC2 BioGrid Itoh Y (2007) 
125 HDAC3 BioGrid Liu XF (2004) 
126 HDAC4 BioGrid Leong H (2005) 
127 HDAC5 BioGrid van Rooij E (2010) 
128 HDAC7 BioGrid Malik S (2010) 
129 HDAC9 BioGrid van Rooij E (2010) 
130 HEXIM1 GeneCards I2D: score=0.32 STRING: ENSP00000328773 
131 HNF4A GeneCards I2D: score=1.00 STRING: ENSP00000312987 
132 HNF4G GeneCards STRING: ENSP00000379701 
133 HSP90AA1 BioGrid Nair SC (1996) 
134 HSP90AB1 GeneCards I2D: score=1.00 STRING: ENSP00000325875 
135 HSPA4 BioGrid Nair SC (1996) 
136 HSPA8 BioGrid Tateishi Y (2004) 
137 IGF1 GeneCards STRING: ENSP00000302665 
138 IGF1R BioGrid Santen RJ (2005) 
139 IL25 GeneCards I2D: score=0.21 
140 ING1 BioGrid Toyama T (2003) 
141 IRS1 BioGrid Morelli C (2003) 
142 IRS2 BioGrid Morelli C (2003) 
143 ISL1 BioGrid Gay F (2000) 
144 ITGB3BP GeneCards I2D: score=0.90 STRING: ENSP00000271002 
145 JUN BioGrid Teyssier C (2001) 
146 JUNB GeneCards I2D: score=0.98 STRING: ENSP00000303315 
147 JUND GeneCards I2D: score=0.92 STRING: ENSP00000252818 
148 KAT2A BioGrid Oishi H (2006) 
149 KAT2B GeneCards STRING: ENSP00000263754 
150 KAT5 BioGrid Gaughan L (2001) 
151 KAT6A BioGrid Yin H (2007) 
152 KDM1A BioGrid Garcia-Bassets I (2007) 
153 KDM4B BioGrid Shi L (2011) 
154 KDM5A BioGrid Chan SW (2001) 
155 KDM6B GeneCards MINT-8286415 MINT-8286424 
156 KIF11 GeneCards STRING: ENSP00000260731 
157 KIF1A BioGrid Albers M (2005) 
158 KLF5 BioGrid Guo P (2010) 
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159 LCK GeneCards I2D: score=0.99 STRING: ENSP00000337825 
160 LCOR BioGrid Fernandes I (2003) 
161 LDB1 BioGrid Johnsen SA (2009) 
162 LINC00312 GeneCards MINT-50571 MINT-50573 MINT-50906 I2D: score=0.04 
163 LMO4 BioGrid Singh RR (2005) 
164 LOC100505603 GeneCards MINT-14693 MINT-14694 I2D: score=0.87 
165 LRIF1 BioGrid Li HJ (2007) 
166 LYZ GeneCards I2D: score=0.12 
167 MAD2L1 GeneCards STRING: ENSP00000296509 
168 MAP3K1 GeneCards MINT-50709 I2D: score=0.28 STRING: ENSP00000382423 
169 MAPK1 BioGrid Metivier R (2002) 
170 MAPK11 GeneCards STRING: ENSP00000333685 
171 MAPK14 GeneCards I2D: score=0.98 STRING: ENSP00000229794 
172 MAPK3 GeneCards I2D: score=0.99 STRING: ENSP00000263025 
173 MBD2 BioGrid Chatagnon A (2010) 
174 MDM2 BioGrid Duong V (2007) 
175 MED1 BioGrid Fujita T (2003) 
176 MED10 BioGrid Fujita T (2003) 
177 MED12 BioGrid Kang YK (2002) 
178 MED13 BioGrid Kang YK (2002) 
179 MED14 BioGrid Burakov D (2000) 
180 MED16 BioGrid Kang YK (2002) 
181 MED17 BioGrid Kang YK (2002) 
182 MED20 BioGrid Kang YK (2002) 
183 MED21 BioGrid Kang YK (2002) 
184 MED23 BioGrid Kang YK (2002) 
185 MED24 BioGrid Kang YK (2002) 
186 MED25 BioGrid Lee HK (2007) 
187 MED30 GeneCards I2D: score=0.92 
188 MED4 GeneCards I2D: score=0.92 
189 MED6 BioGrid Lee HK (2007) 
190 MED7 BioGrid Lee HK (2007) 
191 MEN1 BioGrid Dreijerink KM (2006) 
192 MGMT BioGrid Teo AK (2001) 
193 MKNK2 GeneCards I2D: score=0.97 STRING: ENSP00000250896 
194 MLL2 BioGrid Shi L (2011) 
195 MMS19 GeneCards I2D: score=0.98 STRING: ENSP00000359818 
196 MNAT1 BioGrid Talukder AH (2003) 
197 MPG BioGrid Likhite VS (2004) 
198 MRPS15 GeneCards I2D: score=0.02 
199 MRPS17 GeneCards I2D: score=0.05 
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200 MRPS2 GeneCards I2D: score=0.03 
201 MRPS22 GeneCards I2D: score=0.25 
202 MRPS27 GeneCards I2D: score=0.07 
203 MRPS31 GeneCards I2D: score=0.28 
204 MRPS35 GeneCards I2D: score=0.03 
205 MRPS6 GeneCards I2D: score=0.04 
206 MSH2 BioGrid Wada-Hiraike O (2005) 
207 MSH6 BioGrid Oishi H (2006) 
208 MTA1 BioGrid Mishra SK (2003) 
209 MTA2 BioGrid Okada M (2008) 
210 MTA3 BioGrid Okada M (2008) 
211 MTCH2 BioGrid Albers M (2005) 
212 MUC1 BioGrid Wei X (2006) 
213 MVP BioGrid Abbondanza C (1998) 
214 MYC BioGrid Cheng AS (2006) 
215 MYL6 BioGrid Ambrosino C (2010) 
216 MYLK2 GeneCards I2D: score=0.08 
217 MYO1C BioGrid Ambrosino C (2010) 
218 MYOD1 BioGrid Jin W (2008) 
219 MYSM1 GeneCards STRING: ENSP00000418734 
220 NCOA1 BioGrid Kraichely DM (2000) 
221 NCOA2 BioGrid Kraichely DM (2000) 
222 NCOA3 BioGrid Suen CS (1998) 
223 NCOA4 BioGrid Alen P (1999) 
224 NCOA6 BioGrid Mahajan MA (2000) 
225 NCOA7 BioGrid Lazennec G (1997) 
226 NCOR1 BioGrid Fujita T (2003) 
227 NCOR2 BioGrid Fujita T (2003) 
228 NDRG2 GeneCards EBI-78473,EBI-3895741 
229 NDUFV3 GeneCards STRING: ENSP00000346196 
230 NFKB1 GeneCards I2D: score=1.00 STRING: ENSP00000226574 
231 NGG1 BioGrid Benecke A (2002) 
232 NOS3 GeneCards I2D: score=0.96 
233 NPM1 BioGrid Ambrosino C (2010) 
234 NPPA BioGrid Albers M (2005) 
235 NR0B1 GeneCards I2D: score=1.00 STRING: ENSP00000368253 
236 NR0B2 BioGrid Seol W (1998) 
237 NR1D1 GeneCards STRING: ENSP00000246672 
238 NR1D2 GeneCards STRING: ENSP00000310006 
239 NR1H2 GeneCards STRING: ENSP00000253727 
240 NR1H4 GeneCards I2D: score=0.97 STRING: ENSP00000315442 
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241 NR1I2 BioGrid Seol W (1998) 
242 NR2C1 BioGrid Hu YC (2002) 
243 NR2C2 BioGrid Shyr CR (2002) 
244 NR2C2AP GeneCards STRING: ENSP00000332823 
245 NR2E1 GeneCards STRING: ENSP00000357982 
246 NR2F1 BioGrid Metivier R (2002) 
247 NR2F6 BioGrid Zhu XG (2000) 
248 NR4A1 GeneCards STRING: ENSP00000243050 
249 NR4A2 GeneCards STRING: ENSP00000344479 
250 NR5A1 GeneCards STRING: ENSP00000362690 
251 NRBP1 GeneCards STRING: ENSP00000233557 
252 NRIP1 BioGrid Heery DM (1997) 
253 NSD1 BioGrid Huang N (1998) 
254 OTUB1 BioGrid Stanisic V (2009) 
255 PABPC5 GeneCards I2D: score=0.24 
256 PAK1 GeneCards I2D: score=0.98 STRING: ENSP00000278568 
257 PAK6 BioGrid Lee SR (2002) 
258 PARP1 BioGrid Ju BG (2006) 
259 PDLIM1 BioGrid Johnsen SA (2009) 
260 PELP1 BioGrid Vadlamudi RK (2001) 
261 PGC BioGrid Bourdoncle A (2005) 
262 PGR BioGrid Giulianelli S (2012) 
263 PHB BioGrid Giulianelli S (2012) 
264 PHB2 BioGrid Martini PG (2003) 
265 PIAS1 BioGrid Kobayashi S (2004) 
266 PIAS2 BioGrid Kotaja N (2000) 
267 PIAS3 GeneCards I2D: score=0.99 STRING: ENSP00000376765 
268 PIK3CA GeneCards I2D: score=0.96 STRING: ENSP00000263967 
269 PIK3R1 BioGrid Castoria G (2001) 
270 PIK3R2 BioGrid Cabodi S (2004) 
271 PIK3R3 GeneCards I2D: score=0.96 STRING: ENSP00000262741 
272 PLA2G7 GeneCards I2D: score=0.05 
273 PNRC2 BioGrid Albers M (2005) 
274 POLR1B GeneCards I2D: score=0.40 STRING: ENSP00000263331 
275 POLR2A BioGrid Ambrosino C (2010) 
276 POLR2D GeneCards I2D: score=0.16 
277 POU2F1 BioGrid Prefontaine GG (1999) 
278 POU2F2 BioGrid Prefontaine GG (1999) 
279 POU4F1 BioGrid Budhram-Mahadeo V (1998) 
280 POU4F2 BioGrid Budhram-Mahadeo V (1998) 
281 PPARA GeneCards STRING: ENSP00000262735 
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282 PPARD GeneCards STRING: ENSP00000310928 
283 PPARG BioGrid DiRenzo J (1997) 
284 PPARGC1A BioGrid DiRenzo J (1997) 
285 PPARGC1B BioGrid DiRenzo J (1997) 
286 PPID BioGrid Nair SC (1996) 
287 PPP1CC BioGrid Flores-Delgado G (2007) 
288 PPP5C GeneCards 
EBI-78473,EBI-716663 I2D: score=0.05 STRING: 
ENSP00000012443 
289 PRDM2 BioGrid Abbondanza C (2000) 
290 PRKACA GeneCards I2D: score=0.98 STRING: ENSP00000309591 
291 PRKCZ BioGrid Yi P (2008) 
292 PRKDC BioGrid Ju BG (2006) 
293 PRMT1 BioGrid Koh SS (2001) 
294 PRMT2 BioGrid Qi C (2002) 
295 PRPF6 GeneCards I2D: score=0.99 STRING: ENSP00000266079 
296 PSEN2 GeneCards STRING: ENSP00000355747 
297 PSMB9 GeneCards MINT-3291999 I2D: score=0.07 
298 PSMC5 BioGrid vom Baur E (1996) 
299 PSMD1 GeneCards I2D: score=0.96 STRING: ENSP00000309474 
300 PTCD3 GeneCards I2D: score=0.05 
301 PTEN BioGrid Lin HK (2004) 
302 PTGES3 BioGrid Nair SC (1996) 
303 PTMA BioGrid Martini PG (2003) 
304 PTPN1 GeneCards MINT-6761899 I2D: score=0.99 STRING: ENSP00000360683 
305 PTPN6 GeneCards MINT-6761906 I2D: score=0.98 STRING: ENSP00000391592 
306 RABGEF1 BioGrid La Rosa P (2011) 
307 RAC3 GeneCards EBI-78473,EBI-767084 
308 RAN BioGrid Castoria G (2012) 
309 RARA GeneCards I2D: score=1.00 STRING: ENSP00000254066 
310 RARB GeneCards STRING: ENSP00000332296 
311 RARG GeneCards STRING: ENSP00000332695 
312 RBBP4 BioGrid Creekmore AL (2008) 
313 RBBP5 BioGrid Shi L (2011) 
314 RBBP6 BioGrid Peidis P (2010) 
315 RBBP7 BioGrid Creekmore AL (2008) 
316 RBFOX2 BioGrid Norris JD (2002) 
317 RBM10 GeneCards STRING: ENSP00000366829 
318 RBM23 GeneCards I2D: score=0.62 STRING: ENSP00000352956 
319 RBM39 BioGrid Jung DJ (2002) 
320 RELA BioGrid Nettles KW (2008) 
321 REXO4 BioGrid Montano MM (2000) 
322 RFX4 GeneCards I2D: score=0.35 STRING: ENSP00000376585 
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323 RGS3 GeneCards I2D: score=0.11 STRING: ENSP00000259406 
324 RLIM BioGrid Johnsen SA (2009) 
325 RNF14 GeneCards I2D: score=0.95 STRING: ENSP00000324956 
326 RNF4 BioGrid Moilanen AM (1998) 
327 RORA GeneCards STRING: ENSP00000261523 
328 RORB GeneCards STRING: ENSP00000366093 
329 RORC GeneCards STRING: ENSP00000327025 
330 RPL18 BioGrid Moilanen AM (1998) 
331 RPL36AL GeneCards I2D: score=0.08 
332 RPL7 BioGrid Ambrosino C (2010) 
333 RPL7A BioGrid Ambrosino C (2010) 
334 RPLP0 BioGrid Ambrosino C (2010) 
335 RPLP0P6 GeneCards I2D: score=0.02 
336 RPS11 GeneCards I2D: score=0.08 
337 RPS18 GeneCards I2D: score=0.10 
338 RPS20 GeneCards I2D: score=0.22 
339 RPS4X BioGrid Ambrosino C (2010) 
340 RPS6KA1 BioGrid Joel PB (1998) 
341 RPS6KA3 BioGrid Clark DE (2001) 
342 RPS8 BioGrid Ambrosino C (2010) 
343 RPS9 BioGrid Ambrosino C (2010) 
344 RXRA BioGrid DiRenzo J (1997) 
345 RXRG GeneCards STRING: ENSP00000352900 
346 SAFB BioGrid Oesterreich S (2000) 
347 SAFB2 BioGrid Oesterreich S (2000) 
348 SENP5 GeneCards EBI-78473,EBI-3895753 
349 SETD7 BioGrid Subramanian K (2008) 
350 SF1 BioGrid Zhou D (2001) 
351 SGK3 BioGrid Wang Y (2011) 
352 SHC1 BioGrid Song RX (2002) 
353 SIN3A BioGrid Ellison-Zelski SJ (2009) 
354 SIRT1 BioGrid Elangovan S (2011) 
355 SKI BioGrid Elangovan S (2011) 
356 SKIL BioGrid Band AM (2011) 
357 SLC30A9 GeneCards I2D: score=0.92 STRING: ENSP00000264451 
358 SMAD2 BioGrid Ito I (2010) 
359 SMAD3 BioGrid Ito I (2010) 
360 SMAD4 GeneCards I2D: score=1.00 STRING: ENSP00000341551 
361 SMARCA2 BioGrid Ichinose H (1997) 
362 SMARCA4 BioGrid Ichinose H (1997) 
363 SMARCB1 BioGrid Okada M (2008) 
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364 SMARCC2 BioGrid Okada M (2008) 
365 SMARCD1 BioGrid Hsiao PW (2003) 
366 SMARCD3 GeneCards I2D: score=0.93 STRING: ENSP00000262188 
367 SMARCE1 BioGrid Kiskinis E (2006) 
368 SMURF1 BioGrid Ito I (2010) 
369 SMYD3 BioGrid Kim H (2009) 
370 SOD1 GeneCards STRING: ENSP00000270142 
371 SOS1 GeneCards I2D: score=0.95 STRING: ENSP00000384675 
372 SOS2 BioGrid Yang Z (2004) 
373 SP1 BioGrid Petz LN (2004) 
374 SP2 BioGrid He S (2005) 
375 SP3 BioGrid Dong J (2006) 
376 SPOP BioGrid Byun B (2008) 
377 SRA1 BioGrid Watanabe M (2001) 
378 SRC BioGrid Monroe DG (2003) 
379 SREBF1 GeneCards I2D: score=0.96 STRING: ENSP00000348069 
380 STAT3 BioGrid Wang LH (2001) 
381 STAT5A BioGrid Faulds MH (2001) 
382 STAU1 GeneCards I2D: score=0.30 
383 STK11 GeneCards STRING: ENSP00000324856 
384 STRN GeneCards I2D: score=0.84 STRING: ENSP00000263918 
385 STUB1 BioGrid Tateishi Y (2004) 
386 SUMO1 BioGrid Sentis S (2005) 
387 SVIL BioGrid Ting HJ (2002) 
388 TAB2 BioGrid Cutrupi S (2012) 
389 TADA3 BioGrid Li CW (2010) 
390 TAF10 GeneCards I2D: score=1.00 STRING: ENSP00000299424 
391 TAF1A BioGrid Loven MA (2003) 
392 TAF1B BioGrid Loven MA (2003) 
393 TAF2 BioGrid Suen CS (1998) 
394 TAP1 GeneCards I2D: score=0.93 STRING: ENSP00000346206 
395 TBP BioGrid Lazennec G (1997) 
396 TCF20 GeneCards I2D: score=0.97 STRING: ENSP00000352463 
397 TDG BioGrid Chen D (2003) 
398 TFF1 BioGrid Yi P (2008) 
399 THRA GeneCards I2D: score=1.00 STRING: ENSP00000264637 
400 THRB GeneCards I2D: score=1.00 STRING: ENSP00000348827 
401 TNFRSF14 GeneCards I2D: score=0.96 STRING: ENSP00000347948 
402 TOP2B BioGrid Ju BG (2006) 
403 TP53 BioGrid Liu G (2000) 
404 TRAM1 BioGrid Kraichely DM (2000) 
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405 TRIM24 BioGrid vom Baur E (1996) 
406 TRIM25 BioGrid Nakajima A (2007) 
407 TRIM28 GeneCards I2D: score=0.97 STRING: ENSP00000253024 
408 TRIM59 GeneCards I2D: score=0.87 STRING: ENSP00000311219 
409 TRIP4 BioGrid Kim HJ (1999) 
410 TRRAP BioGrid Fujita T (2003) 
411 TSC2 GeneCards I2D: score=0.94 STRING: ENSP00000219476 
412 TUBA1A BioGrid Benecke A (2002) 
413 TUBA1B GeneCards I2D: score=0.14 STRING: ENSP00000336799 
414 TUBB GeneCards I2D: score=0.04 
415 TUBB1 BioGrid Benecke A (2002) 
416 TUBB2A GeneCards STRING: ENSP00000369703 
417 UBC BioGrid Stanisic V (2009) 
418 UBE2I BioGrid Kobayashi S (2004) 
419 UBE3A BioGrid Sun J (2012) 
420 UIMC1 BioGrid Yan J (2007) 
421 USF1 GeneCards I2D: score=0.75 STRING: ENSP00000356999 
422 UTP14A GeneCards I2D: score=0.81 
423 VAV3 GeneCards I2D: score=0.98 STRING: ENSP00000359073 
424 VDR GeneCards STRING: ENSP00000229022 
425 WDR5 BioGrid Shi L (2011) 
426 WDR5B GeneCards I2D: score=0.18 STRING: ENSP00000330381 
427 WIPI1 GeneCards I2D: score=0.88 STRING: ENSP00000262139 
428 XBP1 BioGrid Ding L (2003) 
429 XPO1 BioGrid Castoria G (2012) 
430 XRCC5 BioGrid Ju BG (2006) 
431 XRCC6 BioGrid Ju BG (2006) 
432 YWHAH GeneCards I2D: score=0.98 STRING: ENSP00000248975 
433 YWHAQ BioGrid Zilliacus J (2001) 
434 ZBTB16 BioGrid Martin PJ (2003) 
435 ZBTB17 GeneCards I2D: score=0.95 STRING: ENSP00000364895 
436 ZC3HAV1 GeneCards I2D: score=0.17 
437 ZNF398 BioGrid Conroy AT (2002) 
438 ZNHIT3 GeneCards I2D: score=0.96 
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APPENDIX 2 
 
Curated list of interacting molecules with ESR2 interaction databases: 
Sl. No. Gene Symbol Database Reference 
1 ACAD11 GeneCards I2D: score=0.01 
2 ACSM2B GeneCards I2D: score=0.13 
3 ACTB GeneCards I2D: score=0.06 
4 ACTN1 GeneCards I2D: score=0.07 
5 ACTN3 GeneCards I2D: score=0.09 
6 ACTR3 GeneCards I2D: score=0.06 
7 AKAP13 GeneCards I2D: score=0.98 STRING: ENSP00000354718 
8 AKAP8 GeneCards I2D: score=0.15 
9 AKAP9 GeneCards I2D: score=0.12 
10 AKT1 GeneCards I2D: score=0.07 STRING: ENSP00000270202 
11 ANAPC5 GeneCards I2D: score=0.06 
12 ANKFY1 GeneCards I2D: score=0.15 
13 AP2A1 GeneCards I2D: score=0.07 
14 ARID5A BioGRID Georgescu SP (2005) 
15 ARPC2 GeneCards I2D: score=0.08 
16 ASB2 GeneCards I2D: score=0.08 
17 ATG2A GeneCards I2D: score=0.03 
18 BAIAP2L1 GeneCards I2D: score=0.03 
19 BAZ1A GeneCards I2D: score=0.29 
20 BCAS2 GeneCards I2D: score=0.07 STRING: ENSP00000358554 
21 BCLAF1 GeneCards I2D: score=0.19 
22 BICD1 GeneCards I2D: score=0.05 
23 BRD8 GeneCards I2D: score=0.66 
24 C10orf47 GeneCards I2D: score=0.02 
25 C14orf43 GeneCards I2D: score=0.63 
26 C19orf68 GeneCards I2D: score=0.02 
27 C22orf28 GeneCards I2D: score=0.03 
28 C9orf114 GeneCards I2D: score=0.03 
29 CALM1 GeneCards I2D: score=0.77 STRING: ENSP00000349467 
30 CALM2 GeneCards I2D: score=0.77 
31 CALM3 GeneCards I2D: score=0.77 
32 CAND1 BioGRID Bennett EJ (2010) 
33 CCAR1 GeneCards I2D: score=0.50 
34 CCDC106 GeneCards I2D: score=0.05 
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35 CCNC BioGRID Kang YK (2002) 
36 CCNC GeneCards I2D: score=0.15 STRING: ENSP00000358222 
37 CDC16 GeneCards I2D: score=0.76 
38 CDC5L GeneCards I2D: score=0.06 
39 CDK8 BioGRID Kang YK (2002) 
40 CGN GeneCards I2D: score=0.02 
41 CHM GeneCards I2D: score=0.05 
42 CLASP2 GeneCards I2D: score=0.07 
43 CLCF1 GeneCards I2D: score=0.01 
44 CNN1 GeneCards I2D: score=0.06 
45 CNTRL GeneCards I2D: score=0.07 
46 COIL GeneCards I2D: score=0.06 
47 COPB2 GeneCards I2D: score=0.02 
48 COPG2 GeneCards I2D: score=0.03 
49 CPSF6 GeneCards I2D: score=0.12 
50 CPT1A GeneCards I2D: score=0.07 
51 CREBBP GeneCards I2D: score=0.99 STRING: ENSP00000262367 
52 CSE1L GeneCards I2D: score=0.07 
53 CTNNB1 GeneCards I2D: score=0.89 
54 CTTN GeneCards I2D: score=0.05 
55 CWC15 GeneCards I2D: score=0.10 
56 CWC27 GeneCards I2D: score=0.03 
57 DAP3 GeneCards I2D: score=0.11 STRING: ENSP00000341692 
58 DBN1 GeneCards I2D: score=0.02 
59 DDX17 GeneCards I2D: score=0.93 STRING: ENSP00000380033 
60 DDX39A GeneCards I2D: score=0.08 
61 DDX3X GeneCards I2D: score=0.10 
62 DDX41 GeneCards I2D: score=0.07 
63 DDX5 GeneCards I2D: score=0.80 STRING: ENSP00000225792 
64 DDX50 GeneCards I2D: score=0.05 
65 DDX54 BioGRID Rajendran RR (2003) 
66 DLGAP4 GeneCards I2D: score=0.08 
67 DNTTIP1 GeneCards I2D: score=0.04 
68 DNTTIP2 GeneCards I2D: score=0.12 STRING: ENSP00000352137 
69 DOK6 GeneCards I2D: score=0.02 
70 EDC4 GeneCards I2D: score=0.15 
71 EEF1A2 GeneCards I2D: score=0.04 
72 EFTUD2 GeneCards I2D: score=0.05 
73 EIF2A GeneCards I2D: score=0.04 
74 EIF3I BioGRID Albers M (2005) 
75 EP300 GeneCards I2D: score=0.99 STRING: ENSP00000263253 
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76 EPB41L5 GeneCards I2D: score=0.02 
77 EPS15L1 GeneCards I2D: score=0.06 
78 ESR1 GeneCards I2D: score=1.00 STRING: ENSP00000206249 
79 ESR2 BioGRID Powell E (2010) 
80 ESRRA GeneCards STRING: ENSP00000000442 
81 ESRRB GeneCards STRING: ENSP00000261532 
82 ESRRG GeneCards STRING: ENSP00000386171 
83 EXOSC10 GeneCards I2D: score=0.03 
84 EXOSC4 GeneCards I2D: score=0.04 
85 FAM120A GeneCards I2D: score=0.02 
86 FAM179B GeneCards I2D: score=0.04 
87 FAM82A2 GeneCards I2D: score=0.07 
88 FBLL1 GeneCards I2D: score=0.11 
89 FIP1L1 GeneCards I2D: score=0.08 
90 FLG GeneCards I2D: score=0.04 
91 FLNB GeneCards I2D: score=0.03 
92 FLNC GeneCards I2D: score=0.03 
93 FMR1 GeneCards I2D: score=0.06 
94 FOXL2 GeneCards I2D: score=0.07 
95 FTSJ3 GeneCards I2D: score=0.07 
96 FXR2 GeneCards I2D: score=0.09 
97 GCC2 GeneCards I2D: score=0.04 
98 GFAP GeneCards I2D: score=0.07 
99 GIGYF1 GeneCards I2D: score=0.03 
100 GNA14 GeneCards STRING: ENSP00000365807 
101 GNA15 GeneCards STRING: ENSP00000262958 
102 GNAL GeneCards STRING: ENSP00000334051 
103 GNB2L1 GeneCards I2D: score=0.08 
104 GNB3 GeneCards I2D: score=0.10 
105 GNG2 GeneCards STRING: ENSP00000334448 
106 GNL2 GeneCards I2D: score=0.05 
107 GNL3 GeneCards I2D: score=0.06 
108 GOLGA3 GeneCards I2D: score=0.07 
109 GOLGA4 GeneCards I2D: score=0.04 
110 GSN GeneCards I2D: score=0.02 
111 GSPT1 GeneCards I2D: score=0.04 
112 GTF3C1 GeneCards I2D: score=0.12 
113 GTF3C2 GeneCards I2D: score=0.10 
114 GTF3C3 GeneCards I2D: score=0.14 
115 GTF3C4 GeneCards I2D: score=0.03 
116 GTF3C5 GeneCards I2D: score=0.11 
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117 GTPBP4 GeneCards I2D: score=0.04 
118 H2BFS GeneCards I2D: score=0.05 
119 HCFC1 GeneCards I2D: score=0.90 
120 HCFC2 GeneCards I2D: score=0.03 
121 HEATR4 GeneCards I2D: score=0.05 
122 HIST1H1C GeneCards I2D: score=0.17 
123 HIST1H4A GeneCards I2D: score=0.10 
124 HIST1H4B GeneCards I2D: score=0.10 
125 HIST1H4C GeneCards I2D: score=0.10 
126 HIST1H4D GeneCards I2D: score=0.10 
127 HIST1H4E GeneCards I2D: score=0.10 
128 HIST1H4F GeneCards I2D: score=0.10 
129 HIST1H4H GeneCards I2D: score=0.10 
130 HIST1H4I GeneCards I2D: score=0.10 
131 HIST1H4J GeneCards I2D: score=0.10 
132 HIST1H4K GeneCards I2D: score=0.10 
133 HIST1H4L GeneCards I2D: score=0.10 
134 HIST2H4A GeneCards I2D: score=0.10 
135 HIST2H4B GeneCards I2D: score=0.10 
136 HIST4H4 GeneCards I2D: score=0.10 
137 HNF4A GeneCards STRING: ENSP00000312987 
138 HNF4G GeneCards STRING: ENSP00000379701 
139 HNRNPCL1 GeneCards I2D: score=0.12 
140 HNRNPH2 GeneCards I2D: score=0.08 
141 HP1BP3 GeneCards I2D: score=0.12 
142 HR GeneCards I2D: score=0.03 
143 HSP90AA1 BioGRID Powell E (2010) 
144 HSPA1A GeneCards I2D: score=0.29 
145 HSPA1B GeneCards I2D: score=0.29 
146 HSPA6 GeneCards I2D: score=0.26 
147 HSPA8 GeneCards I2D: score=0.24 
148 HTATSF1 GeneCards I2D: score=0.09 
149 JMJD1C BioGRID Iannone MA (2001) 
150 KANK2 GeneCards I2D: score=0.06 
151 KAT5 BioGRID Gaughan L (2001) 
152 KATNAL2 GeneCards I2D: score=0.04 
153 KHDRBS1 GeneCards I2D: score=0.06 
154 KLF5 BioGRID Nakajima Y (2011) 
155 KRI1 GeneCards I2D: score=0.04 
156 LACTB GeneCards I2D: score=0.02 
157 LAD1 GeneCards I2D: score=0.02 
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158 LAMB1 GeneCards I2D: score=0.02 
159 LARP1 GeneCards I2D: score=0.09 
160 LAS1L GeneCards I2D: score=0.08 
161 LCK GeneCards I2D: score=0.76 STRING: ENSP00000337825 
162 LIMA1 GeneCards I2D: score=0.32 
163 LOC100505603 GeneCards I2D: score=0.09 
164 LOC100507025 GeneCards I2D: score=0.10 
165 LONP1 GeneCards I2D: score=0.08 
166 LRRC1 GeneCards I2D: score=0.04 
167 LRRC59 GeneCards I2D: score=0.03 
168 LYAR GeneCards I2D: score=0.09 
169 MAD2L1 GeneCards I2D: score=0.96 STRING: ENSP00000296509 
170 MAPK1 BioGRID Tremblay A (2001) 
171 MAPK11 GeneCards I2D: score=0.97 STRING: ENSP00000333685 
172 MDM2 BioGRID Sanchez M (2012) 
173 MED1 GeneCards I2D: score=0.98 STRING: ENSP00000300651 
174 MED10 BioGRID Kang YK (2002) 
175 MED12 GeneCards I2D: score=0.88 STRING: ENSP00000363193 
176 MED13 GeneCards I2D: score=0.93 
177 MED14 GeneCards I2D: score=0.93 STRING: ENSP00000323720 
178 MED16 GeneCards I2D: score=0.86 STRING: ENSP00000325612 
179 MED17 GeneCards I2D: score=0.86 STRING: ENSP00000251871 
180 MED20 GeneCards I2D: score=0.02 STRING: ENSP00000265350 
181 MED21 GeneCards I2D: score=0.04 STRING: ENSP00000282892 
182 MED23 GeneCards I2D: score=0.75 STRING: ENSP00000357047 
183 MED24 GeneCards I2D: score=0.96 STRING: ENSP00000348610 
184 MED27 GeneCards I2D: score=0.34 
185 MED4 GeneCards I2D: score=0.87 
186 MED6 GeneCards I2D: score=0.38 STRING: ENSP00000256379 
187 MED7 GeneCards I2D: score=0.03 STRING: ENSP00000286317 
188 MKI67 GeneCards I2D: score=0.25 
189 MKNK2 BioGRID Slentz-Kesler K (2000) 
190 MLLT1 GeneCards I2D: score=0.04 
191 MMS19 GeneCards I2D: score=0.89 STRING: ENSP00000359818 
192 MRPL44 GeneCards I2D: score=0.03 
193 MRPL45 GeneCards I2D: score=0.02 
194 MRPS15 GeneCards I2D: score=0.03 
195 MRPS2 GeneCards I2D: score=0.03 
196 MRPS21 GeneCards I2D: score=0.02 
197 MRPS22 GeneCards I2D: score=0.05 
198 MRPS27 GeneCards I2D: score=0.01 
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199 MRPS31 GeneCards I2D: score=0.24 
200 MRPS5 GeneCards I2D: score=0.05 
201 MRPS9 GeneCards I2D: score=0.04 
202 MSH2 BioGRID Wada-Hiraike O (2005) 
203 MTA2 GeneCards I2D: score=0.37 
204 MYBBP1A GeneCards I2D: score=0.07 
205 MYH13 GeneCards I2D: score=0.05 
206 MYH14 GeneCards I2D: score=0.08 
207 MYH4 GeneCards I2D: score=0.05 
208 MYH7 GeneCards I2D: score=0.12 
209 MYH7B GeneCards I2D: score=0.04 
210 MYL6 GeneCards I2D: score=0.05 
211 MYLK2 GeneCards I2D: score=0.05 
212 MYO1C GeneCards I2D: score=0.09 
213 MYO1D GeneCards I2D: score=0.06 
214 MYO3B GeneCards I2D: score=0.08 
215 MYOD1 GeneCards I2D: score=0.83 STRING: ENSP00000250003 
216 NAT10 GeneCards I2D: score=0.03 
217 NBPF8 GeneCards I2D: score=0.03 
218 NCBP1 GeneCards I2D: score=0.04 
219 NCOA1 GeneCards I2D: score=1.00 STRING: ENSP00000320940 
220 NCOA2 BioGRID Iannone MA (2001) 
221 NCOA3 GeneCards I2D: score=1.00 STRING: ENSP00000361066 
222 NCOA6 GeneCards I2D: score=1.00 STRING: ENSP00000351894 
223 NCOA7 GeneCards I2D: score=0.98 STRING: ENSP00000357341 
224 NCOR1 GeneCards I2D: score=0.99 STRING: ENSP00000268712 
225 NCOR2 GeneCards I2D: score=0.97 STRING: ENSP00000348551 
226 NEBL GeneCards I2D: score=0.04 
227 NEFH GeneCards I2D: score=0.05 
228 NFKBIB BioGRID Iannone MA (2001) 
229 NKRF GeneCards I2D: score=0.02 
230 NOLC1 GeneCards I2D: score=0.05 
231 NOP56 GeneCards I2D: score=0.15 
232 NR0B1 GeneCards I2D: score=1.00 STRING: ENSP00000368253 
233 NR0B2 GeneCards I2D: score=0.99 STRING: ENSP00000254227 
234 NR1D1 GeneCards STRING: ENSP00000246672 
235 NR1D2 GeneCards STRING: ENSP00000310006 
236 NR1H2 GeneCards STRING: ENSP00000253727 
237 NR2C1 GeneCards STRING: ENSP00000333275 
238 NR2C2 GeneCards STRING: ENSP00000320447 
239 NR2C2AP GeneCards STRING: ENSP00000332823 
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240 NR2E1 GeneCards STRING: ENSP00000357982 
241 NR2F1 GeneCards STRING: ENSP00000325819 
242 NR2F6 GeneCards STRING: ENSP00000291442 
243 NR4A1 GeneCards STRING: ENSP00000243050 
244 NR4A2 GeneCards STRING: ENSP00000344479 
245 NR5A1 GeneCards STRING: ENSP00000362690 
246 NRBP1 GeneCards STRING: ENSP00000233557 
247 NRIP1 GeneCards I2D: score=0.99 
248 NUP205 GeneCards I2D: score=0.10 
249 OXT GeneCards I2D: score=0.95 STRING: ENSP00000217386 
250 PABPC1L GeneCards I2D: score=0.02 
251 PABPC3 GeneCards I2D: score=0.04 
252 PABPC5 GeneCards I2D: score=0.06 
253 PBRM1 GeneCards I2D: score=0.81 
254 PELP1 GeneCards I2D: score=0.98 STRING: ENSP00000301396 
255 PES1 GeneCards I2D: score=0.09 
256 PIAS1 GeneCards I2D: score=1.00 STRING: ENSP00000249636 
257 PIAS2 GeneCards I2D: score=0.98 STRING: ENSP00000381648 
258 PIAS3 GeneCards I2D: score=0.75 STRING: ENSP00000376765 
259 PIK3R4 GeneCards I2D: score=0.05 
260 PIP GeneCards I2D: score=0.02 
261 PKP3 GeneCards I2D: score=0.09 
262 PNRC1 GeneCards I2D: score=0.20 
263 PNRC2 BioGRID Albers M (2005) 
264 PNRC2 GeneCards I2D: score=0.09 
265 POLR1E GeneCards I2D: score=0.05 
266 POM121 GeneCards I2D: score=0.04 
267 POM121C GeneCards I2D: score=0.03 
268 PPARA GeneCards STRING: ENSP00000262735 
269 PPARD GeneCards STRING: ENSP00000310928 
270 PPARG GeneCards STRING: ENSP00000287820 
271 PPARGC1A GeneCards I2D: score=0.99 
272 PPP5C GeneCards 
EBI-78505,EBI-716663 I2D: score=0.07 STRING: 
ENSP00000012443 
273 PPRC1 GeneCards I2D: score=0.19 
274 PRDX3 GeneCards I2D: score=0.06 
275 PRDX4 GeneCards I2D: score=0.06 
276 PREPL GeneCards I2D: score=0.03 
277 PRKDC GeneCards I2D: score=0.78 
278 PRKRA GeneCards I2D: score=0.18 
279 PRMT2 GeneCards I2D: score=0.79 STRING: ENSP00000347906 
280 PRPF31 GeneCards I2D: score=0.09 
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281 PRPH GeneCards I2D: score=0.11 
282 PRRC2C GeneCards I2D: score=0.02 
283 PSMC3IP GeneCards I2D: score=0.09 STRING: ENSP00000377384 
284 PSMC5 GeneCards I2D: score=0.90 
285 PSMD1 GeneCards I2D: score=0.18 
286 PSMD12 GeneCards I2D: score=0.15 
287 PTCD3 GeneCards I2D: score=0.04 
288 PTPN23 GeneCards I2D: score=0.04 
289 PURA GeneCards I2D: score=0.03 
290 PURB GeneCards I2D: score=0.42 
291 PWP1 GeneCards I2D: score=0.06 
292 RALY GeneCards I2D: score=0.17 
293 RARA GeneCards STRING: ENSP00000254066 
294 RARB GeneCards STRING: ENSP00000332296 
295 RARG GeneCards STRING: ENSP00000332695 
296 RBFOX2 GeneCards I2D: score=0.88 STRING: ENSP00000413035 
297 RBM10 GeneCards I2D: score=0.04 
298 RBM14 GeneCards I2D: score=0.93 
299 RBM25 GeneCards I2D: score=0.09 
300 RBM28 GeneCards I2D: score=0.17 
301 RBM39 GeneCards I2D: score=0.99 STRING: ENSP00000253363 
302 RBM43 GeneCards I2D: score=0.04 
303 RBM47 GeneCards I2D: score=0.06 
304 RBMXL2 GeneCards I2D: score=0.05 
305 REXO4 BioGRID Montano MM (2000) 
306 REXO4 GeneCards I2D: score=0.89 STRING: ENSP00000361010 
307 RFC1 GeneCards I2D: score=0.03 
308 RFC2 GeneCards I2D: score=0.02 
309 RFC4 GeneCards I2D: score=0.03 
310 RIMS2 GeneCards I2D: score=0.06 
311 RORA GeneCards STRING: ENSP00000261523 
312 RORB GeneCards STRING: ENSP00000366093 
313 RORC GeneCards STRING: ENSP00000327025 
314 RPF2 GeneCards I2D: score=0.07 
315 RPL10A GeneCards I2D: score=0.02 
316 RPL17 GeneCards I2D: score=0.03 
317 RPL18A GeneCards I2D: score=0.02 
318 RPL23 GeneCards I2D: score=0.02 
319 RPL23A GeneCards I2D: score=0.05 
320 RPL29 GeneCards I2D: score=0.02 
321 RPL32 GeneCards I2D: score=0.02 
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322 RPL36 GeneCards I2D: score=0.02 
323 RPL36AL GeneCards I2D: score=0.04 
324 RPL3L GeneCards I2D: score=0.08 
325 RPL7 GeneCards I2D: score=0.05 
326 RPL7A GeneCards I2D: score=0.23 
327 RPLP0 GeneCards I2D: score=0.02 
328 RPS11 GeneCards I2D: score=0.02 
329 RPS13 GeneCards I2D: score=0.02 
330 RPS16 GeneCards I2D: score=0.05 
331 RPS17 GeneCards I2D: score=0.02 
332 RPS18 GeneCards I2D: score=0.05 
333 RPS24 GeneCards I2D: score=0.05 
334 RPS25 GeneCards I2D: score=0.05 
335 RPS26 GeneCards I2D: score=0.02 
336 RPS27A GeneCards I2D: score=0.02 
337 RPS27L GeneCards I2D: score=0.03 
338 RPS3 GeneCards I2D: score=0.05 
339 RPS4X GeneCards I2D: score=0.03 
340 RPS4Y1 GeneCards I2D: score=0.02 
341 RPS6 GeneCards I2D: score=0.03 
342 RPS7 GeneCards I2D: score=0.02 
343 RPS9 GeneCards I2D: score=0.03 
344 RRBP1 GeneCards I2D: score=0.06 
345 RRP1 GeneCards I2D: score=0.04 
346 RRP12 GeneCards I2D: score=0.13 
347 RRP1B GeneCards I2D: score=0.15 
348 RXRA GeneCards STRING: ENSP00000419692 
349 RXRG GeneCards STRING: ENSP00000352900 
350 SCN1A GeneCards I2D: score=0.01 
351 SEMG2 GeneCards I2D: score=0.05 
352 SENP3 GeneCards I2D: score=0.06 
353 SERBP1 GeneCards I2D: score=0.76 
354 SERPINH1 BioGRID Iannone MA (2001) 
355 SF3A1 GeneCards I2D: score=0.07 
356 SF3B3 GeneCards I2D: score=0.09 
357 SHROOM3 GeneCards I2D: score=0.03 
358 SIN3A GeneCards I2D: score=0.03 
359 SIPA1L2 GeneCards I2D: score=0.02 
360 SLC7A6 GeneCards I2D: score=0.04 
361 SMAD2 GeneCards I2D: score=0.95 STRING: ENSP00000262160 
362 SMAD3 GeneCards I2D: score=0.88 STRING: ENSP00000332973 
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363 SMAD4 GeneCards I2D: score=0.95 STRING: ENSP00000341551 
364 SMARCA5 GeneCards I2D: score=0.31 
365 SMARCC2 GeneCards I2D: score=0.86 
366 SMARCE1 GeneCards I2D: score=0.99 STRING: ENSP00000323967 
367 SMC1A GeneCards I2D: score=0.03 
368 SMN1 GeneCards I2D: score=0.08 
369 SMN2 GeneCards I2D: score=0.08 
370 SMTN GeneCards I2D: score=0.10 
371 SND1 GeneCards I2D: score=0.10 
372 SP1 BioGRID Jin W (2008) 
373 SP1 GeneCards I2D: score=0.93 STRING: ENSP00000329357 
374 SPRR1B GeneCards I2D: score=0.07 
375 SPTBN2 GeneCards I2D: score=0.04 
376 SRC GeneCards I2D: score=0.91 STRING: ENSP00000350941 
377 SREBF1 GeneCards I2D: score=0.95 STRING: ENSP00000348069 
378 SRRM2 GeneCards I2D: score=0.14 
379 SRSF2 GeneCards I2D: score=0.12 
380 SRSF5 GeneCards I2D: score=0.18 
381 SSR1 GeneCards I2D: score=0.04 
382 STAT5A BioGRID Faulds MH (2001) 
383 STAU1 GeneCards I2D: score=0.10 
384 STK31 GeneCards I2D: score=0.10 
385 SURF6 GeneCards I2D: score=0.05 
386 SYNGAP1 GeneCards I2D: score=0.05 
387 TAF15 GeneCards I2D: score=0.11 
388 TCOF1 GeneCards I2D: score=0.12 
389 TEX10 GeneCards I2D: score=0.03 
390 THOC6 GeneCards I2D: score=0.01 
391 THRA GeneCards STRING: ENSP00000264637 
392 THRB GeneCards STRING: ENSP00000348827 
393 TRAM1 BioGRID Kraichely DM (2000) 
394 TRIM24 GeneCards I2D: score=0.95 STRING: ENSP00000340507 
395 TRIM59 GeneCards I2D: score=0.80 STRING: ENSP00000311219 
396 TRIP4 BioGRID Iannone MA (2001) 
397 TTC21B GeneCards I2D: score=0.04 
398 UBC BioGRID Picard N (2008) 
399 UBC GeneCards STRING: ENSP00000344818 
400 UBE3A BioGRID Picard N (2008) 
401 UBN1 GeneCards I2D: score=0.12 
402 UBR3 GeneCards I2D: score=0.02 
403 VDR GeneCards STRING: ENSP00000229022 
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404 VIM GeneCards I2D: score=0.14 
405 VMAC GeneCards I2D: score=0.02 
406 VPS41 GeneCards I2D: score=0.10 
407 WDR18 GeneCards I2D: score=0.01 
408 WDR62 GeneCards I2D: score=0.04 
409 WIPI1 GeneCards I2D: score=0.53 STRING: ENSP00000262139 
410 WNK4 GeneCards I2D: score=0.14 
411 WWP1 BioGRID Nakajima Y (2011) 
412 YWHAH GeneCards I2D: score=0.76 STRING: ENSP00000248975 
413 YWHAQ BioGRID Zilliacus J (2001) 
414 YWHAQ GeneCards I2D: score=0.57 STRING: ENSP00000238081 
415 ZBTB17 GeneCards I2D: score=0.93 STRING: ENSP00000364895 
416 ZC3H18 GeneCards I2D: score=0.03 
417 ZC3HAV1 GeneCards I2D: score=0.09 
418 ZFP91 GeneCards I2D: score=0.10 
419 ZFR GeneCards I2D: score=0.07 
420 ZNF512B GeneCards I2D: score=0.09 
421 ZNF638 GeneCards I2D: score=0.09 
422 ZNHIT3 BioGRID Iannone MA (2001) 
 
.                              
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APPENDIX 3 
 
Curated list of interacting  molecules from both ESR1 and ESR2 for ER system 
simulation: 
Sl. No. Gene Symbol Database Reference 
1 ABCC5 GeneCards I2D: score=0.14 
2 ACAD11 GeneCards I2D: score=0.01 
3 ACSM2B GeneCards I2D: score=0.13 
4 ACTB BioGrid Ambrosino C (2010) 
5 ACTC1 BioGrid Ambrosino C (2010) 
6 ACTN1 GeneCards I2D: score=0.07 
7 ACTN3 GeneCards I2D: score=0.09 
8 ACTN4 BioGrid Khurana S (2011) 
9 ACTR2 BioGrid Ambrosino C (2010) 
10 ACTR3 BioGrid Ambrosino C (2010) 
11 AHR BioGrid Klinge CM (2000) 
12 AHRR BioGrid Klinge CM (2000) 
13 AKAP13 BioGrid Rubino D (1998) 
14 AKAP8 GeneCards I2D: score=0.15 
15 AKAP9 GeneCards I2D: score=0.12 
16 AKT1 BioGrid Campbell RA (2001) 
17 AKT2 BioGrid Sun M (2001) 
18 ANAPC5 GeneCards I2D: score=0.06 
19 ANKFY1 GeneCards I2D: score=0.15 
20 AP1B1 GeneCards STRING: ENSP00000350199 
21 AP2A1 GeneCards I2D: score=0.07 
22 AR GeneCards I2D: score=1.00 STRING: ENSP00000363822 
23 ARG1 GeneCards I2D: score=0.09 
24 ARHGDIA BioGrid Barone I (2011) 
25 ARHGEF15 GeneCards I2D: score=0.19 
26 ARID5A BioGRID Georgescu SP (2005) 
27 ARNT GeneCards I2D: score=1.00 STRING: ENSP00000351407 
28 ARPC2 GeneCards I2D: score=0.08 
29 ASB2 GeneCards I2D: score=0.08 
30 ASF1A GeneCards STRING: ENSP00000229595 
31 ASH2L BioGrid Shi L (2011) 
32 ASPG GeneCards STRING: ENSP00000389003 
33 ATAD2 BioGrid Zou JX (2007) 
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34 ATAD3C GeneCards I2D: score=0.22 
35 ATG2A GeneCards I2D: score=0.03 
36 ATP5J GeneCards STRING: ENSP00000389649 
37 BAG1 BioGrid Zeiner M (1995) 
38 BAIAP2L1 GeneCards I2D: score=0.03 
39 BARD1 BioGrid Dizin E (2010) 
40 BAZ1A GeneCards I2D: score=0.29 
41 BAZ1B BioGrid Kitagawa H (2003) 
42 BCAR1 BioGrid Cabodi S (2004) 
43 BCAS2 GeneCards I2D: score=0.41 STRING: ENSP00000358554 
44 BCLAF1 GeneCards I2D: score=0.19 
45 BDNF GeneCards I2D: score=0.98 STRING: ENSP00000414303 
46 BICD1 GeneCards I2D: score=0.05 
47 BLCAP GeneCards EBI-78473,EBI-3895726 
48 BLOC1S1 BioGrid Mishra SK (2003) 
49 BRCA1 BioGrid Wang C (2005) 
50 BRD8 GeneCards I2D: score=0.66 
51 BTF3 GeneCards I2D: score=0.70 STRING: ENSP00000369965 
52 C10orf47 GeneCards I2D: score=0.02 
53 C14orf43 GeneCards I2D: score=0.63 
54 C16orf53 GeneCards MINT-7013584  I2D: score=0.39 
55 C19orf68 GeneCards I2D: score=0.02 
56 C22orf28 GeneCards I2D: score=0.03 
57 C9orf114 GeneCards I2D: score=0.03 
58 CALM1 BioGrid Garcia Pedrero JM (2002) 
59 CALM2 GeneCards I2D: score=0.99 
60 CALM3 GeneCards I2D: score=0.99 
61 CAND1 BioGRID Bennett EJ (2010) 
62 CAV1 BioGrid Schlegel A (2001) 
63 CBLL1 BioGrid Gong EY (2010) 
64 CCAR1 GeneCards I2D: score=0.50 
65 CCDC106 GeneCards I2D: score=0.05 
66 CCNC BioGrid Kang YK (2002) 
67 CCND1 BioGrid Zwijsen RM (1997) 
68 CCNH BioGrid Talukder AH (2003) 
69 CCNT1 GeneCards I2D: score=0.83 STRING: ENSP00000261900 
70 CDC16 GeneCards I2D: score=0.76 
71 CDC25B BioGrid Ma ZQ (2001) 
72 CDC5L GeneCards I2D: score=0.06 
73 CDK11B BioGrid Wang Y (2009) 
74 CDK7 BioGrid Wang Y (2009) 
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75 CDK8 BioGrid Wang Y (2009) 
76 CDKN1A BioGrid Maynadier M (2008) 
77 CEBPA BioGrid Boruk M (1998) 
78 CEBPB BioGrid Stein B (1995) 
79 CGN GeneCards I2D: score=0.02 
80 CHD3 BioGrid Okada M (2008) 
81 CHD9 GeneCards I2D: score=0.71 STRING: ENSP00000381522 
82 CHM GeneCards I2D: score=0.05 
83 CHUK GeneCards I2D: score=0.98 STRING: ENSP00000359424 
84 CITED1 BioGrid Yahata T (2001) 
85 CLASP2 GeneCards I2D: score=0.07 
86 CLCF1 GeneCards I2D: score=0.01 
87 CNN1 GeneCards I2D: score=0.06 
88 CNTRL GeneCards I2D: score=0.07 
89 COBRA1 BioGrid Aiyar SE (2004) 
90 COIL GeneCards I2D: score=0.06 
91 COL18A1 GeneCards STRING: ENSP00000352798 
92 COL1A2 GeneCards STRING: ENSP00000297268 
93 COPB2 GeneCards I2D: score=0.02 
94 COPG2 GeneCards I2D: score=0.03 
95 COPS5 BioGrid Callige M (2005) 
96 CPEB1 GeneCards STRING: ENSP00000414187 
97 CPSF6 GeneCards I2D: score=0.12 
98 CPT1A GeneCards I2D: score=0.07 
99 CREBBP BioGrid Heery DM (1997) 
100 CRIPAK GeneCards I2D: score=0.44 STRING: ENSP00000323978 
101 CSE1L GeneCards I2D: score=0.07 
102 CSNK2B GeneCards I2D: score=0.98 STRING: ENSP00000365025 
103 CTNNB1 BioGrid Kouzmenko AP (2004) 
104 CTSD GeneCards STRING: ENSP00000236671 
105 CTTN GeneCards I2D: score=0.05 
106 CUEDC2 BioGrid Pan X (2011) 
107 CUL3 BioGrid Byun B (2008) 
108 CUL4B GeneCards I2D: score=0.33 STRING: ENSP00000384109 
109 CWC15 GeneCards I2D: score=0.10 
110 CWC27 GeneCards I2D: score=0.03 
111 DAP3 BioGrid Hulkko SM (2000) 
112 DBN1 GeneCards I2D: score=0.02 
113 DDX17 BioGrid Fujita T (2003) 
114 DDX39A GeneCards I2D: score=0.08 
115 DDX3X BioGrid Fujita T (2003) 
APPENDIX 3 
 
 
238 
 
116 DDX41 GeneCards I2D: score=0.07 
117 DDX5 BioGrid Fujita T (2003) 
118 DDX50 GeneCards I2D: score=0.05 
119 DDX54 BioGrid Rajendran RR (2003) 
120 DLGAP4 GeneCards I2D: score=0.08 
121 DNM1L GeneCards EBI-78473,EBI-724571 
122 DNTTIP1 GeneCards I2D: score=0.04 
123 DNTTIP2 BioGrid Bu H (2004) 
124 DOK6 GeneCards I2D: score=0.02 
125 DSCAM GeneCards STRING: ENSP00000383303 
126 DUT BioGrid Albers M (2005) 
127 E2F1 BioGrid Liu W (2012) 
128 EBAG9 GeneCards I2D: score=0.12 
129 EDC4 GeneCards I2D: score=0.15 
130 EEF1A2 GeneCards I2D: score=0.04 
131 EFTUD2 GeneCards I2D: score=0.05 
132 EGFR GeneCards EBI-4309277, MINT-6169656 
133 EHMT2 BioGrid Purcell DJ (2011) 
134 EIF2A GeneCards I2D: score=0.04 
135 EIF3I GeneCards I2D: score=0.33 STRING: ENSP00000362688 
136 ELAVL1 GeneCards I2D: score=0.21 
137 EP300 BioGrid Fujita T (2003) 
138 EPB41L5 GeneCards I2D: score=0.02 
139 EPS15L1 GeneCards I2D: score=0.06 
140 ERBB2 BioGrid Yang Z (2004) 
141 EREG GeneCards STRING: ENSP00000244869 
142 ESR1 BioGrid Ikeda M (2002) 
143 ESR2 BioGrid Monroe DG (2003) 
144 ESRRA GeneCards I2D: score=0.99 STRING: ENSP00000000442 
145 ESRRB GeneCards STRING: ENSP00000261532 
146 ESRRG GeneCards STRING: ENSP00000386171 
147 EXOSC10 GeneCards I2D: score=0.03 
148 EXOSC4 GeneCards I2D: score=0.12 
149 EZH2 GeneCards I2D: score=0.35 
150 FAM120A GeneCards I2D: score=0.02 
151 FAM179B GeneCards I2D: score=0.04 
152 FAM82A2 GeneCards I2D: score=0.07 
153 FBLL1 GeneCards I2D: score=0.11 
154 FHL1 GeneCards I2D: score=0.68 STRING: ENSP00000359724 
155 FHL2 BioGrid Kobayashi S (2004) 
156 FIP1L1 GeneCards I2D: score=0.08 
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157 FKBP4 BioGrid Nair SC (1996) 
158 FKBP5 BioGrid Nair SC (1996) 
159 FLG GeneCards I2D: score=0.04 
160 FLII BioGrid Jeong KW (2009) 
161 FLNB GeneCards I2D: score=0.03 
162 FLNC GeneCards I2D: score=0.03 
163 FMR1 GeneCards I2D: score=0.06 
164 FOS BioGrid Baron S (2007) 
165 FOXA1 GeneCards STRING: ENSP00000250448 
166 FOXL2 GeneCards I2D: score=0.90 STRING: ENSP00000333188 
167 FOXM1 GeneCards STRING: ENSP00000342307 
168 FOXO1 BioGrid Zhao HH (2001) 
169 FOXO3 GeneCards I2D: score=0.98 STRING: ENSP00000339527 
170 FOXO4 BioGrid Schuur ER (2001) 
171 FTSJ3 GeneCards I2D: score=0.07 
172 FXR2 GeneCards I2D: score=0.09 
173 GADD45A BioGrid Yi YW (2000) 
174 GADD45B BioGrid Yi YW (2000) 
175 GADD45G BioGrid Yi YW (2000) 
176 GCC2 GeneCards I2D: score=0.04 
177 GFAP GeneCards I2D: score=0.07 
178 GIGYF1 GeneCards I2D: score=0.03 
179 GNA13 GeneCards STRING: ENSP00000400717 
180 GNA14 GeneCards STRING: ENSP00000365807 
181 GNA15 GeneCards STRING: ENSP00000262958 
182 GNAI1 GeneCards I2D: score=0.13 STRING: ENSP00000343027 
183 GNAI2 GeneCards STRING: ENSP00000312999 
184 GNAL GeneCards STRING: ENSP00000334051 
185 GNAO1 GeneCards STRING: ENSP00000262493 
186 GNAZ GeneCards STRING: ENSP00000248996 
187 GNB2L1 GeneCards I2D: score=0.08 
188 GNB3 GeneCards I2D: score=0.10 
189 GNG2 GeneCards STRING: ENSP00000334448 
190 GNL2 GeneCards I2D: score=0.05 
191 GNL3 GeneCards I2D: score=0.06 
192 GOLGA3 GeneCards I2D: score=0.07 
193 GOLGA4 GeneCards I2D: score=0.04 
194 GRB2 GeneCards I2D: score=1.00 STRING: ENSP00000339007 
195 GRIP1 BioGrid Yi YW (2000) 
196 GSN BioGrid Yi YW (2000) 
197 GSPT1 GeneCards I2D: score=0.04 
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198 GTF2B BioGrid Yi YW (2000) 
199 GTF2H1 BioGrid Yi YW (2000) 
200 GTF3C1 GeneCards I2D: score=0.12 
201 GTF3C2 GeneCards I2D: score=0.10 
202 GTF3C3 GeneCards I2D: score=0.14 
203 GTF3C4 GeneCards I2D: score=0.03 
204 GTF3C5 GeneCards I2D: score=0.11 
205 GTPBP4 GeneCards I2D: score=0.04 
206 H2BFS GeneCards I2D: score=0.05 
207 HAX1 GeneCards EBI-78473,EBI-357001 
208 HCFC1 GeneCards I2D: score=0.90 
209 HCFC2 GeneCards I2D: score=0.03 
210 HDAC1 BioGrid Kawai H (2003) 
211 HDAC2 BioGrid Itoh Y (2007) 
212 HDAC3 BioGrid Liu XF (2004) 
213 HDAC4 BioGrid Leong H (2005) 
214 HDAC5 BioGrid van Rooij E (2010) 
215 HDAC7 BioGrid Malik S (2010) 
216 HDAC9 BioGrid van Rooij E (2010) 
217 HEATR4 GeneCards I2D: score=0.05 
218 HEXIM1 GeneCards I2D: score=0.32 STRING: ENSP00000328773 
219 HIST1H1C GeneCards I2D: score=0.17 
220 HIST1H4A GeneCards I2D: score=0.10 
221 HIST1H4B GeneCards I2D: score=0.10 
222 HIST1H4C GeneCards I2D: score=0.10 
223 HIST1H4D GeneCards I2D: score=0.10 
224 HIST1H4E GeneCards I2D: score=0.10 
225 HIST1H4F GeneCards I2D: score=0.10 
226 HIST1H4H GeneCards I2D: score=0.10 
227 HIST1H4I GeneCards I2D: score=0.10 
228 HIST1H4J GeneCards I2D: score=0.10 
229 HIST1H4K GeneCards I2D: score=0.10 
230 HIST1H4L GeneCards I2D: score=0.10 
231 HIST2H4A GeneCards I2D: score=0.10 
232 HIST2H4B GeneCards I2D: score=0.10 
233 HIST4H4 GeneCards I2D: score=0.10 
234 HNF4A GeneCards I2D: score=1.00 STRING: ENSP00000312987 
235 HNF4G GeneCards STRING: ENSP00000379701 
236 HNRNPCL1 GeneCards I2D: score=0.12 
237 HNRNPH2 GeneCards I2D: score=0.08 
238 HP1BP3 GeneCards I2D: score=0.12 
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239 HR GeneCards I2D: score=0.03 
240 HSP90AA1 BioGrid Nair SC (1996) 
241 HSP90AB1 GeneCards I2D: score=1.00 STRING: ENSP00000325875 
242 HSPA1A GeneCards I2D: score=0.29 
243 HSPA1B GeneCards I2D: score=0.29 
244 HSPA4 BioGrid Nair SC (1996) 
245 HSPA6 GeneCards I2D: score=0.26 
246 HSPA8 BioGrid Tateishi Y (2004) 
247 HTATSF1 GeneCards I2D: score=0.09 
248 IGF1 GeneCards STRING: ENSP00000302665 
249 IGF1R BioGrid Santen RJ (2005) 
250 IL25 GeneCards I2D: score=0.21 
251 ING1 BioGrid Toyama T (2003) 
252 IRS1 BioGrid Morelli C (2003) 
253 IRS2 BioGrid Morelli C (2003) 
254 ISL1 BioGrid Gay F (2000) 
255 ITGB3BP GeneCards I2D: score=0.90 STRING: ENSP00000271002 
256 JMJD1C BioGRID Iannone MA (2001) 
257 JUN BioGrid Teyssier C (2001) 
258 JUNB GeneCards I2D: score=0.98 STRING: ENSP00000303315 
259 JUND GeneCards I2D: score=0.92 STRING: ENSP00000252818 
260 KANK2 GeneCards I2D: score=0.06 
261 KAT2A BioGrid Oishi H (2006) 
262 KAT2B GeneCards STRING: ENSP00000263754 
263 KAT5 BioGrid Gaughan L (2001) 
264 KAT6A BioGrid Yin H (2007) 
265 KATNAL2 GeneCards I2D: score=0.04 
266 KDM1A BioGrid Garcia-Bassets I (2007) 
267 KDM4B BioGrid Shi L (2011) 
268 KDM5A BioGrid Chan SW (2001) 
269 KDM6B GeneCards MINT-8286415 MINT-8286424 
270 KHDRBS1 GeneCards I2D: score=0.06 
271 KIF11 GeneCards STRING: ENSP00000260731 
272 KIF1A BioGrid Albers M (2005) 
273 KLF5 BioGrid Guo P (2010) 
274 KRI1 GeneCards I2D: score=0.04 
275 LACTB GeneCards I2D: score=0.02 
276 LAD1 GeneCards I2D: score=0.02 
277 LAMB1 GeneCards I2D: score=0.02 
278 LARP1 GeneCards I2D: score=0.09 
279 LAS1L GeneCards I2D: score=0.08 
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280 LCK GeneCards I2D: score=0.99 STRING: ENSP00000337825 
281 LCOR BioGrid Fernandes I (2003) 
282 LDB1 BioGrid Johnsen SA (2009) 
283 LIMA1 GeneCards I2D: score=0.32 
284 LINC00312 GeneCards MINT-50571 MINT-50573 MINT-50906 I2D: score=0.04 
285 LMO4 BioGrid Singh RR (2005) 
286 LOC100505603 GeneCards MINT-14693 MINT-14694 I2D: score=0.87 
287 LOC100507025 GeneCards I2D: score=0.10 
288 LONP1 GeneCards I2D: score=0.08 
289 LRIF1 BioGrid Li HJ (2007) 
290 LRRC1 GeneCards I2D: score=0.04 
291 LRRC59 GeneCards I2D: score=0.03 
292 LYAR GeneCards I2D: score=0.09 
293 LYZ GeneCards I2D: score=0.12 
294 MAD2L1 GeneCards STRING: ENSP00000296509 
295 MAP3K1 GeneCards MINT-50709 I2D: score=0.28 STRING: ENSP00000382423 
296 MAPK1 BioGrid Metivier R (2002) 
297 MAPK11 GeneCards STRING: ENSP00000333685 
298 MAPK14 GeneCards I2D: score=0.98 STRING: ENSP00000229794 
299 MAPK3 GeneCards I2D: score=0.99 STRING: ENSP00000263025 
300 MBD2 BioGrid Chatagnon A (2010) 
301 MDM2 BioGrid Duong V (2007) 
302 MED1 BioGrid Fujita T (2003) 
303 MED10 BioGrid Fujita T (2003) 
304 MED12 BioGrid Kang YK (2002) 
305 MED13 BioGrid Kang YK (2002) 
306 MED14 BioGrid Burakov D (2000) 
307 MED16 BioGrid Kang YK (2002) 
308 MED17 BioGrid Kang YK (2002) 
309 MED20 BioGrid Kang YK (2002) 
310 MED21 BioGrid Kang YK (2002) 
311 MED23 BioGrid Kang YK (2002) 
312 MED24 BioGrid Kang YK (2002) 
313 MED25 BioGrid Lee HK (2007) 
314 MED27 GeneCards I2D: score=0.34 
315 MED30 GeneCards I2D: score=0.92 
316 MED4 GeneCards I2D: score=0.92 
317 MED6 BioGrid Lee HK (2007) 
318 MED7 BioGrid Lee HK (2007) 
319 MEN1 BioGrid Dreijerink KM (2006) 
320 MGMT BioGrid Teo AK (2001) 
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321 MKI67 GeneCards I2D: score=0.25 
322 MKNK2 GeneCards I2D: score=0.97 STRING: ENSP00000250896 
323 MLL2 BioGrid Shi L (2011) 
324 MLLT1 GeneCards I2D: score=0.04 
325 MMS19 GeneCards I2D: score=0.98 STRING: ENSP00000359818 
326 MNAT1 BioGrid Talukder AH (2003) 
327 MPG BioGrid Likhite VS (2004) 
328 MRPL44 GeneCards I2D: score=0.03 
329 MRPL45 GeneCards I2D: score=0.02 
330 MRPS15 GeneCards I2D: score=0.02 
331 MRPS17 GeneCards I2D: score=0.05 
332 MRPS2 GeneCards I2D: score=0.03 
333 MRPS21 GeneCards I2D: score=0.02 
334 MRPS22 GeneCards I2D: score=0.25 
335 MRPS27 GeneCards I2D: score=0.07 
336 MRPS31 GeneCards I2D: score=0.28 
337 MRPS35 GeneCards I2D: score=0.03 
338 MRPS5 GeneCards I2D: score=0.05 
339 MRPS6 GeneCards I2D: score=0.04 
340 MRPS9 GeneCards I2D: score=0.04 
341 MSH2 BioGrid Wada-Hiraike O (2005) 
342 MSH6 BioGrid Oishi H (2006) 
343 MTA1 BioGrid Mishra SK (2003) 
344 MTA2 BioGrid Okada M (2008) 
345 MTA3 BioGrid Okada M (2008) 
346 MTCH2 BioGrid Albers M (2005) 
347 MUC1 BioGrid Wei X (2006) 
348 MVP BioGrid Abbondanza C (1998) 
349 MYBBP1A GeneCards I2D: score=0.07 
350 MYC BioGrid Cheng AS (2006) 
351 MYH13 GeneCards I2D: score=0.05 
352 MYH14 GeneCards I2D: score=0.08 
353 MYH4 GeneCards I2D: score=0.05 
354 MYH7 GeneCards I2D: score=0.12 
355 MYH7B GeneCards I2D: score=0.04 
356 MYL6 BioGrid Ambrosino C (2010) 
357 MYLK2 GeneCards I2D: score=0.08 
358 MYO1C BioGrid Ambrosino C (2010) 
359 MYO1D GeneCards I2D: score=0.06 
360 MYO3B GeneCards I2D: score=0.08 
361 MYOD1 BioGrid Jin W (2008) 
APPENDIX 3 
 
 
244 
 
362 MYSM1 GeneCards STRING: ENSP00000418734 
363 NAT10 GeneCards I2D: score=0.03 
364 NBPF8 GeneCards I2D: score=0.03 
365 NCBP1 GeneCards I2D: score=0.04 
366 NCOA1 BioGrid Kraichely DM (2000) 
367 NCOA2 BioGrid Kraichely DM (2000) 
368 NCOA3 BioGrid Suen CS (1998) 
369 NCOA4 BioGrid Alen P (1999) 
370 NCOA6 BioGrid Mahajan MA (2000) 
371 NCOA7 BioGrid Lazennec G (1997) 
372 NCOR1 BioGrid Fujita T (2003) 
373 NCOR2 BioGrid Fujita T (2003) 
374 NDRG2 GeneCards EBI-78473,EBI-3895741 
375 NDUFV3 GeneCards STRING: ENSP00000346196 
376 NEBL GeneCards I2D: score=0.04 
377 NEFH GeneCards I2D: score=0.05 
378 NFKB1 GeneCards I2D: score=1.00 STRING: ENSP00000226574 
379 NFKBIB BioGRID Iannone MA (2001) 
380 NGG1 BioGrid Benecke A (2002) 
381 NKRF GeneCards I2D: score=0.02 
382 NOLC1 GeneCards I2D: score=0.05 
383 NOP56 GeneCards I2D: score=0.15 
384 NOS3 GeneCards I2D: score=0.96 
385 NPM1 BioGrid Ambrosino C (2010) 
386 NPPA BioGrid Albers M (2005) 
387 NR0B1 GeneCards I2D: score=1.00 STRING: ENSP00000368253 
388 NR0B2 BioGrid Seol W (1998) 
389 NR1D1 GeneCards STRING: ENSP00000246672 
390 NR1D2 GeneCards STRING: ENSP00000310006 
391 NR1H2 GeneCards STRING: ENSP00000253727 
392 NR1H4 GeneCards I2D: score=0.97 STRING: ENSP00000315442 
393 NR1I2 BioGrid Seol W (1998) 
394 NR2C1 BioGrid Hu YC (2002) 
395 NR2C2 BioGrid Shyr CR (2002) 
396 NR2C2AP GeneCards STRING: ENSP00000332823 
397 NR2E1 GeneCards STRING: ENSP00000357982 
398 NR2F1 BioGrid Metivier R (2002) 
399 NR2F6 BioGrid Zhu XG (2000) 
400 NR4A1 GeneCards STRING: ENSP00000243050 
401 NR4A2 GeneCards STRING: ENSP00000344479 
402 NR5A1 GeneCards STRING: ENSP00000362690 
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403 NRBP1 GeneCards STRING: ENSP00000233557 
404 NRIP1 BioGrid Heery DM (1997) 
405 NSD1 BioGrid Huang N (1998) 
406 NUP205 GeneCards I2D: score=0.10 
407 OTUB1 BioGrid Stanisic V (2009) 
408 OXT GeneCards I2D: score=0.95 STRING: ENSP00000217386 
409 PABPC1L GeneCards I2D: score=0.02 
410 PABPC3 GeneCards I2D: score=0.04 
411 PABPC5 GeneCards I2D: score=0.24 
412 PAK1 GeneCards I2D: score=0.98 STRING: ENSP00000278568 
413 PAK6 BioGrid Lee SR (2002) 
414 PARP1 BioGrid Ju BG (2006) 
415 PBRM1 GeneCards I2D: score=0.81 
416 PDLIM1 BioGrid Johnsen SA (2009) 
417 PELP1 BioGrid Vadlamudi RK (2001) 
418 PES1 GeneCards I2D: score=0.09 
419 PGC BioGrid Bourdoncle A (2005) 
420 PGR BioGrid Giulianelli S (2012) 
421 PHB BioGrid Giulianelli S (2012) 
422 PHB2 BioGrid Martini PG (2003) 
423 PIAS1 BioGrid Kobayashi S (2004) 
424 PIAS2 BioGrid Kotaja N (2000) 
425 PIAS3 GeneCards I2D: score=0.99 STRING: ENSP00000376765 
426 PIK3CA GeneCards I2D: score=0.96 STRING: ENSP00000263967 
427 PIK3R1 BioGrid Castoria G (2001) 
428 PIK3R2 BioGrid Cabodi S (2004) 
429 PIK3R3 GeneCards I2D: score=0.96 STRING: ENSP00000262741 
430 PIK3R4 GeneCards I2D: score=0.05 
431 PIP GeneCards I2D: score=0.02 
432 PKP3 GeneCards I2D: score=0.09 
433 PLA2G7 GeneCards I2D: score=0.05 
434 PNRC1 GeneCards I2D: score=0.20 
435 PNRC2 BioGrid Albers M (2005) 
436 POLR1B GeneCards I2D: score=0.40 STRING: ENSP00000263331 
437 POLR1E GeneCards I2D: score=0.05 
438 POLR2A BioGrid Ambrosino C (2010) 
439 POLR2D GeneCards I2D: score=0.16 
440 POM121 GeneCards I2D: score=0.04 
441 POM121C GeneCards I2D: score=0.03 
442 POU2F1 BioGrid Prefontaine GG (1999) 
443 POU2F2 BioGrid Prefontaine GG (1999) 
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444 POU4F1 BioGrid Budhram-Mahadeo V (1998) 
445 POU4F2 BioGrid Budhram-Mahadeo V (1998) 
446 PPARA GeneCards STRING: ENSP00000262735 
447 PPARD GeneCards STRING: ENSP00000310928 
448 PPARG BioGrid DiRenzo J (1997) 
449 PPARGC1A BioGrid DiRenzo J (1997) 
450 PPARGC1B BioGrid DiRenzo J (1997) 
451 PPID BioGrid Nair SC (1996) 
452 PPP1CC BioGrid Flores-Delgado G (2007) 
453 PPP5C GeneCards EBI-78473,EBI-716663 I2D: score=0.05 STRING: ENSP00000012443 
454 PPRC1 GeneCards I2D: score=0.19 
455 PRDM2 BioGrid Abbondanza C (2000) 
456 PRDX3 GeneCards I2D: score=0.06 
457 PRDX4 GeneCards I2D: score=0.06 
458 PREPL GeneCards I2D: score=0.03 
459 PRKACA GeneCards I2D: score=0.98 STRING: ENSP00000309591 
460 PRKCZ BioGrid Yi P (2008) 
461 PRKDC BioGrid Ju BG (2006) 
462 PRKRA GeneCards I2D: score=0.18 
463 PRMT1 BioGrid Koh SS (2001) 
464 PRMT2 BioGrid Qi C (2002) 
465 PRPF31 GeneCards I2D: score=0.09 
466 PRPF6 GeneCards I2D: score=0.99 STRING: ENSP00000266079 
467 PRPH GeneCards I2D: score=0.11 
468 PRRC2C GeneCards I2D: score=0.02 
469 PSEN2 GeneCards STRING: ENSP00000355747 
470 PSMB9 GeneCards MINT-3291999 I2D: score=0.07 
471 PSMC3IP GeneCards I2D: score=0.09 STRING: ENSP00000377384 
472 PSMC5 BioGrid vom Baur E (1996) 
473 PSMD1 GeneCards I2D: score=0.96 STRING: ENSP00000309474 
474 PSMD12 GeneCards I2D: score=0.15 
475 PTCD3 GeneCards I2D: score=0.05 
476 PTEN BioGrid Lin HK (2004) 
477 PTGES3 BioGrid Nair SC (1996) 
478 PTMA BioGrid Martini PG (2003) 
479 PTPN1 GeneCards MINT-6761899 I2D: score=0.99 STRING: ENSP00000360683 
480 PTPN23 GeneCards I2D: score=0.04 
481 PTPN6 GeneCards MINT-6761906 I2D: score=0.98 STRING: ENSP00000391592 
482 PURA GeneCards I2D: score=0.03 
483 PURB GeneCards I2D: score=0.42 
484 PWP1 GeneCards I2D: score=0.06 
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485 RABGEF1 BioGrid La Rosa P (2011) 
486 RAC3 GeneCards EBI-78473,EBI-767084 
487 RALY GeneCards I2D: score=0.17 
488 RAN BioGrid Castoria G (2012) 
489 RARA GeneCards I2D: score=1.00 STRING: ENSP00000254066 
490 RARB GeneCards STRING: ENSP00000332296 
491 RARG GeneCards STRING: ENSP00000332695 
492 RBBP4 BioGrid Creekmore AL (2008) 
493 RBBP5 BioGrid Shi L (2011) 
494 RBBP6 BioGrid Peidis P (2010) 
495 RBBP7 BioGrid Creekmore AL (2008) 
496 RBFOX2 BioGrid Norris JD (2002) 
497 RBM10 GeneCards STRING: ENSP00000366829 
498 RBM14 GeneCards I2D: score=0.93 
499 RBM23 GeneCards I2D: score=0.62 STRING: ENSP00000352956 
500 RBM25 GeneCards I2D: score=0.09 
501 RBM28 GeneCards I2D: score=0.17 
502 RBM39 BioGrid Jung DJ (2002) 
503 RBM43 GeneCards I2D: score=0.04 
504 RBM47 GeneCards I2D: score=0.06 
505 RBMXL2 GeneCards I2D: score=0.05 
506 RELA BioGrid Nettles KW (2008) 
507 REXO4 BioGrid Montano MM (2000) 
508 RFC1 GeneCards I2D: score=0.03 
509 RFC2 GeneCards I2D: score=0.02 
510 RFC4 GeneCards I2D: score=0.03 
511 RFX4 GeneCards I2D: score=0.35 STRING: ENSP00000376585 
512 RGS3 GeneCards I2D: score=0.11 STRING: ENSP00000259406 
513 RIMS2 GeneCards I2D: score=0.06 
514 RLIM BioGrid Johnsen SA (2009) 
515 RNF14 GeneCards I2D: score=0.95 STRING: ENSP00000324956 
516 RNF4 BioGrid Moilanen AM (1998) 
517 RORA GeneCards STRING: ENSP00000261523 
518 RORB GeneCards STRING: ENSP00000366093 
519 RORC GeneCards STRING: ENSP00000327025 
520 RPF2 GeneCards I2D: score=0.07 
521 RPL10A GeneCards I2D: score=0.02 
522 RPL17 GeneCards I2D: score=0.03 
523 RPL18 BioGrid Moilanen AM (1998) 
524 RPL18A GeneCards I2D: score=0.02 
525 RPL23 GeneCards I2D: score=0.02 
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526 RPL23A GeneCards I2D: score=0.05 
527 RPL29 GeneCards I2D: score=0.02 
528 RPL32 GeneCards I2D: score=0.02 
529 RPL36 GeneCards I2D: score=0.02 
530 RPL36AL GeneCards I2D: score=0.08 
531 RPL3L GeneCards I2D: score=0.08 
532 RPL7 BioGrid Ambrosino C (2010) 
533 RPL7A BioGrid Ambrosino C (2010) 
534 RPLP0 BioGrid Ambrosino C (2010) 
535 RPLP0P6 GeneCards I2D: score=0.02 
536 RPS11 GeneCards I2D: score=0.08 
537 RPS13 GeneCards I2D: score=0.02 
538 RPS16 GeneCards I2D: score=0.05 
539 RPS17 GeneCards I2D: score=0.02 
540 RPS18 GeneCards I2D: score=0.10 
541 RPS20 GeneCards I2D: score=0.22 
542 RPS24 GeneCards I2D: score=0.05 
543 RPS25 GeneCards I2D: score=0.05 
544 RPS26 GeneCards I2D: score=0.02 
545 RPS27A GeneCards I2D: score=0.02 
546 RPS27L GeneCards I2D: score=0.03 
547 RPS3 GeneCards I2D: score=0.05 
548 RPS4X BioGrid Ambrosino C (2010) 
549 RPS4Y1 GeneCards I2D: score=0.02 
550 RPS6 GeneCards I2D: score=0.03 
551 RPS6KA1 BioGrid Joel PB (1998) 
552 RPS6KA3 BioGrid Clark DE (2001) 
553 RPS7 GeneCards I2D: score=0.02 
554 RPS8 BioGrid Ambrosino C (2010) 
555 RPS9 BioGrid Ambrosino C (2010) 
556 RRBP1 GeneCards I2D: score=0.06 
557 RRP1 GeneCards I2D: score=0.04 
558 RRP12 GeneCards I2D: score=0.13 
559 RRP1B GeneCards I2D: score=0.15 
560 RXRA BioGrid DiRenzo J (1997) 
561 RXRG GeneCards STRING: ENSP00000352900 
562 SAFB BioGrid Oesterreich S (2000) 
563 SAFB2 BioGrid Oesterreich S (2000) 
564 SCN1A GeneCards I2D: score=0.01 
565 SEMG2 GeneCards I2D: score=0.05 
566 SENP3 GeneCards I2D: score=0.06 
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567 SENP5 GeneCards EBI-78473,EBI-3895753 
568 SERBP1 GeneCards I2D: score=0.76 
569 SERPINH1 BioGRID Iannone MA (2001) 
570 SETD7 BioGrid Subramanian K (2008) 
571 SF1 BioGrid Zhou D (2001) 
572 SF3A1 GeneCards I2D: score=0.07 
573 SF3B3 GeneCards I2D: score=0.09 
574 SGK3 BioGrid Wang Y (2011) 
575 SHC1 BioGrid Song RX (2002) 
576 SHROOM3 GeneCards I2D: score=0.03 
577 SIN3A BioGrid Ellison-Zelski SJ (2009) 
578 SIPA1L2 GeneCards I2D: score=0.02 
579 SIRT1 BioGrid Elangovan S (2011) 
580 SKI BioGrid Elangovan S (2011) 
581 SKIL BioGrid Band AM (2011) 
582 SLC30A9 GeneCards I2D: score=0.92 STRING: ENSP00000264451 
583 SLC7A6 GeneCards I2D: score=0.04 
584 SMAD2 BioGrid Ito I (2010) 
585 SMAD3 BioGrid Ito I (2010) 
586 SMAD4 GeneCards I2D: score=1.00 STRING: ENSP00000341551 
587 SMARCA2 BioGrid Ichinose H (1997) 
588 SMARCA4 BioGrid Ichinose H (1997) 
589 SMARCA5 GeneCards I2D: score=0.31 
590 SMARCB1 BioGrid Okada M (2008) 
591 SMARCC2 BioGrid Okada M (2008) 
592 SMARCD1 BioGrid Hsiao PW (2003) 
593 SMARCD3 GeneCards I2D: score=0.93 STRING: ENSP00000262188 
594 SMARCE1 BioGrid Kiskinis E (2006) 
595 SMC1A GeneCards I2D: score=0.03 
596 SMN1 GeneCards I2D: score=0.08 
597 SMN2 GeneCards I2D: score=0.08 
598 SMTN GeneCards I2D: score=0.10 
599 SMURF1 BioGrid Ito I (2010) 
600 SMYD3 BioGrid Kim H (2009) 
601 SND1 GeneCards I2D: score=0.10 
602 SOD1 GeneCards STRING: ENSP00000270142 
603 SOS1 GeneCards I2D: score=0.95 STRING: ENSP00000384675 
604 SOS2 BioGrid Yang Z (2004) 
605 SP1 BioGrid Petz LN (2004) 
606 SP2 BioGrid He S (2005) 
607 SP3 BioGrid Dong J (2006) 
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608 SPOP BioGrid Byun B (2008) 
609 SPRR1B GeneCards I2D: score=0.07 
610 SPTBN2 GeneCards I2D: score=0.04 
611 SRA1 BioGrid Watanabe M (2001) 
612 SRC BioGrid Monroe DG (2003) 
613 SREBF1 GeneCards I2D: score=0.96 STRING: ENSP00000348069 
614 SRRM2 GeneCards I2D: score=0.14 
615 SRSF2 GeneCards I2D: score=0.12 
616 SRSF5 GeneCards I2D: score=0.18 
617 SSR1 GeneCards I2D: score=0.04 
618 STAT3 BioGrid Wang LH (2001) 
619 STAT5A BioGrid Faulds MH (2001) 
620 STAU1 GeneCards I2D: score=0.30 
621 STK11 GeneCards STRING: ENSP00000324856 
622 STK31 GeneCards I2D: score=0.10 
623 STRN GeneCards I2D: score=0.84 STRING: ENSP00000263918 
624 STUB1 BioGrid Tateishi Y (2004) 
625 SUMO1 BioGrid Sentis S (2005) 
626 SURF6 GeneCards I2D: score=0.05 
627 SVIL BioGrid Ting HJ (2002) 
628 SYNGAP1 GeneCards I2D: score=0.05 
629 TAB2 BioGrid Cutrupi S (2012) 
630 TADA3 BioGrid Li CW (2010) 
631 TAF10 GeneCards I2D: score=1.00 STRING: ENSP00000299424 
632 TAF15 GeneCards I2D: score=0.11 
633 TAF1A BioGrid Loven MA (2003) 
634 TAF1B BioGrid Loven MA (2003) 
635 TAF2 BioGrid Suen CS (1998) 
636 TAP1 GeneCards I2D: score=0.93 STRING: ENSP00000346206 
637 TBP BioGrid Lazennec G (1997) 
638 TCF20 GeneCards I2D: score=0.97 STRING: ENSP00000352463 
639 TCOF1 GeneCards I2D: score=0.12 
640 TDG BioGrid Chen D (2003) 
641 TEX10 GeneCards I2D: score=0.03 
642 TFF1 BioGrid Yi P (2008) 
643 THOC6 GeneCards I2D: score=0.01 
644 THRA GeneCards I2D: score=1.00 STRING: ENSP00000264637 
645 THRB GeneCards I2D: score=1.00 STRING: ENSP00000348827 
646 TNFRSF14 GeneCards I2D: score=0.96 STRING: ENSP00000347948 
647 TOP2B BioGrid Ju BG (2006) 
648 TP53 BioGrid Liu G (2000) 
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649 TRAM1 BioGrid Kraichely DM (2000) 
650 TRIM24 BioGrid vom Baur E (1996) 
651 TRIM25 BioGrid Nakajima A (2007) 
652 TRIM28 GeneCards I2D: score=0.97 STRING: ENSP00000253024 
653 TRIM59 GeneCards I2D: score=0.87 STRING: ENSP00000311219 
654 TRIP4 BioGrid Kim HJ (1999) 
655 TRRAP BioGrid Fujita T (2003) 
656 TSC2 GeneCards I2D: score=0.94 STRING: ENSP00000219476 
657 TTC21B GeneCards I2D: score=0.04 
658 TUBA1A BioGrid Benecke A (2002) 
659 TUBA1B GeneCards I2D: score=0.14 STRING: ENSP00000336799 
660 TUBB GeneCards I2D: score=0.04 
661 TUBB1 BioGrid Benecke A (2002) 
662 TUBB2A GeneCards STRING: ENSP00000369703 
663 UBC BioGrid Stanisic V (2009) 
664 UBE2I BioGrid Kobayashi S (2004) 
665 UBE3A BioGrid Sun J (2012) 
666 UBN1 GeneCards I2D: score=0.12 
667 UBR3 GeneCards I2D: score=0.02 
668 UIMC1 BioGrid Yan J (2007) 
669 USF1 GeneCards I2D: score=0.75 STRING: ENSP00000356999 
670 UTP14A GeneCards I2D: score=0.81 
671 VAV3 GeneCards I2D: score=0.98 STRING: ENSP00000359073 
672 VDR GeneCards STRING: ENSP00000229022 
673 VIM GeneCards I2D: score=0.14 
674 VMAC GeneCards I2D: score=0.02 
675 VPS41 GeneCards I2D: score=0.10 
676 WDR18 GeneCards I2D: score=0.01 
677 WDR5 BioGrid Shi L (2011) 
678 WDR5B GeneCards I2D: score=0.18 STRING: ENSP00000330381 
679 WDR62 GeneCards I2D: score=0.04 
680 WIPI1 GeneCards I2D: score=0.88 STRING: ENSP00000262139 
681 WNK4 GeneCards I2D: score=0.14 
682 WWP1 BioGRID Nakajima Y (2011) 
683 XBP1 BioGrid Ding L (2003) 
684 XPO1 BioGrid Castoria G (2012) 
685 XRCC5 BioGrid Ju BG (2006) 
686 XRCC6 BioGrid Ju BG (2006) 
687 YWHAH GeneCards I2D: score=0.98 STRING: ENSP00000248975 
688 YWHAQ BioGrid Zilliacus J (2001) 
689 ZBTB16 BioGrid Martin PJ (2003) 
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690 ZBTB17 GeneCards I2D: score=0.95 STRING: ENSP00000364895 
691 ZC3H18 GeneCards I2D: score=0.03 
692 ZC3HAV1 GeneCards I2D: score=0.17 
693 ZFP91 GeneCards I2D: score=0.10 
694 ZFR GeneCards I2D: score=0.07 
695 ZNF398 BioGrid Conroy AT (2002) 
696 ZNF512B GeneCards I2D: score=0.09 
697 ZNF638 GeneCards I2D: score=0.09 
698 ZNHIT3 GeneCards I2D: score=0.96 
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ESTROGEN RECEPTOR STATUS PREDICTION FOR BREAST 
CANCER USING ARTIFICIAL NEURAL NETWORK 
 
Gopal K. Dhondalay, Dong L. Tong, Graham R. Ball 
 
John van Geest Cancer Research Centre, School of Science and Technology, Nottingham Trent 
University, Nottingham, UK NG11 8NS 
E-MAIL: 
gopal.dhondalay@ntu.c.uk 
 
Abstract: 
 
The status of estrogen receptor (ER) has been profoundly associated with breast cancer. 
Numerous studies have been conducted to identify informative genes that are associated to ER status. 
However, the integrity of the reported genes is still inconclusive as the results are derived from small 
cohort of breast cancer patients (< 200 samples).  
 
In this paper, we studied gene signatures from a cohort of 278 breast cancer samples, labelled 
in ER positive and ER negative classes, using artificial neural network (ANN). Our model has showed 
its efficacy for selecting significant genes compared to the previous study. The result also showed that 
the highly ranked genes have been previously reported in association to the breast cancer development. 
 
Keywords: Estrogen receptor; Breast cancer; Microarray data; Artificial neural network; Prediction 
 
1.     Introduction 
 
Estrogen receptor (ER) is a type of hormone receptor protein that acts as a stabiliser in 
hormonal system. From the literature, ER status, i.e. ER positive (over-expression) or ER negative 
(suppression), has been associated to breast cancer development, in which it has been normally 
over-expressed in breast cancer. For instance, Yaich et al [16] examined the influence on the 
alterations of ER-associated gene in 26 primary breast cancers. Chanrion et al [4] studied the 
expression of 47 genes in the molecular association to a cohort of 199 primary breast tumours. 
They identified 10 genes which showed the over-expression characteristics scattered in different 
ER positive molecular subgroups. Chen et al [5] in an approach to find novel predictive gene 
signatures of chemotherapy response, found genes to be significantly related to ER status. In 
another recent study Budczies et al [3] found 346 genes in a signature  correlated  to  ER  status  in  
paraffin  embedded breast cancer core biopsies. 
 
There are numerous data mining approaches that have been proposed for analysing 
breast gene microarray data. For instance, Bloom et al [2] proposed a standard 3-layered 
backpropagation  neural  network  to  classify oligonucleotide-based   breast   microarray   data   
and   the average  classification  accuracy  of  67%  was  achieved  in their study. Meanwhile, Liu, 
Krishnan and Mondry [10] compared the prediction performance of greedy search and simulated 
annealing (SA) to classify 49 breast cancer microarrays into ER positive and ER negative classes. 
They reported 31 significant genes with the prediction accuracies of 89.8% in both greedy and 
SA approaches. Zhou, Wang and Dougherty [17], on the other hand, used linear regression 
method to select significant genes that are associated to BRCA1 and BRCA2 mutation-positive 
breast cancer. They used 22 breast tumour samples obtained from 21 patients. 
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Although, ER status in breast cancer has been studied in the past, however, the reported 
results are mostly based on small cohort of samples. Little studies in the ER status using large 
cohort of breast cancer patients. Thus, the objective of this paper is to study the ER status in a 
large cohort of breast cancer samples (278 samples) and to identify gene signatures that are 
responsible for the expression in the ER status using artificial neural network (ANN). 
 
For the remaining of this paper, we first describe our ANN method. We then describe the 
data set and the comparison results. Finally, we conclude the paper. 
 
2.     Artificial neural networks (ANNs) 
  
 A bespoke ANN model has been developed aiming at the ion identification from high 
throughput proteomics data in our previous studies [1, 8, 13]. This similar model has been recently 
applied to study the gene profiles in microarray data [9]. In this paper, we use the same model to 
predict ER status for breast cancer patients. Figure 1 illustrates the workflow of our model. For 
the detail of our algorithm, please refer to our previous study [13]. 
 
In brief, the data are first divided into 3 sample subsets, i.e. training, test and validation sets. 
The sample partition ratio is 60:20:20, i.e. 60% of the data is used to train the network, 20% act as 
the early stopping criteria for the network and the remaining 20% is used to validate the network 
model. A 3-layered ANN with backpropagation learning was constructed for predicting the 
training samples. In the network training process, stepwise approach is adopted, in which the 
number of input nodes (i.e. genes) will be increase by one each time the network is trained. In 
other words, we perform an exhaustive search throughout the whole gene population to find 
potential candidate genes in solving our problem. The search will iterate until the termination 
criteria is met. The validation set is then used to further  examine  the  significance  of  the  
identified  genes. The whole data partition, training and validation processes are repeated for 50 
times. Figure 1 is a diagrammatic representation of ANN model.  
 
We set the network epochs to 3000, 1000 threshold window times if no further 
improvement on mean squared error (MSE) with threshold of 0.01, learning rate of 0.1, momentum   
rate   of   0.5   and   random   cross-validation sampling of 50 times. We use backpropagation 
learning algorithm with an exhaustive stepwise search and sigmoidal activation function. The 
MSE error was used to compute the network error as it is the most widely used error 
measurement for ANN. 
 
Figure 1. Diagrammatic representation of ANN model 
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3.     Breast cancer gene microarray data 
 
The cDNA data set, labelled as E-GEOD-20194 (MAQC   II), was downloaded   from   the 
EMBL-EBI database library (http://www.ebi.ac.uk/arrayexpress/). The dataset  contains  278  
samples categorized  into  2  classes. One-hundred-sixty-four  samples  were  confirmed  as 
estrogen receptor positive (ER+) class and the remaining 114 samples in estrogen receptor 
negative (ER-). Each sample in the data set is associated with 22283 genes. 
 
It is worth to note that this is a relatively new microarray  data  that  is  submitted  by  
MicroArray Quality Control (MAQC) consortium [12]. This is the only publicly available  breast  
gene  microarray  data  that  comprised  of large cohort of breast cancer patients, as we are aware 
of. Most of the existing breast gene microarray analysis was performed based on a small number 
of samples (< 200 samples). 
 
4.     Results 
 
We compared our results with the result reported by Liu and his co-workers [11], a study 
carried out by the MAQC consortium emphasizing on this data set. 
 
To show an unbiased result comparison, we compared the top 100 genes selected by our 
model with the top 100 genes reported by Liu et al. [11]. Due to the limitation of space here, 
we only present the top 20 genes in this paper. Table 1 below summarises the comparison 
between the top 
100 genes. The top 20 genes selected by our model is presented in Table 2. 
 
A total  9  genes  were  overlapped  with  the  top  100 genes reported by Liu et al. These 
overlapping genes are EGFR (probe set ID 201983_s_at), ESR1 (probe set ID 205225_at), IL6ST 
(probe   set IDs 211000_s_at & 212195_at), MAPT (probe set ID 203929_s_at), DACH (probe 
set ID   205471_s_at), GATA3 (probe set ID 209602_s_at), GREB1 (probe set ID 205862_at) and 
SERPINA5 (probe set ID 209443_at). Among these overlapping genes, gene ESR1 is the highest 
ranked gene in our model (see Table 2). We are not able to compare the rank order of the genes as 
it is not supplied in the original study. 
 
The highly ranked genes by our model have revealed significant association with the ER 
status. Most of the identified genes, specifically genes ESR1, GATA3 and CA12, have been 
previously reported in the association to breast cancer [6, 7, 14, 15]. 
 
Gene ESR1 (probe set ID 205225_at) produces estrogen receptors which are ligand 
activated transcription factors belongs to the nuclear hormone superfamily. It plays a role in 
regulating the expression of specific genes that involve in the cellular processes, such as growth, 
differentiation and function of reproductive systems. 
 
Gene GATA3 (gene probe set I D s 209602_at, 209603_at, 209604_at), on the other hand, 
encodes transcription  factors  of  GATA  family  which  act  as  the regulators of T-cell and 
endothelial cell development.  
 
Meanwhile, gene CA12 (gene probe set ids 215867_x_at, 203963_at, 210735_s_at) 
participates in the processes, such as respiration, bore resorption, formation of saliva, gastric acids 
and celebrospinal fluid. CA12 gene produces a type-1 membrane protein which is highly expressed 
in normal tissues, including colon, pancreas and kidney. However, it also shows a relative high 
expression in renal carcinomas. 
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Table 1. The comparison result based on the genes selected in the data set 
Studies No. of selected genes Overlapped genes Non-overlapping genes 
ANN 100 9 91 
Liu et al [11] 100 - - 
 
 
 
 
Table 2. The top 20 genes selected by ANN. 
Rank Order  Probe set ID  Accession No.  Gene Symbol  
1 205225_at NM_000125 ESR1 
2 209603_at AI796169 GATA3 
3 212956_at AI348094 KIAA0882 
4 214164_x_at BF752277 FLJ20151 
5 215867_x_at AL050025 CA12 
6 209602_s_at AI796169 GATA3 
7 214440_at NM_000662 NAT1 
8 204508_s_at BC001012 FLJ20151 
9 209604_s_at BC003070 GATA3 
10 203963_at NM_001218 CA12 
11 218195_at NM_024573 FLJ12910 
12 212960_at BE646554 KIAA0882 
13 209173_at AF088867 AGR2 
14 210735_s_at BC000278 CA12 
15 203628_at H05812 IGF1R 
16 211712_s_at BC005830 ANXA9 
17 218976_at NM_021800 JDP1 
18 212196_at AW242916 IL6ST 
19 205009_at NM_003225 TFF1 
20 202089_s_at  NM_012319  LIV-1  
 
An ANN prediction model was constructed based on the top 100 selected genes. Using the 
validation set, our model achieves 77.62% of classification accuracy with sensitivity of 96.32% 
and specificity of 58.78% for ER positive class. For ER negative class, the sensitivity of 58.78% 
and specificity of 96.32% were achieved. This showed that our model is robust for identifying the 
most significant set of genes from high dimensional gene microarray data.  
 
We also performed the receiver operating sample subset is depicted in Figure 2. The y-axis 
of the curve was plot based on the equation 1 and the x-axis of the curve is based on the equation 
2. The area under the ROC curve for the validation sample subset is 0.935. 
 
 
Sensitivity = (Positive correctly classified samples)/(Total positive samples in the class)            (1) 
 
Specificity = (Negative correctly classified samples)/(Total negative samples in the class)         (2) 
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Figure 2: The averaged ROC curve based on 50 random sampling for each sample set 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.     Discussion and Conclusions 
 
Our model has shown the ability to identify the most significant gene subset from the breast 
gene microarray data. Although only 9 out of 100 selected genes by our model are overlapped 
with the top 100 genes reported by Liu et al. [11], our model has significantly selected 3 most 
important predictor genes which have been previously associated with breast cancer. The ESR1 
gene which is highest ranked by ANN shows that it is a strong predictor to discriminate ER 
status in breast cancer. Gene ESR1 has been profoundly used as a general marker for cancer 
prognosis in the literature [7]. 
 
Furthermore, we apply random cross-validation on the data set to obtain the unbiased top 
100 genes from the data set. We use exhaustive search method coupled with backpropagation of 
errors to perform a thorough search on the   entire   gene   population   to   ensure   that   the   most 
significant gene subset  will  always  be  selected  by  our model. Liu et al, on the other hand, used 
Naive Bayesian approach to identify their top 100 genes. Consequently, some of the “true” marker 
genes may be overlooked in their search process. 
 
Based on the top 100 genes selected by our model, we achieved an average classification 
accuracy of 77.62% in the validation set and high sensitivity value (96.32%) in the ER positive 
class. However, low sensitivity value (58.78%) in the ER negative class is obtained. This might 
due to a lack of standard threshold used by the immunohistochemistry to label ER status on the 
samples. The low sensitivity in ER negative class may suggest that high possibility of 
misclassifying true negative samples as positives in the pathological screening. Therefore, study on 
the boundary measures of the threshold for immunohistochemistry assay will be carried out in 
future. In addition, we will also conduct the same experiments with different data mining 
approaches to investigate the implications of different mining algorithms on the classification 
performance and gene selection. This future study will help in formulating the most significant and 
overlapped gene markers for ER status in breast gene microarray data. 
 
We believe our approach is robust in providing the most relevant set of genes that are 
highly associated to the ER status in the breast cancer. We use an exhaustive search method and 
the universal computation power of ANN to identify the most significant genes from high 
dimension (>22000 genes) and large cohort of >200 breast cancer patients. 
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Abstract: 
Estrogen receptor (ER) status is an important consideration in the prognosis and 
management of  breast cancer patients, dictating treatment and patient management. While 
the prognosis of ER positive  patients is generally poorer because of treatments such as 
Tamoxifen this situation has been reversed. Some detail is known of the ER pathway, 
however this has been based on reductionist studies of small numbers of markers. Here we 
present an Artificial Neural Network (ANN) using a feed forward back-propagation 
algorithm applied to a three layer multi-layer perceptron  based approach that facilitates a 
wider more holistic approach to the identification of genes associated with ER status and the 
modeling of their interactions with one another in the context of a pathway. 
 
I. INTRODUCTION 
 
The treatment of breast cancer covers a wide spectrum of heterogeneity from locally 
advanced to metastatic spread of disease[1] and a range of molecular subtypes have been 
identified. Surgical treatment includes axillary lymph node resection, radical mastectomy which 
aids control locoregional 
disease progression causing distant metastasis. Radiotherapy is another integral part of treatment 
given to breast chest and axilla to prevent brain lung and bone metastasis. 
 
It is well known that estrogen receptor (ER) plays a pivotal role in the biology of breast 
cancer [2]. It is an commonly used prognostic factor predicting a favourable response to treatment 
and better survival prospects. Hormonal treatment is given for breast cancers expressing positive 
estrogens and progesterone hormone receptors. Antiestrogens, progestins, aromatase inhibitors, 
gonadotropin releasing hormone analogues and ablative endocrine procedures can be included 
under hormonal treatment. Selective estrogen receptor modulators (SERM) like Tamoxifen and 
Raloxifen and aromatase inhibitors like Letrozole and Anastrazole are the two main classes of 
drugs used in ER positive breast cancer [3].  
 
Current investigations of the ER pathway have largely focused on analysis of annotated 
literature based databases such as ingenuity pathways analysis. 
 
Artificial Neural Networks (ANNs) are a form of machine learning capable of accurately 
modeling biological systems  and identifying biomarkers. They are capable producing models that 
discriminate well between multiple classes for blind data [4], [5] while allowing parameterization 
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to determine the influence of causal agents within the system. ANNs have been applied to a 
number of gene micro-array studies in cancer in a number of ways [6], [7]. Many of the studies 
conducted pre-filter the probe-set before ANN analysis. A number of studies have indicated the 
approach can produce generalized models with a greater accuracy than conventional statistical 
techniques in medical diagnostics [4],[8] without relying on predetermined relationships as in 
other modeling techniques. 
 
Network inference is a branch of systems biology wherein interactions among the 
contender of the system are logically connected to each other representing behavior of the system. 
The simplest network in systems graph is a pairwise relation between Nodes (called vertices) 
through Edges (called links). The nodes of cellular systems may be genes or mRNA, protein or 
other molecules. Edges are comprised with a source node and a target node representing the 
relation between nodes. Depending on the availability of information edges can have positive or 
negative values, representing activation or inhibition; or weights quantifying confidence levels, 
strength, or reaction speeds. 
 
Here we apply an ANN based network inference approach to model and identify the key 
interactions between identified genes associated with the Estrogen Receptor pathway. From these 
interactions we aim to:- Identify probes and thus genes that interact with ER from a gene 
expression array study through an ANN based data mining approach; identify the strongest 
interactions between these probes through an ANN based network inference approach and evaluate 
the biological relevance of the findings. 
 
II. COMPUTATIONAL APPROACHES 
 
A. Data sets used for analysis. 
 
A pre-normalized microarray breast cancer cDNA expression profile was downloaded from 
freely available EMBL-EBI database library (http://www.ebi.ac.uk/arrayexpress). The cDNA 
microarray profile was found to be developed on Affymetrix HG-133U array from E-GEOD-
20194 study. The breast cancer microarray dataset contained 22283 gene probes in 278 arrays of 
primary breast cancer samples before neo-adjuvant therapy. The samples were categorized into 2 
classes based on immune-histochemical Estrogen Receptor (ER) status as ER positive (ER+; 164 
samples) class and the remaining as ER negative (ER-; 114 samples). 
 
B. Phase 1 Identification of biomarker probes associated with Estrogen Receptor status. 
 
The analysis and modeling of gene-gene interactions from a whole microarray probe set is 
an extreme undertaking. If a whole Affymetrix probe-set (having in excess of 22,000 probes was 
to be analyzed using a bidirectional interaction modeling then in excess of 9x108 interactions 
would have to be modeled, analyzed and filtered. The computational requirements coupled with 
the potential for false discovery in such an interaction model would be both very large making 
analysis very difficult. To reduce these constraints the probe-set used for network inference was 
first analyzed to identify the top 100 most appropriate genes. This was achieved by coupling a 
filter and a wrapper method with early stopping and a Monte Carlo cross validation approach 
(utilizing a 60:20:20 randomized split of the data), analyzing single probes based on their ability to 
predict for an unseen data set. This process was repeated 10 times and the results averaged and 
compared. 
 
This approach has been used successfully in a number of studies to identify genes showing 
high sensitivity, specificity and biological relevance that are associated with a given clinical 
question [4], [9],[10]. A more detailed description of this approach is presented in [4]. P-values for 
each of the top genes are quoted for further validation.  
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C. Phase 2 Artificial Neural Network based Network inference. 
 
The top 100 genes identified in phase 1 of the analysis were applied to an ANN based 
network inference algorithm [11]. This approach utilizes a feed forward back propagation 
algorithm to predict the expression level of a given probe from the other 99 probes in the set. The 
model is trained to optimum performance on unseen data using Monte Carlo cross validation. It is 
then parameterized to determine a weighting of the link from input probe to output probe. This link 
has both a sign and a magnitude. This process is repeated for the remaining 99 probes setting each 
probe as the output generating a total of 100 models. 
 
The parameterizations of each of these models are then integrated to produce an interaction 
matrix. The 100 strongest interactions (representing the top 1% of interactions) were then further 
selected for visualization. Using this multifactorial nonlinear ANN based inference approach has 
an advantage over simple linear regression based approaches in that the interaction may be 
nonlinear and that bi-directionality can be modeled.  
 
D. Visualization 
 
The gene interaction values from the software generates tab delimitated text formatted file. 
The format of the output file comprises three columns represented as source and target, 
sandwiching the interaction values in terms of weighted vectors in between. For the visualization 
of the gene  interactions in this study, we have used a free standalone Cytoscape Ver 2.7.3 
software (www.cytoscape.org). Interactions (edges) are represented as either positive (green) or 
negative (red) with magnitude of interaction represented by the width of the line and directionality 
represented by arrows.  
 
III. RESULTS 
 
A. Probe selection 
 
Examination of the rank order of probes indicated good concordance between the 10 
repeats of the analysis. The mean RMS error for seen data for classification between ER positive 
and negative was 0.113 +/- 0.008. The mean RMS error for blind data was 0.118 +/- 0.009. In all 
10 repeats the highest performing probe was ESR1 representing the gene coding for Estrogen 
Receptor alpha. Receiver operator characteristic curves (ROC) were plotted for the models and a 
mean area of 0.930 was produced for seen data and 0.917 for blind data. The top 100 predictive 
probes were taken forward for further analysis. Here the top 20 only are presented for the sake of 
brevity (Table 1). 
 
The genes found in the top 100 were :-ACADSB, ADCY9, AGR2, AKR7A3(x2), 
ANXA9(x2), APBB2(x2), C1orf34, C6orf29, CA12(x3), CDH3, CELSR1, CGI-49, CIRBP,  
LSTN2, COX6C, CRIP1, CRNKL1, CYP2B6, DACH(x2), DNALI1, DP1, EGFR, ELOVL2, 
ENPP1, ESR1(x2), FBP1, FLJ10647, FLJ12910, FLJ20151(Also CA12)(x2), FOXA1, GAMT, 
GATA3(x3),  GFRA1, GREB1, IGF1R(x2), IGFBP4, IL6ST(x4), JDP1, KIAA0040, KIAA0232, 
KIAA0876(x2), KIAA0882(x2), KIAA1243, LASS6(x2), LIV-1(x2), MAGED2, MAPT(x3), 
MCCC2, MGC2601, MLPH, MYB, NAT1, NME3, NPD009(x2), PBX1(x2), PDEF(x2), PH-4, 
PTP4A2, RAB5EP, RARA, RHOB, RNB6, SCUBE2, SEMA3F, SERPINA5, SKP1A, TFF1, 
TFF3, TONDU, UGCG(x2), VAV3(x2), WWP1(x2) and XBP1. Only 73 genes are listed as some 
probes were   repeated multiple times for the same gene (numbers of times indicated in 
parenthesis). 
 
B. Network inference. 
 
The top 100 interactions are illustrated in Figure 1. Red interactions indicate a negative 
interaction, Green interactions indicate a positive interaction. Examination of the network map 
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indicates a strong connectivity to GATA3 (GATA binding protein 3) with positive influence, 
FOXA1(forkhead box A1) with positive influence, TONDU (transcription cofactor vestigial-like 
protein 1) with negative influence, CDH3 (cadherin 3, type 1, Pcadherin) with negative influence 
and SOX11 (transcription factor SOX-11)with negative influence. The strongest negative 
interaction in the network was  between CDH3 and SOX11. The strongest positive interaction was 
between FLJ20151(a variant of Carbonic Anhydrase 12) and FOXA1. 
 
Table 1: Summary of top ranked 20 genes from stepwise ANN 
 
Rank Order Probe set ID Gene Symbol p-value Regulation 
1 205225_at ESR1 4.49E-05 Up 
2 209603_at GATA3 8.98E-05 Up 
3 212956_at  KIAA0882 1.35E-04 Up 
4 214164_x_at FLJ20151 1.80E-04 Up 
5 215867_x_at CA12 2.24E-04 Up 
6 209602_s_at GATA3 2.69E-04 Up 
7 214440_at NAT1 3.14E-04 Up 
8 204508_s_at FLJ20151 3.59E-04 Up 
9 209604_s_at GATA3 4.04E-04 Up 
10 203963_at CA12 4.49E-04 Up 
11 218195_at FLJ12910 4.94E-04 Up 
12 212960_at KIAA0882 5.39E-04 Down 
13 209173_at AGR2 5.83E-04 Up 
14 210735_s_at CA12 6.28E-04 Up 
15 203628_at IGF1R 6.73E-04 Up 
16 211712_s_at ANXA9 7.18E-04 Up 
17 218976_at JDP1 7.63E-04 Up 
18 212196_at IL6ST 8.08E-04 Up 
19 205009_at TFF1 8.53E-04 Up 
20 202089_s_at LIV-1 8.98E-04 Up 
 
Figure 1. Inferred network for ER status in breast cancer. 
 
 
 
ANNEXURE 2: 
Gopal K Dhondalay, Christophe Lemetre and Graham R Ball. Modelling estrogen receptor pathways in breast cancer 
using an Artificial Neural Networks based inference approach. Proceedings of the IEEE-EMBS International conference on 
Biomedical and Health Informatics. Hong Kong, Shenzhen, 5-7 January, 2012. 
(http://ieeexplore.ieee.org/xpls/abs_all.jsp?arnumber=6211745&tag=1) 
 
267 
 
IV. DISCUSSION. 
 
The aims of this study were to identify probes and thus genes that interact with ER from a 
gene expression array study through an ANN based data mining approach; to identify the strongest 
interactions between these probes through an ANN based network inference approach and to 
identify the biological relevance of the findings. 
 
The probe set selected from the array shows a lot of potential in its representation of the 
biology of ER status. Firstly the top probe consistently identified was ESR1 the gene that codes for 
estrogen receptor alpha. The presence of this probe in the highest ranked position indicates the 
other top ranked probes are also of potential biological importance. This conclusion is further 
strengthened by the fact that different probes for the same genes also occur multiple times in the 
top 100. In some cases all of the probes in the top 100 are represented on the array.  
 
From the combination of data mining and network inference the key genes seem to be 
GATA3, FOXA1, TONDU, CDH3, SOX11 and CA12. Of these FOXA1, GATA, TONDU and 
SOX11 are known transcription factors and thus would be likely to be influential in the 
coregulation of other genes. 
 
GATA3 is very well known to be associated with ER phenotype in breast cancer and is 
thought to regulate genes critical to the hormone response phenotype of breast cancer [2],[12]. 
Furthermore a cross regulatory loop has been identified between ESR1 and GATA3 [13]. GATA3 
has 
previously been found to be associated with ER status in breast cancer through ANN data mining 
of expression array data [10]. 
 
FOXA1 is also known to have a strong role in the Estrogen receptor phenotype [14], [15] 
and is likely to influence other genes in the pathway. It has also been associate with poor 
prognostic outcome in breast cancer [9]. In this study it also showed a significant association with 
ER and P- Cadherin. 
 
SOX11has not directly been shown to relate to ER status in breast cancer. It has been 
shown to associate with prognosis in ovarian cancer [16] and could potentially have a role in 
breast cancer. It has been shown to have a role in tumorigenesis and was found by Christodoulou 
et al [17] to be  associated with ER status. 
 
CDH3 (P-Cadherin) has been associated with the basal phenotype in breast cancer [18] and 
with ER independent growth [19]. Furthermore using ANN based techniques [7] identified it as 
associated with ER status in breast cancer.  
 
TONDU has no currently identified role in cancer. 
 
CA12 is associated with hypoxia and poor prognosis in breast cancer. Tumor tissue in 
hypoxic condition is subjected to physiological stress causing accumulation of acidic products of 
glycolytic metabolism. Hypoxia inducible growth factor brings about a change in cellular 
expression programme by activating genes involved in angiogenesis, anaerobic glycolysis, 
adhesion and invasion. It has been shown to associate with ER status in breast cancer through a 
distil enhancer [20]. 
 
ESR1 is not a strong hub in the interaction network which is somewhat surprising on first 
consideration. However given that all of the elements included in the pathway are strongly 
associated with ER some of the variance associated with the marker is likely to have been removed 
by inclusion of these factors. This has the effect of emphasising the interaction between factors 
associated with ER status but not with ER directly. 
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V. CONCLUSIONS 
 
Utilizing the combined approach of ANN based data mining and ANN based network 
inference we have identified 6 genes that associate with the ER system in breast cancer. Of these 4 
are known to be strongly associated with ER status. Through network inference we have identified 
interactions that with further evaluation have the potential to provide further insights into the 
etiology of Estrogen Receptor in breast cancer. 
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